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ABSTRACT 
 
 
Pursuant to the discovery of the cannabinoid receptors, research in this field has 
grown exponentially over the last 2 decades. With their utility in various disease states 
such as heart disease, cancer, stroke, neurodegenerative and inflammation, cannabinoids 
stand poised to become a great therapeutic agent. This research seeks to better understand 
the functional mechanism of cannabinoids, in the hopes of ascertaining which molecular 
attributes confer desirable selectivity and functional activity. 
Looking first at classical benzchromene core analogues, we have shown that 
presence of an aromatic substitution at C-1' imparts a CB1 agonist, CB2 antagonist. This 
is a unique mechanism and one of the first examples of an agent with dual affinity and 
opposing activity. 
In the triaryl series of compounds, more insight is gained for the functional 
pharmacophore of cannabinoids. With this series of compounds we are able to learn that 
minor changes are able to confer profound differences, such as C-1'-gem-dimethyl 
derivatives are agonists while C-1' ketones are inverse agonists. 
Within these triaryl series, newly synthesized derivatives help to round out the 
functional pharmacology for these compounds - allowing a more direct comparison to the 
previously synthesized classical core compounds. In total, a more thorough understanding 
of the function, which follows form of several cannabinergic compounds, is gained 
through this exercise and research. 
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CHAPTER 1. INTRODUCTION 
1.1. History of Cannabinoids 
Cannabinoids have enjoyed a very long and somewhat sordid history. Originally 
grown for its hemp fiber for use in the fashioning of clothes, ropes and paper, it has a 
history of therapeutic use in India and China for nearly 5000 years.1 The use of Cannabis 
sativa preparations for treatment of a variety of pathological conditions in ancient Indian, 
Chinese, and Egyptian civilizations is well-documented.2 This documentation and 
literature is rife with therapeutic indications for Cannabis with usage as an analgesic,3,4 an 
anesthetic,5 an appetite stimulant,6 an anti-inflammatory agent,7 and several other 
ailments and afflictions.2 Although it took time to spread throughout the Western world 
for recreational and medicinal use, the true evolution of (-)-trans-∆9-tetrahydrocannabinol 
(∆9-THC, the active psychotropic agent of the Cannabis sativa plant) (Figure 1.1) into a 
therapeutic agent has a much more recent history.  
Early in the nineteenth century, natural product interest and research began to 
gain a foothold, and several alkaloids such as morphine, cocaine and strychnine were 
isolated from plant materials. The search for the psychoactive constituent of marijuana 
began during this period of rapid growth in the field of pharmacognosy. It was the 
common belief for many years that the principal active constituent of Cannabis sativa 
was in fact an alkaloid. This would hold true until Marshall and coworkers isolated a 
mixture of terpenes from an ether extract of Indian hemp in 1896,8 which produced the 
same pharmacological effects observed with Cannabis sativa use. This provided the first 
observational evidence that the principal active compound was not an alkaloid but a 
terpene. In the early 1930s Cahn and coworkers isolated cannabinol (Figure 1.1) and 
determined a partial structure after conducting extensive chemical degradation studies.9 
This discovery was followed in rapid succession by the synthesis of several derivatives of 
cannabinol and Δ6a,10a-tetrahydrocannabinol (Δ6a,10a-THC) (Figure 1.1) by the Adams 
group10,11 and the Todd group.12 The pharmacological activities of cannabinol and 
Δ6a,10a-THC, as tested by the Gayer areflexia test for suppression of corneal reflexes in 
the rabbit, were observed to be similar to those of the Cannabis extract, but were 
significantly less potent.  
The isolation and structural characterization of Δ9-THC, was reported in 1964 by 
Gaoni and Mechoulam.13 The activity of this cannabinoid was subsequently studied in a 
number of animal models. These studies ranged from evaluation of the cataleptic reaction 
in mice14 to the effects on motor activity and gross behavior in mice and rats.15 There was 
also extensive experimentation in rhesus monkeys16 which ultimately led to the 
pharmacological characterization of cannabinoids. Following these reports, several other 
constituents of marijuana such as cannabidiol, cannabigerol, cannabichromene, 
cannabicyclol (Figure 1.1) and related cannabinoid acids were isolated and characterized. 
The structural characterization of Δ9-THC provided a springboard to stimulate interest in 
research on cannabinoids. This resulted in the design and synthesis of several structurally 
diverse classes of cannabinoids. Studies on the effects of various analogues in animal 
models showed a positive correlation between structure and biological activity indicating  
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the possible involvement of a defined receptor for the cannabinoids. This variety of 
compounds then aided in the discovery and cloning of the cannabinoid receptors and the 
subsequent identification of their endogenous ligands. 
1.2. Cannabinoid Receptors 
1.2.1. History and background of cannabinoid receptors 
The beginning of the exponential growth seen in the field of cannabinoid research 
in the last two decades can be traced to the identification, isolation and cloning of the 
cannabinoid receptors. After the discovery of Δ9-THC, but before the discovery of the 
cannabinoid receptors, research on cannabinoids in the late 1970s and in the early 1980s 
was based on the assumption that the pharmacological effects attributed to cannabinoids 
were mediated not via cannabinoid receptors but by dissolution into and perturbation of 
cellular membranes. Due to their high lipophilicity, it was thought that cannabinoids 
behaved like general anesthetics in terms of their mechanism of action.17 However, the 
highly stereospecific activity associated with several cannabinoids18 suggested receptor 
mediated action. Then, in 1988, Devane and coworkers19 utilized a tritium labeled 
synthetic cannabinoid to tag specific sites in the brain and on neuronal cells. This then 
provided strong evidence for the presence of a specific cannabinoid receptor in the rat 
brain. This discovery directly preceded the isolation of the cDNA of this receptor, its 
expression in Chinese hamster ovary (CHO) cells and subsequent naming as the 
cannabinoid receptor type 1 (CB1).
20 In 1993, a second cannabinoid receptor subtype, 
cannabinoid receptor type 2 (CB2), was isolated and cloned from the human 
promyelocytic cell line HL60 by Munro and coworkers.21 An amino terminal variant of 
the human CB1 receptor has also been reported,
22 in which a 167 base portion of the CB1 
coding sequence is spliced out of the mRNA – termed CB1A. 
The cannabinoid receptors belong to the superfamily of G-protein coupled 
receptors14 (GPCRs), are single polypeptides with seven transmembrane α-helices, an 
extracellular, glycosylated N-terminus and intracellular C-terminus. The CB1 and CB2 
receptor subtypes each possess 68% amino acid identity within their transmembrane 
regions but only 48% homology throughout the entire peptide14 – a trait that is unique 
among the CB1 and CB2 receptors. Many other GPCR families share approximately 75% 
homology among the subtypes. Also, it is noteworthy that the CB1 receptor is highly 
conserved across mouse, rat and human; however, there is only an 81% amino acid 
identity of the CB2 receptor across rat and human variants.
23 
Whether there are additional cannabinoid receptors is still a question that plagues 
many researchers in this field. This is, in part, due to the observation that the endogenous 
cannabinoid ligand, anandamide, induces spinal anti-nociception via a different 
mechanism than Δ9-THC.24 In 2000, Di Marzo and coworkers carried out studies25 using 
transgenic mice26 that lack the CB1 receptor to evaluate the CB1 mediated effects of 
anandamide and Δ9-THC. They found that in these knockout mice anandamide still 
produced CB1-like effects such as catalepsy, analgesia, and loss of spontaneous activity 
whereas Δ9-THC did not. This suggested the presence of a new cannabinoid receptor in 
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the brain. Recent studies have also shown that a number of the cannabinoid ligands bind 
to the orphan receptor GPR55.27-29 This receptor is reported to be expressed in several 
tissues and might function in regulation of vascular tone and immune-cell migration.29 
Anandamide is also known to act on other classes of receptors such as the vanilloid 
receptor, TRPV1. Anandamide activates TRPV1 and produces membrane currents or 
increases in intracellular calcium levels.30-32 The presence of these multiple sites for 
cannabinoid action (along with the aforementioned possibility for yet undiscovered sites) 
coupled with several signaling pathways and associated second messengers is compelling 
evidence for the complex pharmacology associated with cannabinoids.  
1.2.2. The CB1 receptor 
The CB1 receptor is a 52.8 kDa, 472 amino acid polypeptide, found in both the 
CNS and periphery in both neural and non-neural tissues. CB1 is coupled to inhibitory 
Gi/o proteins
33 which bind to its third intracellular loop and its C-terminus.34 CB1 
receptors may also exert an action on Gs proteins to stimulate cyclic AMP (cAMP).
35 The 
amino acid residues in transmembrane regions 3, 5 and 6 of the CB1 receptor are believed 
to be involved in binding with cannabinergic ligands.36 Activation of CB1 causes 
inhibition of adenylyl cyclase and a reduction in cAMP levels. Reduction of cAMP 
affects phosphorylation by protein kinase A which causes modulation of ion channels and 
other secondary messengers. Activation of voltage-sensitive outwardly rectifying K+ 
channels,37 inwardly rectifying K+ channels38 and inhibition of voltage gated N, L, P and 
Q-type Ca+2 channels39 are observed in response to CB1 receptor activation.  
The CB1 receptor regulates different members of the mitogen activated protein 
kinase (MAP kinase) family of enzymes such as: 
1. extracellular signal-regulated kinase (ERK)40-42 
2. c-Jun N-terminal kinase43,44 
3. p38.44,45 
Activation of MAP kinase is associated with: 
1. activation of immediate early genes like c-Fos and Egr1 (Krox-24)41 
2. activation of focal adhesion kinase (important for integrating cytoskeletal changes 
associated with signal transduction events) 
3. activation of phospholipases (PL), PLA, PLC, and PLD46 
4. activation of the Na+/H+ exchanger47 
5. activation of phospholipase A2, which in turn causes release of arachidonic acid 
leading to the synthesis of prostaglandins.48 
There is also evidence of a second pathway initiated by CB1 receptor stimulation 
coupled with sphingomyelinase activation and subsequent release of ceramide.42 
Ceramide then causes activation of the Raf-1/MAP kinase cascade49 and also carnitine 
palmitoyltransferase I in mitochondrial membranes to stimulate ketogenesis and fatty 
acid oxidation.50 The elevation of intracellular ceramide have also been suggested to be 
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one of the possible factors responsible for the apoptotic effects of cannabinoids seen on 
ceramide-related cancers such as glioblastoma.51  
1.2.3. The CB2 receptor 
The CB2 cannabinoid receptor, also referred to as the peripheral cannabinoid 
receptor, is a 41 kDa, 360 amino acid polypeptide predominantly expressed in the 
immune system.52,53 Its amino acid sequence is quite different from that of CB1, 
especially in the amino terminal domain, which is significantly shorter and not as well 
conserved in the CB2 receptor when compared to the CB1 receptor. The amino acid 
residues involved in ligand recognition are also found, as it was for the CB1 receptor, in 
transmembrane domains 3, 5 and 6 for the CB2 receptor.
54 
Like the CB1 receptor, CB2 couples to the inhibitory Gi/o proteins that bind to its 
third intracellular loop and C-terminus. Activation of the CB2 receptor also causes 
inhibition of adenylyl cyclase and therefore a reduction in cAMP levels, as it was with 
CB1. Most of the known signaling pathways of CB2 are identical to those observed with 
CB1. However, unlike the CB1 receptor, the CB2 receptor has no effect on ion channels.
38 
After the discovery of the CB2 receptor it was believed that it was found only in 
the immune system and was completely absent from the CNS.55 More recently, however, 
CB2 expression has been confirmed in the brain on microglia,
56 blood vessels,56 and on 
some neurons.57,58 CB2 has a much higher prevalence than CB1 within the immune 
system. The expression level of the CB2 gene in immune tissues is 10 to 100 times the 
level of the CB1 gene.
59 In fact, the CB2 mRNA content of the spleen and tonsils is 
almost equivalent to the CB1 mRNA content in the CNS.
59 This first led researchers to 
suggest that CB2 receptor might play an important role in immune function – more 
specifically the down-regulation thereof. It is no surprise then that many reports have 
been made over the years regarding the deleterious effects of marijuana smoking on host 
defense mechanisms where marijuana smokers were found to be more susceptible to 
bacterial and viral infections.60 CB2-specific ligands and specific targeting of the immune 
system is possible by virtue of the fact that between transmembrane domains 1 and 7, 
including the loop regions, the CB2 receptor is only 44% identical to the CB1 receptor. 
1.2.4. The GPR55 receptor – A putative cannabinoid receptor 
The GPR55 receptor, first identified and cloned by O’Dowd in 1999,61,62 found 
favor as a putative cannabinoid receptor by an in silico screen due to an amino acid 
sequence in the binding region that is similar. Research groups at the pharmaceutical 
companies Glaxo-Smith-Kline and AstraZeneca then extensively characterized the 
receptor in the hope that it would be responsible for the blood pressure lowering effects 
of cannabinoids. GPR55 demonstrates activation by endogenous, phyto-, and synthetic 
cannabinoids but GPR55 knockout mice generated at Glaxo-Smith-Kline showed no 
alteration in the cannabinoid induced blood pressure regulation after administration of the 
GPR55 agonist abnormal-cannabidiol (Figure 1.2). 
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Some of the known CB1 and CB2 ligands also bind to GPR55. The receptor is 
activated by  Δ9-THC and cannabidiol,29 synthetic cannabinoids such as CP-55,940 and 
the endocannabinoids anandamide (AEA), 2-arachidonoylglycerol (2-AG), and nolandin 
ether (Figure 1.2).29 Recent research suggests that lysophosphatidylinositol and its 2-
arachidonoyl derivative (Figure 1.2) may be the endogenous ligands for GPR5563,64 thus 
giving rise to it being a potential LPI receptor.65 GPR55 appears likely to be a possible 
target for treatment of inflammation and pain as with the other cannabinoid receptors.66-69  
While the CB1 and CB2 receptors couple to Gαi/o proteins, GPR55 is coupled to 
Gα13 and activation of the receptor leads to stimulation of a number of GTPases such as 
Ras homolog gene family, member A (RhoA), cell division control protein 42 homolog 
(cdc42) and Ras-related C3 botulinum toxin substrate 1 (rac1).27 Members of this GTPase 
superfamily appear to regulate a diverse array of cellular events, including the control of 
cell growth, cytoskeletal reorganization, and the activation of protein kinases.70 
Stimulation of GPR55 induces F-actin formation under the control of Gα13, RhoA and 
Rho-associated, coiled-coil containing protein kinase (ROCK).63 GPR55 activation also 
induces intracellular calcium release and activation of the transcription factors nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-κB), nuclear factor of 
activated T-cells (NFAT) and cAMP response element-binding (CREB).63 The 
physiological role of GPR55 remains unclear. Mice with a target deletion of the GPR55 
gene show no specific phenotype.71 GPR55 is has been found to be widely expressed in 
the brain, especially in the cerebellum. It is found in the gastrointestinal tract in the 
jejunum and ileum and also in the adrenal glands but is apparently not highly expressed 
elsewhere in the periphery.29 Osteoblasts and osteoclasts have also been shown to express 
GPR55 and this has been shown to regulate bone cell function.72 
1.3. Cannabinoids in Disease States 
 In the United States of America, heart disease (Section 1.3.1), cancer 
(encompassing all variants under the auspice thereof) (Section 1.3.2), stroke (Section 
1.3.3), Alzheimer’s Disease (Section 1.3.4) and diabetes (Section 1.3.5) are five of the 
top seven causes of deaths. Many of these disease states have complex pathogenesis and 
are amalgamations of several years of poor habits and lifestyles of individuals; however, 
once diagnosed, treatment of many of these disease states is tenuous, at best. There are 
data that strongly point to the usefulness of cannabinoids in all of these disease states. It 
is for the betterment of treatment not only for these diseases, but for cannabinoid use 
therein that this project finds its utility and mission – to better design a cannabinergic 
agents we must first understand how they function. While it is well and good to 
understand the need for a CB1 antagonist and a CB2 receptor agonist to positively impact 
cerebral ischemia in stroke,73 understanding the functional activity of drugs prior to their 
use in vivo is essential for targeted drug design and resource optimization. Furthermore, 
use of this information to develop a functional pharmacophore of cannabinoids helps to 
expedite and further hone the synthetic design of cannabinergic ligands. However, as 
with any project, especially one with this potential benefit, one must understand the target 
disease state to maximize the management thereof. Briefly, I will examine five of the top 
seven disease states and the positive role cannabinoids may play in each.  
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1.3.1. Cannabinoids in heart disease 
1.3.1.1. Pathogenesis of heart disease. While the true derivation and progression 
of this disease is innately complex and multifactorial, there are certain key elements that 
lend themselves to the progression of the disease. One of these main components of heart 
disease is atherosclerosis, which is an inflammatory disease, at its root.74,75 This 
inflammation is a response to damage done to the blood vessels as a result of plaque 
deposit or rupture or small intima tears caused by high blood pressure. Cannabinoids find 
usefulness in treating this pathogenesis from acting as: antihypertensive agents (Section 
1.3.1.2), anti-ischemic agents post-MI (Section 1.3.1.3) or anti-inflammatory agents 
(Section 1.3.1.4). 
1.3.1.2. Cannabinoids as anti-hypertensive agents. While the cardiovascular 
effects of cannabinoids has been known since the 1960s, harnessing their power to 
positively impact the cardiovascular system has languished.76 The first possible impact 
cannabinoids may have on this process is in the realm of blood pressure control. The 
peripheral effects of systemically administered cannabinoids in vivo seem to predominate 
in the overall activity of these compounds.77 IV administration of anandamide causes a 
triphasic response in the blood pressure of anaesthetized rats which transitions from a 
transient drop, to a short-lived spike and ending in a prolonged third phase of lower blood 
pressure78 – similar to the onset of higher doses of clonidine.79 The initial phase of 
lowered blood pressure appears to be due to vagal output, as atropine and cervical 
vagotomy eradicate this initial drop.80 The secondary, more sustained, drop in blood 
pressure shows signs of being CB1-mediated through presynaptic inhibition of 
sympathetic output in the periphery.78,80 In addition to the sympathetic outflow inhibition, 
data exists which suggest that there is a direct vasodilatory effect of cannabinoids, as 
HU-210 has been shown to lower blood pressure in spite of sympathetic blockade.80,81 
Overall, anandamide is hypothesized to work by the aforementioned reduction of 
peripheral vascular resistance as well as a decrease in cardiac contractility.82,83 This dual 
mechanism for blood pressure control is consistent with many other drugs currently on 
the market for the treatment and management of hypertension. Additionally, mitigation of 
these effects occurs by administration of the CB1 inverse agonist SR-141716A.
83 
In humans, there is a noted tachycardia and minor pressor effect upon acute 
administration of cannabinoids; however, this gives way to bradycardia and hypotension 
with repeated dosing.84,85 It is worth noting, that there are differences in levels of 
wakefulness between the laboratory animals and the human test subjects.86 A comparison 
of this effect was noted, where monkeys in a sterile, predictable laboratory environment 
demonstrated the same bradycardia effect noted in previous animal models after initial 
dosing.87 This effect, while notable and profound for exogenously administered 
cannabinoids flies somewhat in the face of convention when one considers the 
normotensive state of CB1 knockout mice
88 and FAAH-deficient mice had a normal 
hemodynamic profile.89 Taken as a whole, these results show how endogenous 
cannabinoids do not exert tonic control of the cardiovascular system, under normal 
conditions; however, under abnormal conditions (i.e. hypertension), endocannabinoid 
tone may blunt the elevation of blood pressure and cardiac contractility.90   
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Many in vitro studies have corroborated some of the current in vivo mechanisms, 
as well as generate hypotheses in their own right. First, in vitro experiments conducted in 
isolated, Langendorff-apparatus-perfused, rat hearts91 and in isolated, electrically 
stimulated human atrial muscle,92 have demonstrated HU-210’s and anandamide’s ability 
to decrease cardiac output, as was the case in vivo.93 A second set of experiments sought 
to elucidate the mechanism of HU-210’s vasodilator effects in spite of sympathetic 
blockade; however, those studies have done little to tease apart a true mechanism.77,94,95 
This variability of mechanism also varies from species to species, where a rat aorta may 
experience a 20% reduction,96 while rabbit aorta experiences an 80% relaxation.97 It is 
certain that cannabinoid-induced arachidonic acid production98 and/or nitric oxide (NO) 
production99 are not mechanistic routes for the vasodilatory actions thereof in most 
species or vascular beds, suggesting that cannabinoid vasodilation is site-specific. A final 
mechanism put to in vitro testing is that of alternate receptor activation, more namely 
transient receptor potential vanilloid, type 1 (TRPV1) and the stimulation thereof to 
release calcitonin gene-related peptide (CGRP) from sensory nerves. This has shown 
itself to be of minor consequence, as CB1 knockout
88 and TRPV1 knockout
82 mice both 
present with normal hemodynamic profiles. The potential for involvement of TRPV1 and 
GPCR do provide some insight into the sex-linked differences of vasodilation of 
cannabinoids – with females experiencing a higher degree of vasodilation, possibly due 
to higher levels of estrogens, a well-documented vasodilator.100 
1.3.1.3. Cannabinoids as anti-ischemic agents post-MI. Following a 
myocardial infarction (MI), the ischemic damage that occurs to the cardiac tissue is of top 
concern when evaluating a patient for long-term prognosis. Mitigation of the infarct is of 
the utmost importance, to ensure a full recovery with little to no loss of cardiac function. 
Cannabinoids, especially the endocannabinoids anandamide101 and 
palmitoyethanolamide102 have shown promise in minimizing the infarct size of 
experimental models of myocardial ischemia; however, there is evidence the mechanisms 
thereof are due to an alternate receptor pathway that has yet to be fully 
characterized.101,103 In contradiction to the novel pathway theory, there is data that 
suggest CB1 and CB2 are involved as a cohort, with or without a novel receptor site. CB1- 
and CB2-selective agents have been shown ineffective in minimizing the infarct size. 
Selective antagonism of CB1 or CB2 by SR-141716A or SR-144528, respectively 
abolishes anandamide’s ability to influence infarct size.101 
1.3.1.4. Cannabinoids as anti-inflammatory agents post-MI. As previously 
mentioned, atherosclerosis is one of the major causes of heart disease, and is itself a state 
of chronic inflammation.104 Even at low doses, THC demonstrates a blockade to the 
advancement of atherosclerotic lesions in a murine model thereof.105 Validating the 
mechanism of this being a CB2-mediated effect on the atherosclerotic lesion,
106 
pretreatment with SR-144528 serves to block the beneficial effects of THC in this 
model.105 The same study that helped validate a CB2-mediated regulation of 
atherosclerotic plaque formation also provided evidence of reduced T1-helper response 
and blockade of macrophage migration to the site, both of which contribute to early 
development processes in atherosclerosis. Further evidence to implicate CB2 as the prime 
target arose from an in vivo murine model of established atherosclerosis and in vitro 
macrophage migration. These data, which show that peritoneal macrophages isolated 
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from CB2 knockout mice as well as pretreatment of wild-type macrophages with SR-
144528, did not respond to THC-induced migration.105 Finally, there was evidence 
demonstrating the presence of CB2 receptor expression on the atherosclerotic vessels, at 
the site of plaque formation, but vessels devoid of disease showed no such expression of 
CB2 receptors.
105 Taken in totality, this suggests CB2-selective agonists may be a 
desirable therapeutic agent in the treatment and/or prevention of atherosclerosis; 
however, there is a need for more in vivo work of this hypothesis before any definitive 
answer regarding the vitality of this as a treatment option. 
1.3.2. Cannabinoids in cancer 
1.3.2.1. Cancer rates in The United States of America. Cancer is an 
all-encompassing disease state, and it is as this cohort that it becomes the second leading 
killer of persons in The United States of America. Under this auspice, there are many 
subtypes of cancer to consider, and treatment modalities differ among them. The most 
recent compiled data from The American Cancer Society (2009) shows that among men 
and women, lung & bronchus cancer (Section 1.3.2.2) is the leading type of cancer for 
both groups – approximately 61 deaths per 100,000 males and approximately 40 deaths 
per 100,000 females. Looking specifically at the gender-related cancers, prostate cancer 
(Section 1.3.2.3) is the second highest killer of men at approximately 22 deaths per 
100,000 males, and breast cancer (Section 1.3.2.4) ranks second amongst women at 
approximately 22 deaths per 100,000 females. The pathogenesis of each cancer is far 
more complex and involved of a process to cover in detail within this document. 
However, the crux of any cancer is that cells lose their normal apoptotic signaling and 
persist at an abnormal rate of cell division, eventually entering into lymphatic circulation 
and metastasizing to distant sites and causing similar hyperproliferative growths. 
1.3.2.2. Cannabinoids in lung and bronchial cancers. Being the leading type of 
cancer in The U.S.A. for both men and women, it is logical that we begin the examination 
of cannabinoids in cancer with lung and bronchial cancers. Within lung and bronchial 
cancers, there are several subtypes still, with non-small cell lung cancer (NSCLC) being 
the most prevalent subtype.107 In NSCLC, CB1 and CB2 receptors are overexpressed 
24% and 55%, respectively, of the cases studied.108 There exists several reports that 
point to EGFR hyperexpression and hyperactivation, which promotes resistance of lung 
cancer to current mainstays of chemotherapy. Given, too, that there is known cross-talk 
of GPCRs and EGFR, where GPCRs transactivate EGFRs,109 use of CB1 and/or CB2 
agents to inhibit the untoward effects of EGFR may present therapeutically viable option. 
This EGFR effect has seen positive results in vitro with WIN-55,212-2, a non-selective 
cannabinoid receptor agonist, significantly impeding the growth of A549 cancer cells by 
60-70%.108 The CB2-selective agonist JWH-015 also reduced cell viability by 40-
50%.108 
On the converse of this data lies a much more dubious section of data. In some 
studies, THC at low doses (100 – 300 nM) demonstrated a pro-proliferative action in 
NCI-H292 cells via cross-talk between cannabinoid receptors and EGFR; however, this 
same study showed that µM concentrations of THC demonstrated anti-proliferative 
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action.110 Another similar study demonstrated the upregulation of Ki67, a pro-
proliferative marker, in the lungs of chronic smokers of marijuana.111 It is important to 
note that in both of these cases, the pro-proliferative effects occur with either smoked 
marijuana or at levels achievable by smoking marijuana. That is to say, when smoked, 
Cannabis sativa delivers a very small amount of THC with each dose, and that this 
method of drug delivery is not the most viable option. To discount entirely the use of 
THC and/or its derivatives from this data is not prudent – it merely highlights and 
emphasizes the need for more selective, potent agents with an optimized dosage route for 
lung and bronchial cancers. 
1.3.2.3. Cannabinoids in prostate cancer. The second leading cause of cancer-
related death among men is prostate cancer. With a 1 in 6 chance of developing this 
cancer over the course of a male’s life,107 it becomes of great importance to identify not 
only preventative measures but treatment options to positively impact persons afflicted 
with this disease state. In a pair of studies conducted by Sánchez, et. al. 50 nM doses of 
THC caused a small, but statistically significant increase in the proliferation of LNCaP 
and PC3 cells – an action mimicked by 2-arachidonoylglycerol (2-AG) but opposed by 
anandamide.112,113 Further just-cause for the use of cannabinoids in prostate cancer is that 
other groups have demonstrated that doses of anandamide above 2 µM have shown an 
anti-proliferative effect in PC3, LNCaP and DU145 cells, while 2-AG was pro-
proliferative at the same concentrations.114,115 Similar to the process noted with THC in 
lung and bronchial cancer, it could be due to a dose and/or receptor affinity issue, as 
anandamide is a full agonist at both CB1 and CB2, whereas THC is only a partial agonist 
at both and 2-AG is a full agonist with a higher CB1 selectivity. Thus, my hypothesis 
would be that an effective cannabinoid in prostate cancer would be a potent, full agonist 
of CB1 and CB2, with little or no specificity. However, due to the untoward effects of 
central CB1 agonist, we would desire a peripherally administered and restricted 
compound. Overall, there is viability for cannabinoids in prostate cancer, and an area that 
will hopefully see a burgeoning of data in the near future. 
1.3.2.4. Cannabinoids in breast cancer. As prostate was the second leading 
killer of men, breast cancer is the second leading killer of women, with a similar rate of 
occurrence at 1 in 8 women.107 Equilibrium predominates in breast cancer, with 
conflicting reports of THC being pro- or anti-proliferative. Some studies in MCF-7 cells 
have demonstrated Δ9-THC as a pro-proliferative agent, up to 5 µM;116,117 however, this 
was contradicted by another group with the same cell line – showing that up to 1 mM, 
THC did not promote proliferation but did block 17β-estradiol-induced proliferation.118 
Studies in MDA-MB-231 cells have also yielded a dichotomy of data, with some reports 
of THC being pro-proliferative116 and others showing inhibition of growth in this cells 
line.119 Data also exists from McAllister, et. al. of anti-proliferative effects of THC in 
MDA-MB-468 and EVSA-T cells.119 
In vivo models of breast cancer show an equally confusing gamut of data. A 
xenotransplant of 4T1 paw cells into BALB/c mice saw an increase in tumor burden with 
25 mg/kg of THC injected IP for 21 days.116 A separate model of MMTV-neu mice, 
which spontaneously develop mammary tumors, saw a reduction of not only tumor 
burden but also a decrease in the rate and extent of metastasis to the lungs.120 Overall, as 
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is the case with cancer, data is conflicting and varies widely in the literature. This could 
be simply due to differences in in vitro or in vivo model systems, the drugs utilized, the 
dosage forms or even the cancers themselves. Moreover, there is positive data regarding 
cannabinoids, which would suggest pursuit of cannabinoids in breast cancer to be a 
fruitful endeavor, and one that commands a spot on the research docket. 
1.3.3. Cannabinoids in stroke 
1.3.3.1. Pathogenesis of stroke. The two major mechanisms causing brain 
damage in stroke are ischemia and hemorrhage. Ischemic stroke, which represents about 
80% of all strokes, results from decreased or absent circulating blood which, in-turn 
deprives neurons of life-sustaining substrates. The effects of ischemia are fairly rapid 
because the brain does not store glucose, the chief energy substrate, and is incapable of 
anaerobic metabolism.121 Non-traumatic intracerebral hemorrhage represents 
approximately 10% to 15% of all strokes. Intracerebral hemorrhage originates from deep 
penetrating vessels and causes injury to brain tissue by disrupting connecting pathways 
and causing localized pressure injury. In either case, destructive biochemical substances 
released from a variety of sources play an important role in tissue destruction. 
Formation of microscopic thrombi responsible for impairment of microcirculation 
in the cerebral arterioles and capillaries is a complex phenomenon. Formation of a micro 
thrombus results from ischemia-induced activation of destructive vasoactive enzymes 
released by endothelium, leucocytes, platelets and other neuronal cells. Mechanical 
“plugging” by leucocytes, erythrocytes, platelets and fibrin ensues.122 
Inflammatory response to tissue injury initiated by the rapid production of many 
different inflammatory mediators, tumor necrosis factor (TNF) being one of the key 
agents, activation of microglia and adhesion and migration of peripheral leukocytes.123 
Leukocyte recruitment to the ischemic areas occurs as early as thirty minutes after 
ischemia and reperfusion. In addition to contributing to mechanical obstruction of 
microcirculation, the leucocytes also activate vasoactive substances such as oxygen free 
radicals, arachidonic acid metabolites (cytokines), and nitric acid. The cellular effects of 
these mediators include vasodilatation, vasoconstriction, increased permeability, 
increased platelets aggregation, increased leukocyte adherence to the endothelial wall, 
and immunoregulation. It is through modulation of this inflammatory process that the 
utility of cannabinoids in stroke find their foothold as a therapeutic option. 
1.3.3.2. Cannabinoids as anti-inflammatory agents post-stroke. There are 
several reports of the endocannabinoids, anandamide and 2-AG, released locally 
following neuronal damage to influence the inflammatory and cell differentiation 
processes.7,124 Of particular interest, in conjunction with this release is evidence of CB1 
expression on T-lymphocytes, which may result from endocannabinoid stimulation.125-129 
This helps to bolster the proposed mechanism of anandamide, which is in abundance near 
the infarcted brain area, locally inhibiting T-lymphocyte proliferation.130 While this 
function of CB1 is undoubtedly important, the lion’s share of cannabinoid work as anti-
inflammatory agents post-stroke is through CB2. 
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CB2 has long been known to be expressed on immune organs such as the thymus 
and spleen,53 as well as circulating inflammatory cells such as T-lymphocytes, 
B-lymphocytes, NK cells, monocytes and neutrophils;59,131,132 however, the more recent 
confirmation of CB2 on astrocytes,
133 microglia,134 neural subpopulations and 
oligodendroglial progenitors135 points to a more direct regulation of CB2 in these brain 
inflammatory cells.136 In microglial cells, the level of CB2 expression is highly dependent 
upon the activation state of the cell as it is responding to inflammation, infection or 
stress.7,137 It is during the early inflammatory activation phase where CB1 and CB2 show 
their highest levels of upregulation,7,138-140 thus early treatment, within 90 minutes of 
symptom onset, of the post-ischemic attack is preferred for optimal outcome. In fact, use 
of JWH-133, a CB2-selective agonist, demonstrated not only a reduction of microglial 
activation and inflammatory gene expression in a mouse middle cerebral artery occlusion 
and focal cerebral ischemia model but an improvement of brain infarction size and 
clinical outcomes.141 Confirmation of this mechanism bears itself out in CB2 knockout 
mice, where infarct size is considerably larger in the knockout mice as compared to the 
wild type.142 
A final component of cannabinoids in the inflammatory process of ischemia could 
be via impact of the CD4+ and CD25+ T cells, as they data suggests they to play a role in 
neuroprotection of mice after focal cerebral ischemia.143,144 The cannabinoid mechanism 
in these cells may be due to agonist’s ability to affect proliferation, polarization7,145 
and/or cytolytic capacity146 of the T cells. Studies have helped to confirm this action, with 
WIN-55,212-2 showing favor toward lymphocyte migration within the spleen147 and 2-
AG greatly minimizing mitogen-induced proliferation of mouse splenocytes.148 While 
this data provides positive news for the use of cannabinoids as anti-inflammatory agents 
following a stroke, contrasting data from in vitro and in vivo models persist and pose a 
problem for future therapeutic use of cannabinoid agents. 
1.3.3.3. Cannabinoids as anti-ischemic agents post-stroke. The ischemic 
process of neuronal cell death is due to the cascade of events during the first few hours 
after the onset of ischemia. In these early hours, reactive oxygen species (ROS), calcium 
(Ca+2) and sodium (Na+) increase in the cytosol and are directly proportional to necrosis 
and apoptosis of neurons.149 The increase in Ca+2 occurs via NMDA-medicated pathways 
and is due to a lack of oxygen and glucose during the ischemic attack.150 Given that 
blockade of the Ca+2 channels is associated with neural protection, Ca+2 represents a 
pivotal target in modifying the progression of neuronal cell death during ischemia.151 
As is the case in several facets of cannabinoid research, we do not yet fully know 
the exact mechanisms for neuroprotection of the endocannabinoids and synthetic 
cannabinoids, and data conflict in some aspects. For example, some groups report that 
CB1 agonist activity is the means to neural protection,
152 while others have used 
SR-141716A, a known CB1 inverse agonist, to show the same neuroprotective action via 
a TPVR1-mediated pathway.
153 Some things are quite clear, though, with regard to 
cannabinoid actions on ischemic neurons.  
One such known is that activation of CB1 causes propagation of several 
pro-survival pathways involving mitogen-activated protein kinase (MAPK) kinase 1/2 
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(MEK1/2), extracellular signal-regulated kinase (ERK1/2) and nuclear factor-kappa B 
(NFκB).154,155 In addition to potential for initiating pro-survival pathways, amelioration of 
both global and regional blood flow was observed with low and high doses of THC in 
humans;156 however, more recent studies have shown a potential link between chronic 
cannabis use in a youth and recurrent ischemic stroke.157 An even more recent, 
prospective study of 48 young adults with prior ischemic stroke demonstrated multifocal 
intracranial artery stenosis in those with cannabis consumption.158  
While this may seem daunting news for use of cannabinoids in the ischemic 
stroke setting, it is not a mutually exclusive issue. Keeping this in perspective, the human 
studies are utilizing dried and smoked cannabis, of which THC is the main cannabinoid 
present, and as previously addressed, THC is a poor agent in many of the disease states 
examined. In addition, smoking cannabis could by its own volition, put the person in a 
hypoxic state – albeit for a brief period, but this is not a clinically insignificant variable to 
take into account when dealing with ischemic stroke. Finally, these studies need more 
refinement in terms of selective CB1 and CB2 agents, testing the gamut of activity from 
agonist to antagonist to inverse agonist before making any definitive conclusions about 
cannabinoid use in this disease state. 
1.3.4. Cannabinoids in Alzheimer’s Disease 
1.3.4.1. Background of Alzheimer’s Disease. Alzheimer’s Disease (AD) is 
becoming more and more prevalent a disease as we have an increasingly aged population 
and this is an age-related disease. AD is hallmarked with a progressive loss of cognition 
and memory, and is the most common form of dementia among the elderly.159 
Pathological characterization of AD shows neurofibrillary tangles, amyloid-beta (Aβ) 
plaques and degradation of the synapses, which causes a loss of neurons specifically in 
the hippocampus and neighboring areas of the cerebral cortex. Evidence also exists to 
implicate a sustained activation of microglia in the plaque-bearing areas, causing an area 
of inflammation160,161 and oxidative stress.162,163 
1.3.4.2. Cannabinoids in Alzheimer’s Disease. The previously known high level 
of CB1 in the hippocampal and cerebral cortex regions of the brain
164 gave cursory 
probability of endocannabinoid involvement in the disease progression and pathogenesis. 
The microglial cells in the plaque-bearing areas have an increase in CB1 and CB2 
expression,165 while hippocampal and basal ganglia CB1 expression overall is reduced in 
AD.165,166 Despite their high expression in the plaque regions of the brain, cannabinoid 
receptors are nitrosylated,165 which functionally impairs the GPCRs by altering 
cannabinoid coupling to G-proteins. One final aspect of cannabinoid involvement is the 
increase of FAAH within astrocytes associated with the plaques.167 As FAAH is 
responsible for metabolizing anandamide and 2-AG, this suggests that endocannabinoids 
are involved in the plaque-formation process. 
There has been a good amount of pre-clinical data, which suggests that 
cannabinoid use is associated with positive outcomes in some of the neuropathological 
hallmarks of AD.165 One such study demonstrated an increase in 2-AG pursuant to Aβ-
induced hippocampal damage, which points to this endocannabinoid being 
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neuroprotective.168 Another process important to the neurodegenerative process of AD, as 
it was in stroke, is the increase in Ca+2 influx which leads to neuronal damage. Currently, 
the FDA has approved memantadine for use in AD, and it works as an antagonist of the 
NMDA receptor to limit Ca+2 influx into the neuron to slow disease progression. Similar 
to memantadine, HU-211 – a synthetic, “unnatural” enantiomer of HU-210 – works as a 
selective NMDA receptor inhibitor and consequently helps to protect neurons from 
degradation.169,170 As AD is a very complex process, this potential crossover is but one of 
many ways in which cannabinoids can find usefulness. 
Another possible mechanism of neural protection for cannabinoids is 
demonstrated when CB2 is selectively stimulated, which leads to suppression of microglia 
activity and thus a decrease in the production of TNF-α and nitric oxide.171 Another study 
of WIN-55,212-2 and HU-210 demonstrated a similar decrease in microglia activation 
and TNF-α release.165 Conclusions from these studies strongly point to the hypothesis 
that CB2 overexpression in this instance is a marker and mechanism for neural protection. 
Another potential agent for use is cannabidiol, which has shown efficacy in blocking 
glutamate-induced excitotocicity,172 reduction of proinflammatory mediators,173 
scavenging of reactive oxygen species to reduce lipid peroxidation174 and inhibition of 
tau protein hyperphosphorylation – an additional AD neuropathological feature.175 
While there is currently nothing available for patients suffering from AD to 
completely halt or reverse the progression of the disease, cannabinoids provide a potent 
agent that can augment and mirror current therapies on the market. Developing 
cannabinoids to halt the process of neurodegeneration, or delay it much more than current 
therapies available, remains an ever-present goal of research in this field. Cannabinoids 
have already found a place in AD treatment by combatting the severe aggression that 
accompanies the latter stages of the disease.176 Overall, AD is another exciting and useful 
arena for cannabinoid use and research. 
1.3.5. Cannabinoids in diabetes 
1.3.5.1. Endocannabinoids’ control of metabolism. There exists data which 
show a correlation betwixt endocannabinoids and leptin, an adipocyte-derived signaling 
hormone which are proportional to the fed/satiated state of the animal (i.e. the more well-
fed and satiated the animal, the higher the leptin levels). Leptin’s relationship to 
endocannabinoids seems to be inversely related. Studies demonstrate an increase in 
endocannabinoids in the hypothalamus of food-deprived rats177 – specifically 2-AG levels 
after a 24 hour fast.178 The latter of these studies, conducted by Hanus et al., extend the 
animals out for 12 days of semi starvation and show a direct, negative correlation to 2-
AG concentrations and the duration of starvation.178 Taken together, one may conclude 
that in the acute phase 2-AG levels rise; however, they eventually decline in a prolonged 
fasting state due to lack of biosynthesis, thus perpetuating the cycle of maintaining a 
fasted state – as in anorexia. Another study shows the more direct effect of leptin on 
reducing anandamide and 2-AG in the hypothalamus.179 As a whole, endocannabinoids 
show themselves as potential co-regulators for metabolism and the drive for satiety. 
To that point, a variety of tissues regulates endocannabinoids, especially in the 
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visceral periphery. The duodenum, in periods of food deprivation, increases the local 
levels of anandamide and 2-AG – hypothetically, to act upon sensory and vagal nerves of 
the brain stem and regulate satiety.180,181 As with any hormone system, strict regulation of 
the endocannabinoid system in adipose tissue must occur. PPAR-γ stimulation can inhibit 
2-AG in mature 3t3 F442A mouse adipocytes,182 and decreases CB1 expression and 
increases FAAH expression in human adipocytes.183 This data would suggest CB1 
receptors are involved in the early differentiation of adipocytes, possibly upstream of 
PPAR-γ, and is subsequently down regulated once PPAR-γ is at its peak and 
differentiation is complete. Concomitantly, PPAR-δ – itself activated via physical 
exertion – inhibits CB1 receptor expression.184 Lastly, there exists an inverse relationship 
among both insulin and leptin and endocannabinoid levels,182,185 which may augment 
FAAH expression.186 
The sustained increase in either endocannabinoids or CB1, or both, in several 
peripheral organs and tissues of obese or hyperglycemic animals has gained widespread 
acceptance. Further, data indicate an increase of endocannabinoids in adipocytes and β-
cells.182 The effect upon 2-AG, appears to be a PPAR-γ-mediated effect on the 
biosynthesis of 2-AG from mature hypertrophic adipocytes.182 In both diet-induced obese 
(DIO) mice and Zucker rats, compared to lean, age-matched animals, endocannabinoids 
are starkly decreased in subcutaneous fat,180,187 this data may then indicate that in obese 
and/or hyperglycemic rodents there is clearly a hypoactive endocannabinoid system in 
the adipose store, whereas in the mesenteric fat of DIO mice endocannabinoid levels are 
unaltered.187 
1.3.5.2. Endocannabinoids in type-2 diabetes and metabolic disorders. As 
previously mentioned, the endocannabinoid system plays an integral role in regulating the 
metabolic processes of the body, and its reach extends to many different organ systems. 
One such example demonstrates how CB1 receptors of hypertrophic adipocytes, when 
subjected to constant agonist activity, suppress adiponectin expression182,188 – helping to 
explain why a CB1 antagonist raises adiponectin in adipocytes in obese mice more readily 
than lean mice;189 and how CB1 antagonists restore the lean phenotype to the expression 
of adiponectin-depending genes in the adipose tissue of DIO mice.190 This information, 
coupled with the known protective role of adiponectin against insulin resistance and 
atherogenic inflammation, may lead one to believe that blockade of the endocannabinoid 
system is the key to mitigating obesity and thusly insulin resistance and atherogenic 
inflammation. However, as with many hormone systems – endocannabinoids, included – 
ubiquitous and totalitarian control may result in untoward effects. Though, recent data do 
show CB1 playing a key role in the loss of visceral fat and the enhancement of 
thermogenesis in subcutaneous fat.191 
Mitigation of fat accumulation and type is but one of several factors that play into 
metabolic disorders and into type-2 diabetes. Another hallmark of type-2 diabetes is the 
hyperinsulinemia resulting from insulin resistance. CB1 stimulation has been shown to 
augment basal insulin release by β-cells,182,187,192 which may result in β-cell hypertrophy 
and subsequent dysfunction, perpetuating the development of type-2 diabetes.  A more 
recent study demonstrated that rimonabant (SR-141716A) decreases basal insulin 
hypersecretion in Zucker diabetic rat isolated pancreatic islets, without affecting the 
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glucose-stimulated insulin secretion.193 Coupled with this CB1 overstimulation-induced 
β-cell damage, hyperactive CB1 receptors in the liver of the mouse may be a root cause of 
insulin resistance and hepatosteatosis.194 Lastly, the paramount characteristic of type-2 
diabetes is the resistance of peripheral tissues, especially skeletal muscle, to insulin. 
Blockade of CB1 ameliorates this trait and increases glucose uptake and AMP kinase 
expression of skeletal muscle.195,196 
As one can plainly see, dysregulation of the endocannabinoid system, more 
specifically the over activity thereof, shows strong ties to the development of metabolic 
syndrome and subsequently or concomitantly type-2 diabetes. A trio of studies involving 
rimonabant in Zucker rats further demonstrated this correlation. The first gave indication 
that with oral treatment of rimonabant at 30 mg/kg the presence of hepatic steatosis and 
other related metabolic syndrome features were eradicated.197 Further, this study showed 
an improvement of hepatomegaly and markers associated with hepatic damage.197 
Finally, this study there was a noted improvement in blood lipids toward a more normal 
and healthy state.197 Most notable from this study is that this was shown via pair-fed 
controls that the effect was not merely a result of diet, alone. The second study 
demonstrated the utility of rimonabant in attenuating the morality and chronic renal 
failure seen in obesity and long-term diabetes, again as compared to pair-fed but 
untreated rats.198 The study further demonstrated a sustained lowering of body weight, 
transient hypophagia, increased adiponectin and a confirmation of the first study’s 
rectification of dyslipidemia.198 The third study sought to examine the inflammation 
component, and in so doing demonstrated that rimonabant could successfully lower the 
neutrophil and macrophage levels in obese Zucker rats as a model for both glucose 
intolerance and metabolic syndrome.198 As in the previous 2 studies, rimonabant 
successfully attenuated eating, rectified dyslipidemia and decreased atherosclerotic 
lesions.198 This study did take the data a step further to show a decrease in 
proinflammatory cytokines MCP-1 and interleukin-12 (IL-12).198 As a constellation, 
these studies and data point to the potential of the peripheral, rather than the central, 
endocannabinoid system as being a viable target for the treatment of obesity-related 
disease states. 
1.3.5.3. Endocannabinoids in abdominal obesity and hyperglycemia. There is 
no denying that there is a positive correlation between elevated intra-abdominal obesity 
and type-2 diabetes – given, too, the further direct correlation to an increase in 
atherogenic inflammation and an increase in cardiovascular events.199 As previously 
discussed, the endocannabinoid system lends itself to regulation and differentiation of 
adipose tissue when left unchecked. It has been demonstrated that 2-AG, but not 
anandamide, is increased in visceral, but not subcutaneous, fat;182 an increase in CB1 
expression and endocannabinoid turnover (i.e. increased biosynthetic and degradation 
enzyme expression) in obese individuals;183 and a decrease in endocannabinoid synthesis 
in subcutaneous fat.187 More recently, an observation of the subcutaneous fat of obese, 
type-2 diabetes patients demonstrates a ubiquitous lowering of endocannabinoid tone.200 
These data point to the very real and very serious potential for a dysregulated 
endocannabinoid system to cause an increase in abdominal fat deposit in lieu of 
subcutaneous fat – promoting an increase in the cardiometabolic risks for patients. 
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Further adding to the positive association of the endocannabinoid system, intra-
abdominal obesity and type-2 diabetes, a direct relationship has been shown between 
intra-abdominal obesity and circulating 2-AG.201,202 It was through these studies that a 
more direct correlation between intra-abdominal fat and circulating 2-AG manifest as 
cardiometabolic risk factors – such as low HDL, high triglycerides, low insulin 
sensitivity, glucose intolerance201 and decreased plasma adiponectin.202 Further causal 
link between hyperglycemia and increased 2-AG was observed even in non-obese 
individuals182 – giving more credential to a dysregulated endocannabinoid system as an 
independent risk factor in type-2 diabetes. This was echoed by a prospective, though 
small, study of viscerally obese men who underwent 12 months of therapeutic lifestyle 
changes to dietary habits and physical activity. The results showed an across-the-board 
reduction in not only body mass and fat composition, but a stark decrease in 2-AG 
levels.203 Further, the data showed an inverse correlation between 2-AG and HDL levels 
along with a direct correlation between 2-AG and insulin resistance.203 On its surface, 
this data suggests 2-AG as the culpable target; however, one must be mindful of the fact 
that endocannabinoids are not generally hormone-like in traditional function, so further 
study is needed to determine if 2-AG is secondary to increased peripheral production – 
especially in obesity. 
1.3.5.4. Use of CB1 antagonists and inverse agonists in type-2 diabetes. The 
central tenant in the management of type-2 diabetes is and will forever remain therapeutic 
lifestyle changes such as improved dietary habits and increased physical activity; 
however, there is always the desire to augment these changes to improve outcomes for 
patients. For a time, rimonabant showed great promise as this agent – successfully 
completing four (4) phase III and two (2) phase IIIB clinical trials204-207 and approved for 
use in the EU on June 21, 2006. Its success was short-lived, though, as it the European 
Medicines agency pulled the drug from the market on October 23, 2008 over concerns of 
serious psychiatric problems and even suicide. It was not until January 16, 2009 that the 
European Medicines Agency formally and completely withdrew its approval. Other 
potential agents, such as Merck’s taranabant208-210 and Pfizer’s otenabant211,212 have 
ceased to continue with clinical trial because of similar problems arising during clinical 
trial. 
These drugs are worth mentioning, because during their initial investigation they 
showed great promise themselves and provide valuable insight into the potential of 
cannabinergic drugs’ utility in this arena. The rimonabant in obesity (RIO) trials 
demonstrated rimonabant’s utility in reducing not only food intake but also the signs, 
symptoms and complications of metabolic syndrome.213 Expansion of these trials into the 
RIO-diabetes trial showed the beneficial effects of current standard treatment with 
rimonabant in not only improving body composition but regulating and stabilizing 
glucose control.205 Further, the ARPEGGIO trial began to expose the weaknesses of 
rimonabant, highlighting the increase in anxiety and depression (both with 14% 
occurrence) among the treatment groups. The SERENADE study showed an increase in 
both anxiety and depression, though with less frequency (5.8%) than ARPEGGIO. The 
untoward psychotropic effects, which have long plagued cannabinoid therapies, would 
lead to the downfall of rimonabant, and unfortunately the entire class, both in 
development as well as deployment. 
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As is the case with many new drug classes, there are zeniths and nadirs to contend 
with, and with the current explosion and interest in cannabinoids, we are only now 
beginning to understand this intricately woven and tightly controlled system. As one can 
see from this brief presentation, cannabinoids present a very viable target for use in 
controlling metabolic syndrome and type-2 diabetes; however, there needs to be more 
study on separation of the beneficial and untoward effects. There are efforts underway to 
peripherally restrict cannabinoids,214 but the possibility exists that compounds may be 
synthesized which could specifically exert beneficial effects without the need to be 
restricted to one compartment or the other. Given all of the aforementioned potential for 
cannabinoids and the relatively limited amount of understanding we have for this system, 
I think we have only just begun to see the utility of these compounds and how we can 
develop and use them to benefit and impact a variety of disease states, type-2 diabetes 
being one of many. 
1.4. Goals of the Current Project 
Knowing now how positively one may influence some of the top disease states of 
people via cannabinoids, this project takes on a great deal of merit. This project seeks to 
develop a more guided approach to the design of cannabinoid agents. This begins with 
the validation and refinement of an assay to ascertain functional activity (Chapter 2). 
Then, detailed look at current knowledge of structural pharmacophore data at the C-3 
position of classical cannabinoids, and an exploration of a novel series of C-3-modified 
classical cannabinoids (Chapter 3). Building from the success of the C-3-modified 
classical cannabinoids, I examine the effects on functional activity resulting from the 
modification of the classical benzchromene core (Chapter 4). Considering all previous 
data, I will examine the hybridization of non-classical and classical features to result in 
another novel triaryl class of cannabinoids (Chapter 5). Finally, taking into account the 
current literature and body of evidence for modelling CB1 and CB2, coupling that with 
my own rudimentary modelling and functional data, a rough functional pharmacophore 
was developed to guide future design (Chapter 6). 
As one can see, cannabinoids have a wide-ranging and potentially blockbuster 
impact to healthcare and treatment of disease states. This project seeks to gain more 
knowledge and insight into the function of novel cannabinergic agents synthesized in our 
lab. Through this work, knowledge is generated to elucidate which, if any, components of 
classical and triaryl-core cannabinoids can result in agonist, antagonist, inverse agonist or 
a mixture thereof, as defined by the cubic ternary complex model. Within this model for 
GPCR functional activity, there is an augmentation of the extended ternary complex 
model. Inherent in both of these models is the specificity of certain drugs for a particular 
state. The first assumption made is that the receptor is in equilibrium with an active and 
inactive state (i.e. ready to signal downstream or not). Agonists of this model target the 
active state, and thus shift the equilibrium toward the active state of the receptor. Inverse 
agonists target the inactive conformation of the receptor, and so the equilibrium shifts 
toward the inactive state. Antagonists do not discriminate nor target a particular 
conformation of the receptor, thus the equilibrium is not changed and the total available 
receptor decreases. The added component to the cubic ternary complex model is that the 
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receptor, in the active or inactive state – ligand bound or unbound – can bind and 
sequester G-proteins into a non-signaling state. This added allocation of thermodynamic 
activity allows for the added activity of an inverse agonist. With this model, inverse 
agonists could bind the inactive state and subsequently sequester G-proteins away from 
signaling pathways. This is actually a noted occurrence with cannabinoids, in particular.40 
Through this project’s documentation, I will demonstrate the unique aspects of 
classical and non-classical cannabinoids which impart equally unique functional activity. 
Seemingly, simple interchanges at the C-1′ position cause a non-classical agent to change 
from an agonist at CB2 to an inverse agonist. Additionally, bioisosteric replacement of a 
carbocyclic ring to a heterocyclic ring in classical cannabinoids cause a similar shift from 
agonist to inverse agonist, and within the heterocyclics, transition from a single to a dual 
heteroatom heterocyclic ring yields inverse agonist at CB1 and CB2, respectively. Taking 
these unique functional activities, along with the theories presented in the cubic ternary 
complex model, I will attempt to reconcile and possibly implicate key residue 
interactions within the CB1 and CB2 ligand-binding pocket, which may result in these 
unique activities. 
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CHAPTER 2. ASSAY DEVELOPMENT FOR THE FUNCTIONAL ACTIVITY 
ANALYSIS OF NOVEL CANNABINERGIC COMPOUNDS 
2.1. Introduction 
As previously discussed, there exists a desire for selectively targeting CB1 and 
CB2 receptors to help maximize therapeutic benefit and minimize negative side effects – 
namely the psychotropic effects of CB1 agonists. Along with that, there is a need and 
desire to know the functional activity of drugs (agonist, antagonist, inverse agonist) to 
help elucidate the downstream effect(s) of a drug. To help ascertain the functional 
activity of cannabinoid drugs, two assays hold the lion’s share of utilization ([35S]-GTPγS 
and β-arrestin); however, I will show the development and utility of a third assay that is 
currently available. 
Far and away the most dominant force in functional activity analysis has been the 
[35S]-GTPγS assay. It is useful in that it allows one to obtain the potency, efficacy and 
antagonist affinity without the need to have downstream amplification for agonist 
compounds.215 While this is unquestionably useful, I believe, there is a deficiency 
inherent within that assay. The deficiency lies in the fact that it is an essentially 
irreversible reaction (in the presence of mM Mg+2)216,217, such that once an agonist binds 
to the receptor being assayed, [35S]-GTPγS binds to the Gα-subunit, forming a 
hydrolysis-resistant Gα-[35S]-GTPγS complex, preventing hydrolysis by the GTPase of 
Gα and mitigating rejoining with the Gβγ-complex subunit. Measurement of activation is 
accomplished by filtering the membrane preparation and counting the radioactivity left 
on the filter(s). This does not mimic more physiologic conditions, whereupon agonist 
binding to the receptor GDP dissociates from and GTP binds to the Gα-subunit, 
eventually being hydrolyzed back to GDP by the GTPase domain of the Gα-subunit and 
allowing the Gα-subunit to rejoin the Gβγ-complex subunit. While the [35S]-GTPγS assay 
is a very sensitive assay, able to detect very minute EC50 values of compounds, its 
irreversible nature may present issues when moving drugs from the bench top into a 
living and dynamic system. Additionally, it has been shown that while the reaction is 
nearly irreversible, cannabinoids show evidence of promoting the dissociation of 
[35S]-GTPγS from Gα,218 thus leaving us with false data for the compounds to be tested. 
Another assay utilized is the PathHunter® β-arrestin assay from DiscoveRx. This 
assay utilizes a fragmented β-galactosidase enzyme to detect GPCR activation. In this 
assay system, a small fragment of the β-galactosidase enzyme is fused to the GPCR of 
interest; the remaining larger fragment of β-galactosidase is co-expressed as an N-
terminal deletion mutant. Upon activation of the GPCR, binding of the small and large 
fragments forms the activated β-galactosidase enzyme. Activation of this enzyme leads to 
stimulation of chemiluminescent dye and subsequent detection on a plate reader. While 
there have been reports of this assay’s use in detecting and qualifying inverse agonists;219 
however, when examining the data presented, it is evident that this assay is not as 
sensitive at detecting inverse agonists relative to agonists. Additionally, nowhere within 
the manufacturer literature nor in various other group’s use of this assay has this been 
shown.220,221 While it does accomplish the aforementioned goal of more closely 
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mimicking physiological conditions by not relying upon an essentially irreversible 
activity, lack of or reduced ability to detect inverse agonist activity makes this a less-
viable candidate. Additionally, while manufacturer data suggests that engineering of the 
GPCR of interest does not alter the binding affinity for substrate, it does impart an added 
variable, which should not be fully discounted in biological assays and renders this assay 
even less desirable. 
A bridging of the gap between a need to mimic physiological conditions and to 
detect inverse agonist activity lies with the ACTOne assay available from Codex 
Biosolutions. This assay utilizes, HEK-293 cells transduced with the GPCR of interest 
along with a proprietary cyclic-nucleotide gated ion (CNG) channel, which opens in 
response to increased intracellular cAMP and allows for the influx of K+, Na+ and Ca++. 
A phosphodiesterase inhibitor (Ro 20-1724) is added to the assay well in excess (25 μM) 
to prevent the degredation of cAMP and allow for its real-time detection via the CNG 
channel activation. Detection of this ion flow results from the presence of an extracellular 
cationic-dependent dye, whose fluorescence shows on a plate reader at 540 nm excitation 
and 590 nm emission. As the extracellular concentration of cations decreases, a result of 
increased intracellular cAMP and subsequent influx of cations via the CNG channel, 
emission detected by the plate reader begins to increase, accordingly. Thus, in the case of 
CB1 and CB2, which are coupled to the inhibitory Gi/o, an agonist of either of these 
receptors will cause a decrease in intracellular cAMP and an increase in extracellular 
cations – this increase of cations complexes the cation-sensitive dye so that it does not 
emit upon excitation. Therefore, the emission detection by the plate reader directly 
correlates to the amount of cAMP produced in each of the wells of a plate – allowing for 
a real-time examination of cAMP levels, without any engineering, alteration or 
complexation of the GPCR of interest. It is for its simplicity, ability to detect agonist, 
antagonists and inverse agonists as well as a reversible, non-engineered GPCR presence 
that this assay found utilization. However, initial conductance of the assay was not 
without its problems, and refinement and optimization was paramount in assuring 
accuracy, consistency and comparability of the data across all drugs and receptor types of 
interest.  
Having selected the ACTOne assay based on the aforementioned parameters, 
conductance of the assay proved to be problematic, with responses and EC50 values for 
well-established cannabinoid compounds waxing and waning from day to day and even 
from plate to plate within the same day’s runs. Given that there are several variables at 
play in such a dynamic assay, I took the time and effort to tease apart the individual 
variables to regulate, stabilize and optimize each step of the assay – ensuring accuracy 
and consistency in the data gathered. I conducted experiments to modify the 
manufacturer recommended procedure (Section 2.2.1) to optimize: cAMP stimulants 
(Section 2.2.2), plating density (Section 2.2.3), plate selection (Section 2.2.4), plating 
environment (Section 2.2.5), pertussis toxin dosing (Section 0) and order of addition 
(Section 2.2.6.2), data analysis (Section 2.2.7) and finally arrived at a streamlined 
procedure (Section 2.3). The data presented herein shows the process of honing the assay 
into a tool useful in the procurement of functional activity of novel series of cannabinoids 
generated by my predecessors in the group. 
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2.2. ACTOne Assay Development 
2.2.1. Manufacturer recommended procedure 
2.2.1.1. Commonalities of ACTOne assay protocols. Overall, the treatment of 
the cells among the 3 assay protocols (CB1, CB2 and HEK-CNG) is the same, with 
growth recommended in DMEM with 10% FBS, 250 μg/mL G418 and 1 μg/mL 
puromycin. Each of the cell types are to be kept at 37⁰C with 5% CO2, and not allowed to 
grow beyond 90% confluence – overgrowth may significantly reduce the cell’s response 
to a ligand and take several passages to regenerate. 
The initial recommendation for cell plating is that one should use a Poly-D-Lysine 
coated plate to facilitate cell adherence, and plate cells the preceding day so that they may 
grow overnight. For the 96-well plate, which is what I used, the manufacturer 
recommends plating 70,000 cells/100 μL/well; however, there is the ever-present caveat 
that one must optimize the cell number for each assay. 
Following the overnight growth at 37⁰C, add ACTOne Membrane Potential Dye 
to each of the wells in the plate at a volume equal to the volume of cell suspension added 
the previous day – 100 μL, in my case. The dye is to dwell for two hours at room 
temperature, in a dark place. In the event a serum-free environment is required, remove 
the media and replace with DPBS containing 0.2% to 0.5% BSA prior to adding the dye. 
The differences among the three protocols prompted an initial hypothesis that the 
assay needed examination with greater scrutiny. The purpose of this examination is to 
maintain consistency across the three protocols so that data obtained from conductance 
thereof is able to be cross-compared and correlated. 
2.2.1.2. CB1-specific parameters of the ACTOne assay. Differences among the 
three assay protocols begin with the agent used to stimulate adenylyl cyclase. In the case 
of the CB1 protocol, the agent of choice is isoproterenol – exerting its effects via the 
constitutively expressed Gs-coupled β-adrenoreceptor stimulation. Initial stock of the 
compound to be tested, adenylyl cyclase stimulant and PDE-inhibitor (Ro 20-1724) are 
prepared at five times the final testing concentrations due to the fact that they will be 
diluted 1:5 when added to the assay plate (50 μL compound stock added to 200 μL of cell 
suspension and membrane potential dye). Consistent in all wells of the assay is Ro 
20-1724 at 25 μM and isoproterenol at 300 nM, final concentrations. The compound of 
interest has its concentration varied from column to column in a given row to obtain a 
dose response curve on a logarithmic scale. 
2.2.1.3. CB2-specific parameters of the ACTOne assay. Similarly to the CB1 
protocol, the final concentration of Ro 20-1724 is 25 μM in each well; however, the 
adenylyl cyclase stimulant is different and at a different concentrations. For the CB2 
protocol, NECA becomes the agent of choice to stimulate adenylyl cyclase via Gs-
coupled adenosine A2b receptors constitutively expressed on HEK293 cells. Final 
concentration of NECA is 250 nM in each of the assay wells. Additionally, in the 
documentation from the manufacturer, CP-55,940, which is the standard I use for 
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non-selective CB-agonists, was at ten times higher concentrations in the CB1 protocol 
tests v. the CB2 protocol tests – though the EC50 for CP-55,940 is 0.2 nM and 0.3 nM for 
CB1 and CB2, respectively, in the literature.
222 
2.2.1.4. Parental, HEK-CNG-specific parameters of the ACTOne assay. For 
the parental cells, since there is no over-expression of our GPCR of interest, this protocol 
is useful in determining the EC50 of the adenylyl cyclase stimulant, as well as confirming 
the Gi/o activity observed is not due to another, constitutively expressed, GPCR of 
HEK293 cells. It is of an interesting note that the manufacturer reports the EC50 of NECA 
in HEK293 cells to be 611 nM; however, as previously mentioned, the CB2 protocol only 
calls for a 250 nM NECA concentration in each of the assay wells.  
2.2.2. Assay stimulus standardization 
Since this assay relies on cAMP as the substrate for CNG channel activation and 
subsequent impact upon the cation-sensitive dye, a reproducible and consistent source of 
adenylyl cyclase induction is essential for continuity of data and analysis. Recommended 
within the manufacturer’s directions is the use of isoproterenol for CB1 cells and NECA 
for both CB2 and parental CNG cells to stimulate cAMP production and subsequent CNG 
channel activation of the cells. However, to maintain more consistency within the assay, 
comparing the three cells lines across multiple plates on multiple days, it was my 
hypothesis that the stimulus should be consistent across all runs in order for the results to 
be deemed comparable and consistent. 
2.2.2.1. Manufacturer recommended cell stimulus. Initially, isoproterenol was 
employed at 50 nM, being >10X the EC50 of isoproterenol at CB1 (CB1 = 2.56 nM; CB2 = 
12.3 nM at 50 minutes after addition) (Figure 2.1). As one can see immediately, the 
response gained from isoproterenol in the CB2 cells was virtually nil at 50 minutes. While 
generally good in the CB1 assay, there was still some inconsistency therein, coupled with 
a waning of the response in the CB2 assay after 10 minutes of the kinetic run time 
(Figure 2.2) isoproterenol lost favor as a truly viable candidate. Considering the next 
manufacturer recommended stimulus, NECA, was tried at 100 nM, being >2X the EC50 
of NECA (CB1 = 40.0 nM; CB2 = 316 nM, 50 minutes after addition) (Figure 2.3). There 
was a glimmer of hope for NECA, inasmuch as providing a nearly equal response, albeit 
at an EC50 ~8X that of CB1; however, these hopes were dashed even at nearly 2X the 
EC50 of NECA at CB2, making this agent not readily cross-comparable (Figure 2.4).  
2.2.2.2. CB1 cAMP stimulant trial. In an effort to maintain a consistent 
stimulation of cAMP production, utilizing the knowledge that manufacturer 
recommended agents were adrenergic agonists, eight adrenergic agonists were screened 
as potentials for the  CB1 assay. The agents are: medetomiodine (α-2 agonist), 
norepinephrine (non-selective α- and β-agonist), clonidine (α-2 agonist), epinephrine 
(non-selective α- and β-agonist), oxymetazoline (non-selective α-agonist), yohimbine (α-2 
antagonist), pseudoephedrine (non-selective α-agonist), isoproterenol (non-selective β-
agonist) and NECA (adenosine receptor agonist). Evaluation of the data is relative, such  
 25 
-1 1 -1 0 -9 -8 -7 -6 -5
0
1 0 0
2 0 0
3 0 0
E C 5 0 =
L o g  [D ru g ]  (M )
A
b
s
o
r
b
a
n
c
e
C B 2
C B 1
2.560e-009
E C 5 0 = 1.230e-008
 
Figure 2.1. Isoproterenol EC50 curve at 50 minutes post-addition 
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Figure 2.2. Isoproterenol-induced cAMP production at 50 nM 
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Figure 2.3. NECA EC50 curve at 50 minutes post-addition 
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Figure 2.4. NECA-induced cAMP production in CB1 and CB2 cells 
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that the highest value on the assay plate corresponds to the highest possible value for all 
of the drugs. This analysis allows for a more direct comparison of the data, to show that 
isoproterenol (EC50 = 14 nM; Lit: 123 nM
223), NECA (EC50 = 147.5 nM; Lit: A1 = 26 
nM,224 A2A = 26.1 nM,
225 A2B = 1400 nM,
226 A3 = 129 nM
227) and epinephrine (EC50 = 
110.5 nM; Lit: 8.2 nM228) will each stimulate cAMP production in the CB1 cells to a 
similar level (Figure 2.5). 
2.2.2.3. CB2 cAMP stimulant trial. Similar to the aforementioned trial of 
agonists in the CB1 cells, evaluation of various adrenergic agonists for the CB2 assay was 
conducted with: norepinephrine (non-selective α- and β-agonist), epinephrine (non-
selective α- and β-agonist), oxymetazoline (non-selective α-agonist), pseudoephedrine 
(non-selective α-agonist), formoterol (β2-selective agonist), isoproterenol (non-selective 
β-agonist), and NECA (adenosine receptor agonist) (Figure 2.6). Data was calculated, as 
it was for the CB1 assay, as a relative effectiveness for each of the drugs. As a result of 
this analysis epinephrine, formoterol, isoproterenol and NECA appear to be potential 
agents for further testing and elucidation of properties; however, as previously discussed 
isoproterenol and NECA have viability and consistency issues with the CB2 assay.  
To fully test the CB2 assay stimulants, these potential stimulants, isoproterenol, 
formoterol, epinephrine and NECA, were tested at their respective literature cited EC50 
(150 nM,223 350 nM, 6 nM228 and 125 nM,227 respectively) and EC90 (2500 nM, 1000 nM, 
1000 nM and 1000 nM, respectively) v. CP-55,940. Data from this study demonstrate that 
NECA, at its EC90, is the only one of the 4 capable of stimulating cAMP production 50 
minutes after addition to the assay plate (Figure 2.7); however, it still shows much 
evidence of variability, and this is not at all desired. 
When examining the two cell lines, it is apparent that the data may not be 
accurately compared using equivalent doses of isoproterenol or NECA (Figure 2.8), nor 
is it possible with any of the additional adrenergic agents tested. For the CB1 cells, a final 
concentration of 50 nM of isoproterenol in each well was enough to elucidate a response 
from the cells; however, this same dose in CB2 cells began to decline only 10 minutes 
after addition to the cells (Figure 2.8). NECA was considered next, and at a final 
concentration of 100 nM in each well for CB1, we again see a nice rise in cAMP 
production that is consistent over the entirety of the 60 minute kinetic run; however, in 
CB2, the same dose of NECA would not elucidate a strong enough response to be 
detectable (Figure 2.8). Given the fact that isoproterenol is inconsistent with respect to 
time between the two assays and NECA is inconsistent with respect to dose, a more 
consistent and directly comparable stimulant of cAMP production was needed to help 
stabilize the cAMP levels in the assay and allow for more accurate cross-comparison. 
Forskolin is a well-known, direct stimulant of adenylyl cyclase in assays 
measuring cAMP production, with a 12µM EC50.
229,230 To apply this to my assay, a 
forskolin dose response curve was conducted to ascertain the dose necessary for use in 
both the CB1 and CB2 assays. In both the CB1 and CB2 assays, the dose response was 
quite stark as the dose was increased, with an EC50 of 112 nM and 164 nM for CB1 and 
CB2, respectively and an EC90 of 292 nM and 296 nM for CB1 and CB2, respectively 
(Figure 2.9). The EC50 and EC90 values in both CB1 and CB2 are quite close and both 
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Figure 2.5. CB1 adrenergic drug test for stimulation of cAMP production 
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Figure 2.6. CB2 adrenergic drug test for stimulation of cAMP production 
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Figure 2.7. Selected adrenergic drugs in CB2 cells vs. CP-55,940 
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Figure 2.8. Manufacturer-recommended cAMP stimulants 
Notes: Isoproterenol is 50 nM and NECA is 100 nM for both CB1 and CB2. 
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Figure 2.9. Forskolin as a cAMP stimulant in CB1 and CB2 cells 
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achieved and held at or near maximum response within 20 minutes in both CB1 and CB2 
(Figure 2.10). Given that there was not an appreciable difference  in response of CB1 or 
CB2 cells between 1 μM and the approximate EC90 for both (300 nM), 800 nM was 
chosen as the final concentration of forskolin to use in each well of the assay across all 
three cell lines. Comparing equivalent (500 nM) concentrations of isoproterenol, NECA 
and forskolin between the CB1 and CB2 cells (Figure 2.11), we see clear evidence that 
any of the three cAMP stimulants work well in CB1. However, at CB2, isoproterenol 
starts to wane after only 10 minutes, NECA, while comparable to forskolin, does not 
have the sustained plateau and consistency needed to assure reliability within this assay. 
2.2.3. Cell plating density test 
Having now ascertained which stimulus to utilize in order to induce cAMP 
production, the next pertinent parameter to address is that of plating density. To test for 
activity with each of the varying cell densities, with constant levels of forskolin to serve 
as the stimulus for cAMP production, I selected two non-selective cannabinoid agonists 
(CP-55,940 and WIN-55,212-2), a CB2-selective agonist (HU-308), a CB1-selective 
inverse agonist (SR-141716A) and a CB2-selective inverse agonist (SR-144528). In 
addition, as a point of reference, the manufacturer recommends plating of the cells at 70K 
cells/well, and in a 96-well plate (as I use) there would be 100 μL of cell suspension 
present. 
For the CB1 cells, six plates with densities of 80K cells/well, 70K cells/well, 60K 
cells/well, 50K cells/well, 40K cells/well and 30K cells/well would serve to answer this 
question. Looking at the three agents used in this test (CP-55,940, SR-141716A and 
WIN-55,212-2), it is initially evident that there is not a great deal of difference among the 
varying densities (Figure 2.12). Looking at the EC50 and R
2 values for each of the three 
compounds leaves me with 40K cells/well as the most viable option. This density strikes 
the best balance for all three of the known compounds for EC50 and R
2 value, and this is 
the density utilized for CB1 functional assays for the remainder of the testing. 
For the CB2 cells, six places with densities of 70K cells/well, 60K cells/well, 50K 
cells/well, 40K cells/well, 30K cells/well and 20K cells/well would serve to optimize the 
plating density for CB2 cells. Considering, again, the EC50 and R
2 values for the three 
agents used (CP-55,940, SR-144528 and HU-308), the most viable option becomes 60K 
cells/well (Figure 2.13). Again, this gives us the strongest balance between a good EC50 
of all three compounds with an acceptable, though not perfect, R2 value. Henceforth, 60K 
cells/well will be the density utilized in plating CB2 for functional assay. 
Though there is no optimization for the parental HEK-CNG cells, because it was 
impossible to actually generate a change in cAMP due to the lack of cannabinoid 
receptors, I did institute parameters to provide valid comparisons. Given that the 
constitutively expressed receptors are identical, I deemed it acceptable to take the average 
of CB1 and CB2 plating densities as the plating density for the HEK-CNG cells. Thus, 
50K cells/well was the plating density for the HEK-CNG cell assays conducted as the 
control for all of the compounds tested herein. 
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Figure 2.10. Forskolin response in CB1 and CB2 vs. time 
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Figure 2.11. All viable cAMP stimuli at 500 nM in CB1 and CB2 cells 
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Figure 2.12. CB1 plating density test 
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Figure 2.13. CB2 plating density test 
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2.2.4. Assay plate selection 
 As stated in the manufacturer’s recommendations, cells should be plated 
overnight on Poly-D-Lysine plates; however, cost of Poly-D-Lysine relative to more 
widely available polystyrene plates warranted a test. Plating at identical densities from 
the same batch of cells, I conducted tests of dye mixing times in polystyrene plates to 
compare to the Poly-D-Lysine results previously run at room temperature. Four (4) assay 
plates subjected to 1 hour, 45 minutes, 30 minutes or 15 minutes of dye mixing time in 
polystyrene plates served as the base for this test. Overall, the 1-hour dye mixing time 
was superior, as it was in the Poly-D-Lysine plates; however, there was a notable 
difference in the confluence of the cells in each well with the polystyrene plates. There 
seemed to be a difference in rate of growth, as plating 50,000 cells/well did not achieve 
the same 80-90% confluence that was noted with the Poly-D-Lysine plates. Due to this 
inconsistency of cell growth, the results were not directly comparable to the results of the 
Poly-D-Lysine plates. The decision was to forego the polystyrene plates and utilize the 
Poly-D-Lysine plates to help ensure consistency of results and minimize the number of 
cells needed to achieve confluence.  
2.2.5. Plating environment optimization 
Documentation from Codex Biosolutions states that once the cells are plated there 
is no need to feed them; however, there is a balance that must be stuck between keeping 
the cells viable for assay and not complexing the drugs being assayed, as it is well-known 
that cannabinoids are highly protein bound.231 Normal growth media for the cells is 
DMEM with 10% FBS; 1% P/S; 250 μg/mL G418 and 1 μg/mL puromycin, and is what 
initially was utilized for plating, minus the selection antibiotics of G418 and puromycin. 
The initial test was to see what, if any, difference exists between FBS and BSA and to 
compare different concentrations of the two against one another. Initial concentrations of 
FBS tested were 10%, 5% and 1%. Initial concentrations of BSA tested were 1%, 0.5% 
and 0.25%. In all three of the tested concentrations of BSA there was no discernible 
curve with any of the cAMP production stimulants (epinephrine, formoterol, 
isoproterenol and NECA) tested. Within the FBS concentrations tested, all three were 
comparable; however, 1% FBS did show slightly better across all tested cAMP 
stimulants, so it warranted further testing. 
Using isoproterenol as the cAMP stimulant, FBS at 4 different concentrations 
(1%, 0.75%, 0.5% and 0.25%) were examined. The 1% FBS plate demonstrated 
inconsistency from the previous run, and subsequently lower concentrations of FBS 
proved even more erratic. So, ultimately, the decision was made to continue plating and 
running the assays in DMEM with 10% FBS and 1% P/S. 
2.2.6. Pertussis toxin (PTx) dosing optimization 
In examining CB1 and CB2, which are PTx-sensitive Gi/o-coupled receptors, one 
of the assays necessary to run is a PTx-sensitive Gi/o-inactivation of the coupling of CB1 
or CB2 receptors to Gi/o prior to drug treatment and conductance of the assay. While it is 
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true that the HEK-CNG cells help to rule out the drug effects on any other constitutively 
expressed receptor, it does not validate that the actions are due to CB1 and/or CB2 Gi/o 
GPCR activity. 
2.2.6.1. Duration of PTx pre-treatment. The first question to answer with 
regard to PTx treatment of the cells is how long it is necessary to pretreat the cells. I 
examined two methods when testing this question, both easily fitting into the normal 
procedure for the assay and thus their selection and utility. The first was to add PTx 
directly before the membrane potential dye, which would allow 1 hour of dwell time for 
the PTx prior to drug addition. At all 8 concentrations tested (400 ng/mL, 200 ng/mL, 80 
ng/mL, 40 ng/mL, 20 ng/mL, 8 ng/mL, 4 ng/mL and 0 ng/mL), CP-55,940 was still able 
to exert its full effect of inhibiting forskolin-induced cAMP production (Figure 2.14). 
The next method employed was to add the PTx into the cell suspension reservoir 
at the time of plating and allow the PTx to dwell in the cell suspension overnight, at least 
12 hours prior to drug addition. At all 7 concentrations tested (400 ng/mL, 200 ng/mL, 80 
ng/mL, 40 ng/mL, 20 ng/mL, 8 ng/mL and 4 ng/mL), CP-55,940 was unable to exert its 
full effect of inhibiting forskolin-induced cAMP production (Figure 2.15). Since 
literature precedence had set PTx-sensitive Gi/o-inactivation dosing in a range from 8 
ng/mL to 100 ng/mL, I selected 4 ng/mL to conserve the most resources and still 
maintain a inactivation of Gi/o activity in the assay. Based on these data, I concluded that 
the optimal procedure for PTx-sensitive Gi/o-inactivation is 4 ng/mL with an overnight 
pretreatment. 
To confirm these findings in CB2, the same seven concentrations (400 ng/mL, 200 
ng/mL, 80 ng/mL, 40 ng/mL, 20 ng/mL, 8 ng/mL and 4 ng/mL) of PTx were added to the 
CB2 cells and allowed to sit overnight before screening against CP-55,940. As was the 
case in CB1, CP-55,940 was unable to inhibit forskolin-induced cAMP production across 
the entire spectrum of concentrations tested (Figure 2.16). As a result of this study, and 
to maintain continuity of assay conditions across the cell types, 4 ng/mL was selected as 
the target concentration for future PTx-sensitive Gi/o-inactivation studies of the CB2 cells. 
2.2.6.2. Addition order of PTx treatment. Knowing that 4 ng/mL with an 
overnight dwell time is necessary before inhibition of the Gi/o is achieved, the question 
remained of how to best administer the PTx. This question became relevant due to the 
perception of a lack of cell adhesion to the plates when mixed into the cell suspension. To 
test this, 4 plates: no PTx, PTx in cell suspension, PTx in PBS added at plating and PTx 
in PBS added 2 hours after plating, were tested. The result was that there is no difference 
in how the PTx is added, just that it dwells overnight (Figure 2.17). 
2.2.7. Assay data analysis optimization 
As previously mentioned, readings of the assay plates utilizes a BioTek Synergy 2 
running Gen5 software. GraphPad Prism generates the graphs and non-linear curve fitting 
with EC50 calculations. While the Gen5 software is capable of generating graphs and 
EC50 curves, the manipulation of the data was not as automated and high-throughput as 
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was desired. In addition, extraction of data from Gen5 software and importation into 
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Figure 2.14. CB1 cells with 1 hour pretreatment of PTx vs. CP-55,940 
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Figure 2.15. CB1 cells with overnight PTx pretreatment vs. CP-55,940 
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Figure 2.16. CB2 cells with overnight PTx treatment vs. CP-55,940 
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Figure 2.17. CB2 cells with PTx addition order test 
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GraphPad Prism was a cumbersome and tedious process. Utilizing the “Power Export” 
function of the Gen5 software allowed me to develop custom VBA macros – visual basic 
applications, which allows for user-defined functions and automates processes and 
accessing Windows APIs – for use in Microsoft Excel, which would automate the process 
of data normalization and subsequent importation into and analysis by GraphPad Prism. 
2.2.7.1. GraphPad Prism template building. The initial step in this process was 
to import manually data from one plate of an assay to construct a template in GraphPad 
Prism. The template contains eight XY scatter with single Y value data sheets and graphs. 
Analysis of all eight sheets was accomplished through non-linear regression with the 
built-in “log(agonist) vs. response – Variable slope” equation with automatic outlier 
elimination and an output of a summary EC50 table. After all eight data sheets, results 
sheets and graphs existed, the data tables had their contents removed and the resulting 
shell project saved as a template, with the name “IndividualPlates.” This template resided 
in a subfolder in the directory utilized by Gen5 for data storage and exportation – in this 
case: “C:\Data\Templates\.” 
Since our typical run will be for n = 6 for each drug, there needs to be data 
combined from across six separate plates into one master file for each compound. As 
such, a combined data template was necessary to create. To accomplish this task, a 
project was created such that contained therein was nine XY scatter with 6 replicate Y 
value data sheets and graphs. The data sheets were populated with data and analysis of all 
9 sheets was accomplished through non-linear regression with the built-in “log(agonist) 
vs. response – Variable slope” equation with automatic outlier elimination and an output 
of a summary EC50 table. Following the analysis and subsequent creation of the results 
sheets and population of the graphs, data tables had their contents removed, and the 
resultant shell project saved as a template, with the name “MultiplePlates.” This template 
resides in a subfolder in the directory to be utilized by Gen5 for data storage and 
exportation – in this case: “C:\Data\Templates\.” 
2.2.7.2. Gen5 experiment design. The first task in the design of this experiment 
was to ensure that all data remains in a readily accessible manner for quick retrieval and 
obvious content. Utilizing the parameters of the Gen5 protocol options, I created a 
nomenclature system that automatically generates after the user inputs key, required, data 
at the start of an experiment. A central repository of data, simply “C:\Data\,” came to be 
for this task. Within that folder, a subfolder would be created for the protocol being used 
(CB1 Functional, CB2 Functional or HEK-CNG Functional), i.e. “C:\Data\CB1 
Functional\.” Within the subdivisions of data, further compartmentalization of the 
experiments based on the <Barcode>_<PlateID> fields input by the user at the initial read 
of each plate is implemented. The <Barcode> is the notebook number of the individual 
conducting the assay in the format of “3-letter initials”-“notebook number”-“page in 
notebook”, e.g. BAK-1B-57. The <PlateID> field is the project title for that series of runs 
to make it more readily identifiable as to the contents thereof, e.g. “cAMP Stimulant 
Dose Curves.” With this nomenclature, files would be stored based on the assay run and 
then further segregated by the notebook number, allowing for quick callback to the 
experimental notes, e.g. “C:\Data\CB1 Functional\BAK-1B-57_cAMP Stimulant Dose 
Curves\.” 
 47 
The next task was to ensure that file names followed a similarly intuitive 
nomenclature for ease of reference to the experimental notes in the notebook and the 
obvious contents of each file, were they separated from their parent folder(s). The naming 
scheme is set in the protocol options of each of the 3 protocols being utilized, and follows 
a system similar to that of the folder nomenclature: “<Protocol>_<PlateID> 
(autoenumeration)_<Barcode>_<Date> (YYMMDD).” The <Protocol>, as previously 
mentioned is CB1 Functional, CB2 Functional or HEK-CNG Functional. <PlateID> and 
<Barcode> are the same as previously mentioned. The (autoenumeration) field is a 4 
digit, sequential series of numbers that increases with each run, so that 6 plates with 
identical <Protocol>, <PlateID>, <Barcode> and <Date> will all have unique 
(autoenumeration) values to identify which of the 6 runs it is. Lastly, <Date> is the 
current experiment day’s date; however, in Gen5 you cannot select the format of the date, 
so it always shows as YYMMDD. An example of a filename with full path for the first 
run in a series of 6 would be: “C:\Data\CB1 Functional\BAK-1B-57_cAMP Stimulant 
Dose Curves\CB1 Functional_cAMP Stimulant Dose Curves (0001)_BAK-1B-
57_130516 (YYMMDD).xpt.” This nomenclature system allows for quick reference to 
the notebook, as well as the person responsible for the run and the content of each of the 
files – all aiding in expediting data acquisition and analysis. 
To accomplish the task of making the data acquisition as automated as possible, 
the Gen5 software was customized with a unique experiment design that was copied 
across all three types of cell assays. The first customization was in the sequence of events 
when reading a plate. The sequence for each plate run in these experiments is: 
1. Set Temperature: Set point 25 °C 
2. Read: (F) 540/25,590/20 
3. Pause 
a. Plate In/Out - Plate Out 
b. Popup: “Add DRUG to wells, place plate on reader and then click OK” 
c. Plate In/Out - Plate In 
4. Start Kinetic [Run 1:00:00, Interval 0:01:00] 
a. Read: (F) 540/25,590/20 
5. End Kinetic 
The automation of steps helped to ensure that there was consistency among the days and 
persons running the assays to aid in lack of omission of steps. 
At the completion of the kinetic run, the “Power Export” function was set to 
commence, automatically. This function a Microsoft Excel template that the user may 
customize to output certain parameters of each experimental run. The “Power Export” 
file was named exactly as the experiment from which it was generated, e.g. “C:\Data\CB1 
Functional\BAK-1B-57_cAMP Stimulant Dose Curves\CB1 Functional_cAMP 
Stimulant Dose Curves (0001) BAK-1B-57_130516 (YYMMDD).xlsm.” 
2.2.7.3. Gen5 “Power Export” template building. One of the key components 
in facilitating fast and accurate data analysis was the utilization of the “Power Export” 
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function of Gen5. Properly configured, this generated a Microsoft Excel spreadsheet that 
could perform all necessary data calculations and then automatically import them into 
GraphPad Prism utilizing templates previously mentioned for these experiments. The first 
step in building this template is to ensure that all pertinent data transfers on the 
spreadsheet that exported from Gen5 into Microsoft Excel. To accomplish this, the  
“Read 2” matrix migrated, beginning at cell A1. Beginning at cell A65, I placed the 
“Field Group,” which contained all of the experiment’s nomenclature information, i.e. 
protocol name, plate ID, barcode and reading date/time. Beginning at cell A70, I placed 
the “Well IDs” group, which listed the names of the drugs contained in each well. With 
these fields in place, every time the experiment performs a “Power Export” all of the data 
from Gen5 consistently migrates into a formatted Microsoft Excel spreadsheet. 
With the data now in a more malleable form in Microsoft Excel, it is time to build 
the customized VBA macros that appended to the “Power Export” template inside each 
of the three protocols. Numerous cycles of trial and error, as well as questions asked with 
regard to how best to view the data led to a rough draft of the macro design. Taking this, 
along with how best to normalize/standardize across different plates on different days 
with different receptor types led to the finalized product.  
Primarily, creation of a “Declarations” module is paramount, because this 
facilitates the passage of variables from module to module without having to worry about 
improper nomenclatures or pass through commands. See Supplementary Information 
1.1 for full template code of the Declarations module. 
Next, I created a “switchboard” module that would be responsible for calling all 
of the subsequent modules for data analysis. Through this module all data is packaged, 
normalized to internal standards and importated into GraphPad Prism. See 
Supplementary Information 1.2 for full template code of “Extract” module. 
With this “switchboard” in place, it is time to start examining all of its moving 
parts, beginning with the first call in the process, which is to select the evaluation 
parameters – accomplished via the “CalcType” form. This form contains radio buttons, 
which allow the user to select various analytical parameters for the data, such as the time 
frame, X-axis component, normalization method and calculation method. After the user 
selects one of each of these parameters, the “Run Extraction” button is clicked, causing 
the global options to be updated with the new inputs and control the remainder of the data 
extraction and manipulation process. See Supplementary Information 1.3 for full 
template code of the “CalcType” form module. 
The normalization method chosen, dictates the next VBA function initialized. The 
“NormData” module contains all four of the data normalization methods that I had 
employed at one time or another; however, the one used in the analysis of all the 
forthcoming data was “Norm2.” Wherein the wells with the lowest concentration of drug 
(column 11 on the assay plate) served as the experimental max for that row at any given 
point in time and the “Blank” cells (column 12, rows A and B of the assay plate) serve as 
the experimental minimum. The use of the lowest drug concentration as the experimental 
maximum helped to address the drifting of data, which was noted during the early runs of 
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the assay. The data were then normalized values via Equation 2.1: 
 
𝐴𝑛 + (𝑥 − 𝐴)(𝐵𝑛 − 𝐴𝑛)
𝐵 − 𝐴
 Equation 2.1 
Wherein A = Experimental Basal Response, B = Experimental Maximum Response,  
An = Normalized Minimum Value (0), Bn = Normalized Maximum Value (100) and  
x = raw data value to be normalized. See Supplementary Information 1.4 for full 
template code of the “NormData” module. 
The next parameter manipulated has to do with the time interval of interest. All 
data presented in subsequent chapters utilized the 5 minutes time interval, i.e. values from 
each of the concentrations of drug were examined at every 5 minutes up to 60 minutes. 
However, in some cases it is useful to examine based on the maximum and minimum 
values for the control wells (column 12, rows E and F of the assay plate) to determine the 
optimal time interval. See Supplementary Information 1.5 for full template code of 
“FiveMin” and “ZenNadir” modules. 
Within both the “FiveMin” and “ZenNadir” modules are references to necessary 
information for their completion. The first of which is the concentrations for each of the 
wells in the assay plate. If the file does not exist for this, the VBA code will call a form 
for the user to input the beginning concentration of each row (column 1) for the assay 
plate in nM. After inputting the concentrations in the form and clicking “OK,” VBA code 
runs to translate the nM values into log10 values for use in GraphPad Prism and creates a 
“Concentrations.txt” file so that the values do not have to be re-input by the user for 
subsequent runs of the same plate layout in a day. See Supplementary Information 1.6 
for full template code of the “Concentrations” module. 
As part of the Gen5 experiment setup, the user should input the row names into 
the software; however, in the event that this step goes overlooked, a form will pop up 
during analysis of the data asking the user to input the row names. Upon inputting the 
names and clicking OK, the code runs to create a name file and apply those names to the 
current spreadsheet. See Supplementary Information 1.7 for full template code of the 
“Names” module. 
Following the time, concentration and name executions, it is now time to run the 
appropriate calculation module to refine the data, if need be. All functional data presented 
henceforth will have no additional calculations applied to it beyond the aforementioned 
normalization method. The 6 possible calculation methods are: take only the normalized 
values (the method employed in all forthcoming analysis); to subtract the Ro-containing 
control wells (column 12, rows C and D of the assay plate); to subtract the forskolin-
containing control wells (column 12, rows E and F); to divide by the lowest concentration 
of drug (column 11, same row as data being evaluated and a the same point in time); to 
divide the drug at a given time to that well’s value at time = 0 min; or to divide each drug 
by the forskolin-containing control (column 12, rows E and F). See Supplementary 
Information 1.8 for full template code of the different calculation modules. 
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After any of the calculations are completed, you will notice that there is a call to 
organize the raw data. This is a simple transposition of the data to ready it for importation 
into GraphPad Prism. See Supplementary Information 1.9 for full template code of the 
“Organize” module. With the data now normalized, calculated, organized and ready for 
importation into GraphPad Prism, it is necessary to create individual data sheets that 
GraphPad will use to import into the shelled data sheets that exist in the template. See 
Supplementary Information 1.10 for full template code of the “DataSheets” module. 
After this, the code loops continuously to await completion of the Prism importation. 
After creating the data sheets for each of the 8 drugs on a plate, the VBA macro 
will generate a script to execute when it calls the GraphPad Prism program. See 
Supplementary Information 1.11 for full template code of the “PrismScript” module. 
After the GraphPad Prism script completes its data importation, it creates a “Done.txt” 
file, which is the signal for the all-the-while-looping Microsoft Excel spreadsheet to copy 
itself into the master book, clean up the temporary files and close. I wanted to copy the 
extracted, normalized and calculated data into a master file, because I wanted a 
mechanism to collect all 6 runs in one file to replicate this process for the n=6 analysis of 
each of the drugs tested. See Supplementary Information 1.12 for full template code for 
the “Copy” module. 
With all of these VBA macros and forms in place and functioning, it is necessary 
to insert an easy mechanism to set into motion the “switchboard” and the subsequent 
cascade of events I’ve gone through. To accomplish this task, I inserted an object onto 
the main sheet of the Gen5 “Power Export” template – for this, I used an unfilled, 
unoutlined rectangle that I sized to the A2 cell of the sheet. After inserting this, right 
clicking the object and clicking “Assign Macro” allowed me to select the “Extract” 
macro as its designated target. Once saved, this template will be the default “Power 
Export” for this protocol, and the protocol need only be replicated in triplicate and 
assigned the 3 aforementioned names. Once the “Power Export” executes at the 
completion of a run, I need only click on the object previously inserted that is assigned 
the “Extract” macro to automate data manipulation and importation into GraphPad Prism. 
2.2.7.4. Master extraction template. As each of the runs for a set of drugs 
completes, and as previously mentioned, the data sheet from each mirrors into a master 
Excel workbook located in the same folder as all of the other current data for the 
in-progress 8 compounds. After the completion of the sixth run, it is necessary to perform 
a similar, albeit more simple, action on the master workbook to extract the data from each 
individual run, group them together and export the data from Excel into GraphPad Prism. 
As was the case with the individual run template, the first and foremost module to 
create is the “Declarations” module to allow for passage of variables among the different 
functions contained in the project. See Supplementary Information 1.13 for details of 
this VBA code. 
Since this workbook is merely copying already transformed data from within 
itself into one, centralized, sheet, the amount of VBA code necessary is quite limited 
relative to the previous template. Still contained within it is the scripting necessary to 
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generate data sheets for importation into GraphPad Prism. Therefore, with the click of a 
“button,” set up just as we did for the individual runs – an object assigned to the 
“Extract” macro – we can automate the bundling of all six runs for the eight ligands 
contained in each day’s runs and compile a master sheet of data. See Supplementary 
Information 1.14 for details of the VBA code. 
Execution of this series of macros allows for the easy bundling of 6 plates worth 
of data for 8 different ligands at 11 concentrations each over 60 minutes. Combination of 
the individual plate macros with the master workbook macros reduces data analysis time 
by hours, which allows for a higher, more accurate throughput of compounds.  
2.3. Finalized Assay Conductance 
2.3.1. Materials 
Forskolin, purchased from Tocris Bioscience/R&D Systems (Minneapolis, MN). 
Ro 20-1724 (PDE inhibitor), G418, Puromycin, Pen/Strep (100U/100μg per mL), DPBS, 
Hank’s 1x Buffer, DMEM, Direct Blue 71, HEPES and pluronic acid were purchased 
from ThermoFisher Scientific (Waltham, MA). Fetal Bovine Serum (FBS) purchased 
from Atlanta Biologicals (Lawrenceville, GA). The transfected HEK-293 cells 
coexpressed with modified CNG channels along with Cannabinoid Receptor Type 1 
(CBR-1) or Cannabinoid Receptor Type 2 (CBR-2) and their parental cells (without 
Cannabinoid Receptor Type 1 or 2; HEK-CNG) were purchased from Codex 
BioSolutions - so named ACT:One Cells (Gaithersburg, MD). Membrane potential dye 
was made by combining 1 L Hank’s 1x Buffer with 5.2 g HEPES (20 mM final 
concentration) and adjusting pH to 7.4. To the buffered solution we add 2.9 mL of 
DiSBAC stock – freshly prepared by adding 11.91 mg DiSBAC to 3 mL DMSO – 700 
μL 10% pluronic acid and 1.874 g Direct Blue 71. Cell culture media for the CBR1 and 
CBR2 containing cells was made by combining 890mL DMEM, 100mL FBS, 10mL P/S, 
1250 μL G418 and 100 μL Puromycin. 
2.3.2. Cell culture and frozen cell preparation 
HEK-CNG, CB1 and CB2 transfected cells were maintained in DMEM medium 
containing 10% FBS, 1% Pen/Strep, 250 mcg/mL G418 at 37 ⁰C in 5% CO2; however, 
the CBR-1 and CBR-2 transfected cells were cultured in medium containing an additional 
1 μg/mL Puromycin. The cells, seeded at a density of 2.8 x 106 cells, in a T225 flask 
(Corning; Corning, NY) containing 40 mL of the appropriate culture media and were 
allowed to grow until reaching 80% to 90% confluence. 
2.3.3. CNG channel-coupled cAMP assay 
Cells from 1 appropriately 85-90% confluent flask were harvested. The cells were 
resuspended in 10% FBS DMEM with 1% pen/strep medium at 500,000 cells/mL for  
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CBR-1 and HEK-CNG and 300,000 cells/mL for CBR-2. 100 μL of resuspended cells 
was dispensed into each well of 6 clear, 96-well, Poly-D-Lysine plates (BD via Fisher 
Scientific) using a 12-channel multi-channel pipet (ThermoFisher Scientific; Waltham, 
MA). It is important to note that the plating method needs to be such that the cell 
suspension must be plated by row, rather than by column, to alleviate the false-positive 
change in cAMP noticed on some of my data. Thus, plate column 12, then row 1 
(columns 1 through 11), row 2 (columns 1 through 11), etc. for each plate. After 
overnight culture at 37 ⁰C and 5% CO2 the cells were 75% to 80% confluent. 
After the overnight incubation period, I added 100 μL of membrane potential dye 
to each well of the culture plate and allowed to sit in a dark area at room temperature for 
60 minutes. After the 60 minute incubation period a baseline read in a BioTek Synergy 2 
plate reader with an excitation of 540/25 nm and an emission of 590/20 nm. Following 
the baseline read, 50 μL of ligand stock solution containing: appropriate drug 
concentration (beginning at either 25 μM or 5 μM [5 μM or 1 μM, final], Table 1), 4 μM 
Forskolin (800 nM, final) and 125 μM Ro 20-1724 (25 μM, final) in DPBS with 2.5% 
DMSO was added to the cell culture plate. Columns 1 through 11 contain drug, and 
Column 12 contains control wells. Control wells are: “Blank” (cells, media and dye), 
“Ro” (“Blank” + 25 μM Ro 20-1724 [Final]), “Ro/For” (“Ro” + 800 nM Forskolin 
[Final]) and "CP CTRL” (“Ro/For” + 5 μM CP 55,940 [Final]). The plate was then 
placed on the plate reader with 1 read per well per minute with an excitation of 540/25 
nm and an emission of 590/20 nm for 60 minutes. 
2.3.4. Data analysis 
I analyzed primary data with customized VBA macros, developed internally, in 
Microsoft Excel (Redmond, WA). Column 11 (lowest [drug]), determined the 
experimental maximum response (100 % activity) at each individual time point, and the 
experimental basal response was determined by the average response given by the 2 
“Blank” wells. All data were normalized with these minimum and maximum values via 
Equation 2.1. The EC50 values were calculated from concentration-response curves by 
non-linear regression analysis utilizing GraphPad Prism Software (San Diego, CA). 
2.4. Conclusions 
In this chapter, I have demonstrated optimization of the ACTOne GPCR assay 
from Codex Biosolutions to ensure reproducible, cost-effective and reliable data in a 
high-throughput manner. Additionally, I have provided an example of one method to 
enhance the Gen5 plate reading software with Microsoft Excel’s powerful VBA macro 
capabilities to yield a fast and effective means of analyzing large quantities of data 
generated from conductance of functional assays. 
Future directions for this project could be a further honing of the assay to gain 
even more cost-savings, speed and accuracy of data acquisition. Namely, a more serious 
trial and investigation into the use of the more cost-effective polystyrene plates over the 
Poly-D-Lysine coated plates. 
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CHAPTER 3. FUNCTIONAL EVALUATION OF A NOVEL CLASS OF 
PHENYL-SUBSTITUTED SIDE CHAIN ANALOGUES OF Δ8-THC 
3.1. Introduction 
Classical cannabinoids are tricyclic compounds possessing a benzopyran core – 
these are of either natural origin or synthetic analogues thereof. The naturally occurring, 
prototypes for these compounds are Δ9-THC and Δ8-THC, which both bind to CB1 and 
CB2 receptors and exert a partial agonist activity.
14 Within the classical compounds 
impacting the CB1 receptor there exists novel means of dealing with anti-nociception, 
mitigation of chemotherapeutic-induced nausea and vomiting, decreasing intra-ocular 
pressure in glaucoma, increasing appetite in patients with wasting syndromes, reduction 
of muscle spasticity caused by diseases such as multiple sclerosis and treating diarrhea by 
slowing intestinal motility are present.232,233 With CB2 receptors serving the body as 
modulators of cytokine release, agents targeting these compounds show great promise in 
inflammation, especially in instances of inflammation-induced organ damage.136,165 The 
drawback exists in separating CB1 and CB2 activity to retain or augment the desired 
therapeutic outcome while simultaneously mitigating the negative psychotropic effects, 
ascribed to CB1, of such compounds. This desire for such potentially impactful 
compounds for various disease states which have favorable therapeutic use profiles has 
led to a bevy of research into the classical cannabinoids with regard to their 
pharmacology and structural activity relationships/requirements (SAR). 
Current knowledge of cannabinoid SAR has centered heavily around the classical, 
benzopyran core, and from these studies one may gather three pharmacophoric elements 
exist for classical cannabinoids to exert cannabimimetic activity (Figure 3.1): 
1. C-1 phenolic hydroxyl group 
2. Trans ring junction at the B and C rings 
3. Lipophilic C-3 alkyl side chain 
Literature precedent shows that lengthening of the C-3 alkyl chain (Section 3.2.1) causes 
an increase in the binding affinity of the compounds, with an optimal length of 7 to 8 
carbons. Additionally, unsaturation (Section 3.2.2), especially about the C-1′,2′ bond 
affords an even greater enhancement of binding affinity and selectivity, with the linear 
alkyne and cis 1′,2′ alkene showing optimal activity. Another area of exploration was the 
substitution of C-1′ and C-2′ (Section 3.2.3), which demonstrated the importance of this 
position, with 1′,1′-dimethylation being optimal. Compilation of this knowledge (Figure 
3.2) led to the synthesis of cycloalkyl234 and aromatic235 substituents (Section 3.2.4) 
introduced at C-1′. 
This study seeks to utilize the ACTOne Assay (Chapter 2) to explore the 
functional ramifications of an aromatic substitution at C-1′ (Section 3.3). Taking this 
functional activity data, I will then reconcile these outcomes against homology models 
and current literature standards’ binding to propose hypothetical interactions with CB1 
and CB2, to further develop the SAR and unique mechanism of these compounds. 
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Figure 3.1. Classical cannabinoid with pharmacophore elements 
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Figure 3.2. Design progression of the KM series of compounds 
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3.2. Classical Cannabinoids – Modifying C-3 Substituents to Increase Binding 
For the purposes of examining this novel series of compounds, I will leave C-1 
phenolic hydroxyl and the trans ring junction pharmacophoric elements intact, and I will 
not bring into account the optional elements of the northern and southern hydroxyl 
groups. 
3.2.1. Varying C-3 chain length 
The most logical starting point for modification of the C-3 postion was to 
substitute the n-pentyl of Δ8-THC (1) (CB1 Ki = 47.6 nM; CB2 Ki = 39.3 nM) with 
varying lengths of C-3 substituents (Figure 3.3). This ranged from n-butyl (2) (CB1 Ki = 
65 nM) to n-hexyl (3) (CB1 Ki = 41 nM) to n-heptyl (4) (CB1 Ki = 22 nM) and to n-octyl 
(5) (CB1 Ki = 8.5 nM).
236 Data from this study show that n-octyl (5) has the highest 
affinity, with n-heptyl (4) a near second. 
3.2.2. Unsaturated C-3 side chain analogs 
A next logical step is to undertake the introduction of unsaturation into the C-3 
side chain (Figure 3.4) to probe the binding pockets. Conformationally restricted 
aliphatic chains to helped to elucidate the spatial configuration of the LBP of CB1 and 
CB2 receptors about the hydrophobic C-3 binding pocket. Beginning the process of 
unsaturation one may turn attention first to the C-1′ heptyne derivative (6) (CB1 Ki = 0.65 
nM; CB2 Ki = 3.1 nM)
237 and note that it has, at best, a modest proclivity for CB1 over 
CB2 but good affinity for both overall. Stepping down the unsaturation at C-1′, one may 
examine the C-1′-heptene derivatives as the Z-isomer (7) (CB1 Ki = 0.8 nM; CB2 Ki = 9.5 
nM)238 and E-isomer (8) (CB1 Ki = 1.2 nM; CB2 Ki = 5.3 nM).
238 It is noteworthy that 
these are C-11-hydroxy compounds, but they do not differ, in the case of the Z-isomer at 
CB1, from the C-9-methyl compounds (CB1 Ki = 0.86 nM).
236 Taking these three 
compounds as a group, it is evident that CB1 affinity is unaffected among the three; 
however, the CB2/CB1 ratio changes. Most notably, this change in the ratio occurs with 
compound 7, suggesting that CB2 has less tolerance for acute angle orientation and 
unsaturation of C1′-C2′. 
Moving more distal along the C-3 substituent chain one may examine a large 
number of C-2′ unsaturated compounds, beginning first with the 2′-hexynyl derivative (9) 
(CB1 Ki = 11 nM).
236 2′-octynyl (10) (CB1 Ki = 4.9 nM) does well so long as there is a 
free phenolic hydroxyl; however, when C-1 is methoxy the affinity drops considerably 
(CB1 Ki = 189nM).
236 2′-nonynyl (11) (CB1 Ki = 3.7 nM)236 continues to improve upon 
the binding affinities of both 2′-hexynyl and 2′-octynyl, suggesting that with an optimized 
angle through unsaturation the binding pocket extends further. In terms of the 2′-alkenes, 
the Z-isomers of both 2′-heptene (12) (CB1 Ki = 1.55 nM)239 and 2′-octene (13) (CB1 Ki = 
3.19 nM)236 showed the most promise, with 2′-pentene-5′-hydroxy (14) (CB1 Ki = 125 
nM)239 and 2′-heptene-6′-acetamide (15) (CB1 Ki = 43.4 nM)239 paling in comparison. 
The lack of affinity in the hydrophilic derivatives points strongly to the conclusion that 
this is a relatively exclusively lipophilic pocket of the receptor. 
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Figure 3.3. C-3 chain length analogues and the effect on CB1 binding affinity 
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Figure 3.4. Unsaturated C-3 side chain analogs 
Notes: R2 is OH in all compounds except compound 11 where R2is methoxy.  
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Continuing the trek of unsaturation, one may move one carbon more distal on the 
C-3 chain, where relatively few modifications exist to date. 3′-butynyl (16) (CB1 Ki = 367 
nM)236 fared much worse than 3′-octynyl (17) (CB1 Ki = 9 nM)236, but neither did as well 
as the Z-isomer of 3′-octenyl (18) (CB1 Ki = 3.36 nM)236 (Figure 3.4). This data suggests 
that the hydrophobic pocket of CB1 turns, and the more rigid, straight alkynes likely have 
some steric issues hindering their binding affinity. 
Moving next to the 4′ position, there are 2 derivatives of note, 4′-octynyl (19) 
(CB1 Ki = 19 nM) and the Z-isomer of 4′-octenyl (20) (CB1 Ki = 11 nM)236 (Figure 3.4). 
These two suggest, again, that the binding pocket of CB1 has a curve to it and that the 
more distal on the C-3 side chain the unsaturation is, especially to the alkyne (linear) 
state, the less likely one is to fit that curve and thus one loses binding affinity. 
Next, sites of multiple unsaturation are examined, beginning with 1′,6′-heptadiyne 
(21) (CB1 Ki = 460 nM).
236 2′-pentyne derivatives with a 5′ substitution (Figure 3.4) 
seem to fair best as far as the multiple unsaturation derivatives go, which may seem 
counterintuitive given 21’s lack of affinity. However, the presence of 5′-CN (22) (CB1 Ki 
= 31 nM)236 or 5′-NNN (23) (CB1 Ki = 6.15 nM)236 demonstrates that in the case of 
multiple unsaturation, the LBP requires a H-bond accepting terminus to bind with higher 
affinity. This trend continues when one looks at the 2′-hexyne derivatives containing 6′-
CN (24) (CB1 Ki = 0.77 nM), 6′-NCS (25) (CB1 Ki = 11.5 nM) or 6′-NO2 (26) (CB1 Ki = 
5.34 nM).236 This becomes most evident and useful comparing the 2′-heptyne-6′-
sulfonamide derivatives containing an n-methyl (27) (CB1 Ki = 2.5 nM; CB2 Ki = 0.2 
nM), n-ethyl (28) (CB1 Ki = 20 nM; CB2 Ki = 1.4 nM) and n-butyl (29) (CB1 Ki = 70 nM; 
CB2 Ki = 86 nM) substituted sulfonamide.
240 This data suggests that the CB2 LBP has a 
larger hydrophobic pocket that could be targeted over the CB1 LBP by extending the C-3 
substituent length just enough without causing an eventual hindrance to both – as is the 
case with comound 29. Also of interest is the affinity of 24 and the 5′-azidopent-2′-yne 
(30) (CB1 Ki = 2.14 nM).
241 The interest lies dually in the 3-fold difference of binding 
affinities and in that both are antagonists with 5′-azidopent-2′-yne being a partial agonist 
while hept-2′-ynenitrile is neutral.241 
3.2.3. C-1′ modified compounds 
As previously discussed in Section 3.2.1, optimal activity was found with 
n-heptyl (4) or n-octyl (5), but further derivation found those compounds with a 1′,1′- or 
1′,2′-dimethyl substitution were more potent still.11,242,243 1′,1′-dimethylheptyl (31) (CB1 
Ki = 0.89 nM; CB2 Ki = 1.41 nM) and 1′,2′-dimethylheptyl (32) (CB1 Ki = 0.46 – 0.84 
nM) provided the initial foundation of optimized chain length and substitution pattern for 
derivation into 1′,1′-dimethyl pentyl and hexyl with 5′ or 6′ substituted compounds 
(Figure 3.5). As the size of the substitution increases, the affinity for CB1 starts to 
numerically wane, as is exemplified by 1′,1′-dimethyl-6′-hexanenitrile (33) (CB1 Ki = 
0.36nM), 1′,1′-dimethyl-7′-heptanenitrile (34) (CB1 Ki = 0.6nM) and 1′,1′-dimethyl-6′-
phenyl-7′-heptanenitrile (36) (CB1 Ki = 0.92nM).244 However, these values are not a 
therapeutically viable or targetable difference. A similar trend is noticed when comparing 
the 1′,1′-dimethyl-6′-N,N dimethyl hexane (37) (CB1 Ki = 0.86nM) to  
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Figure 3.5. Acidic and basic modifications to the terminus of Δ8-THC C-3 
substituents 
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1′,1′-dimehtyl-6′-N,N-diethylhexane (38) (CB1 Ki = 13nM).244 p-phenylsulfonamide 
derivatives (39, 40, 41) overall fared worse than smaller substituents, but demonstrated 
the size constraints of the CB1 LBP.
244 Interestingly, this increase in size was not as 
impactful on the CB2 Ki. This tolerance is somewhat evident in the case of 1′,1′-dimethyl-
6′-hexanenitrile (33) (CB1 Ki = 1.75 nM; CB2 Ki = 1.1 nM) versus 1′,1′-dimethyl-6′-
phenyl-7′-heptanenitrile (36) (CB1 Ki = 18.4 nM; CB2 Ki = 5.75 nM) and 1′,1′-dimethyl-
N,N-diethylheptanamide (38) (CB1 Ki = 23.9 nM; CB2 Ki = 2.47 nM).
239 
In an attempt to exploit the apparent hydrophobic binding pocket that exists along 
with the C-3 substituent binding pocket a series of C-1′ cyclic compounds were 
synthesized (Figure 3.6) for testing.245 This hydrophobic pocket is evidenced by the fact 
that 1′,1′-dimethyl compounds bind with far greater affinity than their methylene 
brethren, and further demonstrated by the lack of binding affinity for the 1′-hydroxyl (42) 
(CB1 Ki = 86.4 nM; CB2 Ki = 65.6 nM) and 1′-ketone (43) (CB1 Ki = 21.7 nM; CB2 Ki = 
83.7 nM). Comparing the C-3 heptyl (4) (CB1 Ki = 22 nM) to 1′,1′-dimethylheptyl (32) 
(CB1 Ki = 0.83 nM; CB2 Ki = 0.49 nM) to 1′-cyclopentyl (44) (CB1 Ki = 0.45 nM; CB2 Ki 
= 1.92 nM), 1′-dithiolaneheptyl (45) (CB1 Ki = 0.32 nM; CB2 Ki = 0.52 nM) and 
1′-dioxolane (46) (CB1 Ki = 0.52 nM; CB2 Ki = 0.22 nM) one may see that there is 
evidence of a dual-lobe hydrophobic binding pocket available about C-3 substituent 
pocket. Interestingly, this too brings up an issue of size within both the CB1 and CB2 
receptor LBP, as evidenced in the 1′-dithianeheptyl (47) (CB1 Ki = 1.8 nM; CB2 Ki = 3.6 
nM) and 1′-benzodithioleheptyl (48) (CB1 Ki = 56.9 nM; CB2 Ki = 257 nM).245 This is an 
example, though, of a means to gain a 5-fold selection for CB1 over CB2 receptor 
subtypes. This auxiliary hydrophobic pocket is not a primary binding pocket, as 
evidenced in the C-1′-dithiolane derivative that is without an additional C-1′ substituent 
(49) (CB1 Ki = 168 nM; CB2 Ki = 103 nM).
245 There is some loss of affinity when the C-
1′ contains both dithiolane and cylcohexyl substituents (50) (CB1 Ki = 1.86 nM; CB2 Ki = 
1.05 nM), suggesting that there exists a balance to be struck between hydrophobic 
binding and steric bulk too near the benzchromene core (Figure 3.6). However, this same 
C-1′-cyclohexyl in conjunction with the 1′,1′-dimethyl results in one of the strongest non-
selective binding compounds to date (51) (CB1 Ki = 0.57 nM; CB2 Ki = 0.65 nM).
234  
3.2.4. Aromatic and cyclic substituents at C-1′ 
As one may consider the tolerance for bulky substituents at C-1′ and couple that 
with our previously mentioned knowledge of unsaturation, a next logical step is to 
introduce aromatic and bi/tricyclic substituents in at C-1′. Interestingly, much like the C-
1′ cyclohexyl derivatives of the previous section, the best binding is achieved when the 
molecule contains moieties capable of binding to both the upper and lower hydrophobic 
pockets of the LBP. This is evidenced by comparing p-substituted aryl derivatives when 
the aryl substituents were joined to the benzchromene ring core via direct C-3 
linkage246or 1′,1′-dimethyl linkage235 (Figure 3.7). Examination of these comparator 
compounds one may see that the 1′,1′-dimethyl compounds far exceed the binding 
affinity for the direct C-3 conjugation; however, the directly conjugated compounds do 
offer some selectivity as the p-substituent increases in size, but this is minimal in relation 
to the CB1/CB2 ratios achieved with the 1′-gem-dimethyl compounds. 
 62 
 
Figure 3.6. Cyclic modifications at C-1′ which affect CB1 and CB2 binding 
affinity 
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Figure 3.7. Aromatic modifications of Δ8-THC at C-3 which affect CB1 and CB2 
binding affinity  
 
 
 
CB1 Ki = 95.49 nM 
CB2 Ki = 71.81 nM 
 
CB1 Ki = 3.13 nM 
CB2 Ki = 0.88 nM 
 
CB1 Ki = 119 nM 
CB2 Ki = 51.7 nM 
 
CB1 Ki = 1.85 nM 
CB2 Ki = 0.67 nM 
 
CB1 Ki = 57.77 nM 
CB2 Ki = 107.8 nM 
 
CB1 Ki = 1.77 nM 
CB2 Ki = 7.83 nM 
 
CB1 Ki = 11.73 nM 
CB2 Ki = 9.39 nM 
 64 
The apparent difference in size is intriguing, as the compounds that seem to prefer 
CB2 over CB1 tend to prefer bulky C-3 substituents, whereas the CB1-prefering ligands 
prefer a more compact C-3 substituent (Figure 3.8; Figure 3.9). There seems to be a 
breaking point in this conformational freedom where one loses both selectivity for CB2 
and overall binding affinity. If one would compare C-3 isobornyl (54) (CB1 Ki = 60.2 
nM; CB2 Ki = 6.1 nM) to C-3 1-adamantyl (53) (CB1 Ki = 6.8 nM; CB2 Ki = 52.0 nM), 
one may see that there exists a difference between receptor preference (Figure 3.8).247 
The adamantyl substituent has much less conformational space requirements compared to 
those of the isobornyl (Figure 3.9). It is noteworthy that the C-3 bornyl (52) (CB1 Ki = 
8.9 nM; CB2 Ki = 7.4 nM), which bears a similar Y-axis conformational space to 
isobornyl, lacks the Z-axis conformational space occupied by isobornyl, and thus it is not 
selective for CB1 nor CB2, albeit quite potent. There does still exist a limit within both the 
CB1 and CB2 LBP as evidenced in the C-3 bornylmethyl (56) (CB1 Ki = 32.7 nM; CB2 Ki 
= 30.5 nM) and isobornylmethyl (58) (CB1 Ki = 49 nM; CB2 Ki = 49.5 nM) compounds. 
These compounds have a larger conformational space requirement, which appears to 
mitigate any preference for one receptor subtype over the other and lowers the binding 
affinity to near that of THC. To further support this hypothesis, consider the adamantyl 
derivatives of THC synthesized by Lu, et al (Figure 3.8),248 The C-3 1-adamantyl (53) 
has less conformational requirements (Figure 3.9). However, 2-adamantyl exhibits much 
more conformational freedom – a trait further extrapolated by the 
(2-adamantylidene)methyl (57) (CB1 Ki = 48.6 nM; CB2 Ki = 8.9 nM) derivative. The 
presence of the unsaturation within the (2-adamantylidene)methyl affords a rigid enough 
frame so as to maximize the Y- and Z-axes freedom while still maintaining affinity and 
specificity for the CB2 receptor LBP. As one moves to a (1-adamantyl)methyl (59) (CB1 
Ki = 29.3 nM; CB2 Ki = 26.9 nM) or (2-adamantyl)methyl (60) (CB1 Ki = 79.7 nM; CB2 
Ki = 76 nM) the freedom afforded by the fully saturated methylene linkage causes too 
much freedom and a loss of both specificity and affinity for CB1 and CB2 occurs. 
3.3. Novel Series of C-1′-Dimethyl-Aryl-Δ8-THC Analogs (KM Series) 
3.3.1. Rationale of design 
Amalgamation of all of these data gathered from previous series of cannabinoid 
compounds led to the work of former members of my lab group, which saw the synthesis 
of cycloalkyl234 and aromatic235 substituents introduced at C-1′ (Figure 3.10). All of the 
compounds of this group saw marked improvement in affinity for CB1 and CB2 receptors 
over that of THC (Table 3.1). With such an increase in binding affinity, a need existed to 
establish a functional activity for these compounds.  
3.3.2. Objectives of the current study 
Utilizing this novel series of compounds, I explored the functional pharmacology 
of each in relation to CB1, CB2 and the parental HEK-293-CNG cell lines to understand 
the mechanism of action (MoA) in a cell-based reporter system. Furthermore, to aid in 
explanation of the observed functional data, I will reconcile known literature with regard  
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Figure 3.8. Bicyclic and tricyclic C-3 substituents of Δ8-THC that alter CB1 and 
CB2 binding affinity 
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Figure 3.9. Comparison of the conformational space for adamantyl and bornyl 
side chains of various ∆8-THC analogues 
Notes: Accessible conformers within 8 kcal mol-1 of the global energy minimum for 3-
(adamant-1′-yl)-∆8-THC (53, green), 3-bornyl-∆8-THC (54, magenta), 3-isobornyl-∆8-
THC (52, orange), and 3-bornylmethyl-∆8-THC (58, blue). The accessible 
conformational space for 3-isobornylmethyl-∆8-THC (not shown) is similar to that of 58. 
The global minimum energy conformer for each ligand is shown in stick display. 
Adapted, with permission, from: Lu, D., Guo, J., Duclos, R. I., Bowman, A. L. & 
Makriyannis, A. Bornyl- and Isobornyl-Δ8-tetrahydrocannabinols: A Novel Class of 
Cannabinergic Ligands. Journal of Medicinal Chemistry 51, 6393-6399, 
doi:10.1021/jm8005299 (2008). Copyright 2008 American Chemical Society. 
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Figure 3.10. KM series analogues 
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Table 3.1. Binding affinities for the KM series of compounds 
Compound CB1 Ki (nM) CB2 Ki (nM) 
61 - - 
62 0.57 (±0.05) 0.65 (±0.04) 
63 12.3 (±0.61) 12.3 (±0.61) 
64 3.13 (±0.37) 0.88 (±0.05) 
65 2.53 (±0.54) 1.13 (±0.02) 
66 34.4 (±2.84) 10.65 (±1.27) 
67 11.0 (±1.67) 7.45 (±0.38) 
68 1.85 (±0.16) 0.67 (±0.05) 
69 1.77 (±0.20) 7.83 (±0.79) 
70 76.1 (±1.55) 12.4 (±0.24) 
71 5.26 (±0.94) 0.90 (±0.02) 
72 18.8 (±1.39) 1.68 (±0.20) 
73 2.80 (±0.05) 3.54 (±0.71) 
74 5.03 (±0.39) 1.54 (±0.16) 
75 1.59 (±0.16) 0.54 (±0.03) 
76 9.25 (±0.23) 2.53 (±0.23) 
77 2.72 (±0.29) 0.91 (±0.05) 
78 1.08 (±0.04) 0.27 (±0.01) 
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to binding and employ a CB1 homology model in an effort to provide some in silico 
hypothesis as to the potential residues involved in contributing to the functional activity. 
3.4. Functional Pharmacology 
3.4.1. ACTOne assay 
Assay development and conductance details are found in Chapter 2. Briefly, 
stably transfected HEK-293 cells co-expressed with modified CNG channels along with 
CB1 or CB2 or their parental cells (without CB1 or CB2; HEK-CNG) were plated at an 
appropriate density in a clear, 96-well, Poly-D-Lysine plate and allowed to incubate at 
37°C and 5% overnight. After the overnight incubation period, I added 100 μL of 
ACTOne membrane potential dye to each well of the culture plate and allowed to sit in a 
dark area at room temperature for 60 additional minutes. After the 60 minute incubation 
period a baseline read in a BioTek Synergy 2 plate reader with an excitation of 540/25 
nm and an emission of 590/20 nm. Following the baseline read, 50 μL of drug stock 
solution containing (Figure 3.11): appropriate concentrations of ligand, Forskolin and Ro 
20-1724 in DPBS with 2.5% DMSO in the cell culture plate. The plate was then placed 
on the plate reader with 1 read per well per minute with an excitation of 540/25 nm and 
an emission of 590/20 nm for 60 minutes. 
I analyzed primary data with customized VBA macros, developed internally, in 
Microsoft Excel (Redmond, WA). Column 11 (lowest [drug]) determined the 
experimental maximum response (100 % activity) at each individual time point, and the 
experimental basal response was determined by the average response given by the two 
“Blank” control wells. All data were normalized with these minimum and maximum 
values via Equation 2.1. The EC50 values were calculated from concentration-response 
curves by non-linear regression analysis utilizing GraphPad Prism Software (San Diego, 
CA). 
3.4.2. CB1 functional activity for the KM series 
Plates were run as previously described (Section 3.4.1) in six replicates with 
CP-55,940 as a control. Compound 63 (KM-233), being the prototype, did not manifest 
as high of efficacy as several of the substituted aromatic ring analogs – especially those 
with meta-substitution(s). EC50 values (Table 3.2) ranged from 34 to 516 nM with the 
percent cAMP inhibition ranging from 10 to 70%, 50 minutes after compound addition 
into the assay plate. Of particular note are the meta-substituted compounds 65, 67, 71, 73, 
75 and 77 (Figure 3.12), which show an overall lowering of cAMP production near 70%, 
which is equivalent to the standard of CP-55,940. EC50 values were determined to be 41.8 
nM, 41.2 nM, 78.5 nM, 99.5 nM, 71.2 nM and 127 nM for compounds 65, 67, 71, 73, 75 
and 77, respectively. From the para-substituted derivatives, only 68 (EC50 = 34.0 nM) 
was able to match CP-55,940 at ~70% reduction of cAMP production, all others were 
less efficacious at ~50% reduction (Figure 3.13) – highlighting the importance of 
meta-substitution in these derivatives. The remaining derivatives for this series 63, 66 and  
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Figure 3.11. Drug plate layout and concentrations 
Notes: Columns 1 through 11 contain test compound, and Column 12 contains control 
wells. All listed concentrations are the final concentrations once added to the testing 
plate. In the drug plate all compounds are at 5X that of the listed concentrations in 
Columns 1 through 11. Control wells (Column 12) are: “Blank” (cells, media and dye), 
“Ro” (“Blank” + 125 μM Ro 20-1724 [25 μM, Final]), “Ro/For” (“Ro” + 4 μM Forskolin 
[800 nM, Final]) and "CP CTRL” (“Ro/For” + 25 μM CP-55,940 [5 μM, Final]).  
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Table 3.2. EC50 values for KM series functional assays 
Compound 
CB1  
EC50 (nM) 
CB2  
EC50 (nM) 
CNG  
EC50 (nM) 
CB1 PTx  
EC50 (nM) 
61 n/a - - - 
62 14.2a - - - 
63 204a n/a n/a n/a 
64 350a n/a n/a n/a 
65 41.7a n/a n/a n/a 
66 516a n/a n/a n/a 
67 41.2a n/a n/a n/a 
68 34.0a n/a n/a n/a 
69 72.3a n/a n/a n/a 
70 356a n/a n/a n/a 
71 78.5a n/a n/a n/a 
72 290a n/a n/a n/a 
73 99.5a n/a n/a n/a 
74 237a n/a n/a n/a 
75 71.2a n/a n/a n/a 
76 414a n/a n/a n/a 
77 127a n/a n/a n/a 
78 249a n/a n/a n/a 
Notes: n/a: Not active, based on no statistically significant change in cAMP from 
baseline. “-“ Indicates test not performed. a Indicates a decrease in cAMP compared to 
baseline. 
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Figure 3.12. CB1 functional activity for meta-substituted KM series compounds 
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Figure 3.13. CB1 functional activity of para-substituted derivatives of KM series 
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78 only produced an approximately 30% reduction in cAMP production (Figure 3.14), 
and while 63 is our prototype for this class, it is evident that substitution greatly improves 
its functional activity. 
3.4.3. CB2 functional activity for the KM series 
Plates were run as previously described (Section 3.4.1) in 6 replicates with 
CP-55,940 as a control for all 6 runs (Figure 3.15; Table 3.2). All compounds in the 
series demonstrated an inability to decrease cAMP production via CB2 activation.  
3.4.4. CNG functional activity for the KM series 
Plates were run as previously described in 3 replicates with CP-55,940 as a 
control for all 3 runs (Figure 3.16; Table 3.2). As fully expected, all of the compounds 
failed to elucidate any change in cAMP production, including our standard of CP-55,940. 
There is a small variance among the drugs, but this is not of true consequence as one is 
able to gather from the graph – especially relative to the full agonist graphs noted with 
these compounds in CB1 cells. This lack of activity with the parental HEK-293-CNG 
cells confirms that the KM series acts via CB1, and not via any other constitutively 
expressed receptors present in the HEK cells.  
3.4.5. CB1 PTx-sensitive Gi/o-inactivation for the KM series 
Plates were run as previously described (Section 3.4.1) in 3 replicates with 
CP-55,940 as a control for all 3 runs (Figure 3.17; Table 3.2). All of the compounds in 
the series failed to change cAMP production, including our standard of CP-55,940, 
confirming a PTx-sensitive-Gi/o-mediated CB1 effect. CB2 PTx-sensitive Gi/o-inactivation 
assays were not completed due to a lack of agonist response in the previous assay. 
3.5. Discussion 
3.5.1. Interactions with the CB1 LBP 
As previously discussed (Section 1.2.2), CB1 receptors are seven trans-membrane 
G-protein coupled receptors (GPCRs).14 There exist several homology models which 
have sought to elucidate the residues important for binding  in domains 3, 6 and 7 as well 
as functional activity. 
 To generate hypotheses, gain some insight into the possible explanations and 
interplay between ligand and receptor, I performed docking of the compounds. Dr. 
Chang, University of California at Riverdale, provided 4 models: “ACEA” – 
endocannabinoid model, “HU-210” – classical core model, “SR-141716A” – inverse 
agonist model and “WIN-55,212-2” – non-classical agonist model.249 The KM series of 
compounds, I believe, adopt a similar binding mode within the LBP to that of HU-210, 
thus this was the model used for docking studies. 
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Figure 3.14. CB1 functional activity of misc. KM series derivatives 
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Figure 3.15. CB2 functional activity of KM series compounds, 50 minutes after drug addition 
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Figure 3.16. CNG functional activity of KM series compounds, 50 minutes after compound addition 
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Figure 3.17. CB1 PTx-sensitive Gi/o-inactivation functional activity, 50 minutes after compound addition 
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3.5.1.1. C-1 Hydroxyl. K192(3.28) plays a very important role in both receptor 
binding and function. Since it is a very flexible residue in the LBP, it can manifest 
conformations that allow it to hydrogen bond with either the C-1 hydroxyl, C-11 
(“Northern”) hydryoxyl, C-6 (“Southern”) hydroxyl or even the benzochromene 
oxygen.250 However, newer data suggest that K192(3.28) plays a primary role as H-bond 
acceptor of the C-1 hydroxyl,251 presumably this occurs after being activated by donating 
a H-bond to F189(3.25) (Figure 3.18).249 S383(7.35) interacts by donating a H-bond to 
either the benzchromene oxygen or the C-6 hydroxyl, if present (Figure 3.18A).251 
Additionally, literature data suggest that the resting state of the CB1 receptor exists when 
the salt bridge between K192(3.28) and D366(6.58) is intact.252 
Much the same as the established CB1 interactions of HU-210, I hypothesize that 
the KM series of compounds take advantage of the H-bonding with K192(3.28) with the 
C-1 hydroxyl and S383(7.35) with the benzchromene oxygen (Figure 3.18B) – as most 
classical cannabinoids do. Moreover than orienting the drug in the pocket, ligand 
interaction with K192(3.28) breaks the salt bridge between K192(3.38) and D366(6.58) – 
a reported key stabilizing factor for the inactive state of the CB1 receptor.
252 
3.5.1.2. C-3 lipophilic side chain. A predominantly lipophilic pocket exists, 
seemingly as two lobes – as evidenced in the fact that 3-(1′,1′-dimethylheptyl)-Δ8-THC 
binds with higher affinity than does 3-heptyl-Δ8-THC along with 3D-QSAR models 
which demonstrate this trait.253 In one homology model, residues V196(3.32), 
T197(3.33), F200(3.36), Y275(5.39), W279(5.43), L359(6.51) and M363(6.55) form a 
hydrophobic pocket which encompasses the A-ring and C-3 side chain of HU-210.254 
More recent homology models form this pocket from I354(6.46), C355(6.47), 
W356(6.48), L359(6.51), L360(3.52) and M363(6.55) (Figure 3.19A).249Interestingly, 
mutations studies conducted on this hydrophobic pocket show that M363A(6.55) 
mutation greatly impacts binding affinity for HU-210 but has virtually no impact on THC 
which would suggest that this is an important residue for C-1′ substituted derivatives.255  
Due to the similar CB1 functional activity betwixt HU-210 and the KM series, it is 
hypothesized that the interactions of the lipophilic C-3 substituents are analogous  
(Figure 3.19B). The necessity of the M363(6.55) residue as demonstrated for HU-210 in 
the mutation binding studies bore itself out in the functional arena, as well. This further 
highlights the importance of the C-3 lipophilic side chain to both the binding affinity and 
the functional activity of these compounds. Residue W356(6.48) plays a key role in two 
ways. First, in the inactive state of the CB1 receptor, there is a proposed interaction of 
W356(6.48) and F200(3.36) – a “toggle switch.”256 Stabilization of this interaction may 
lead to the specialized antagonists known as inverse agonists, and this is precisely how 
SR-141716A binds in some homology models – a parallel stacking between these two 
residues creates an aromatic micro domain for SR-141716A.249 However, more recent 
homology models do not suggest this same binding mode for SR-141716A, and thus may 
indicate this is not as necessary an interaction. Second, interaction of W356(6.48) with 
the aryl ring of the KM Series draws the aryl ring more in contact with residues flanking 
W356(6.48), namely I354(6.46) and L359(6.51). It is this additional hydrophobic 
interaction (Figure 3.20) that I hypothesize gives compound 67 its superior functional 
effect, though its binding affinity is lower than related compounds. 
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A B 
Figure 3.18. CB1 LBP interactions with C-1 hydroxyl and benzchromene oxygen 
Notes: Panel A depicts HU-210 H-bonding interactions as set forth in homology models. Panel B depicts the proposed 
interaction of Compound 67 with the LBP H-bonding groups. Homology models contributed by Dr. Chang, University of 
California, Riverdale.249 
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Figure 3.19. CB1 LBP proposed hydrophobic C-3 pocket 
Notes: Panel A depicts the predicted HU-210 C-3 binding pocket of CB1. Panel B is the 
proposed Compound 67 C-3 binding pocket of CB1. The arrow highlights M363(6.55), 
demonstrated in mutation studies to interact with the C-1′-gem-dimethyls. Homology 
models were generously supplied by Dr. Chang, University of California, Riverdale.249 
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Figure 3.20. CB1 LBP proposed additional hydrophobic interactions of 67 with the 
C-3 pocket 
Note: Panel A depicts the side view of 67 in the LBP. Panel B depicts the top view of 67 
in the LPB. Dashed green lines indicate π-π stacking interactions Homology models were 
supplied by Dr. Chang, University of California, Riverdale.249 
v 
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3.5.1.3. ABC ring system. Residues F174(2.61) and F177(2.64) are suggested to 
not provide direct π-π interactions with HU-210, but rather they help to stabilize the 
tricyclic (ABC ring) binding pocket domain of the LBP (Figure 3.21).255  
Residues F200(3.36) and W279(5.43) appear to not play as important a role in 
terms of binding (in the case of AEA and CP-55,940) as they do in terms of receptor 
activation (Figure 3.21).257 That is to say, a ligand’s hydrophobic substituents at the C3 
position may bind well without interacting with these two residues, but agonists MUST 
have interaction with these residues to exert their effect.254 F189(3.25) is key at providing 
a π-π stacking (Figure 3.21) interaction with AEA, and is instrumental in binding of this 
to the pocket as its mutation to alanine causes a 7-fold drop in affinity for the receptor.258 
F189(3.25) also seems to form the “ceiling of the anandamide binding pocket in CB1.”257 
As has been the case with many of the other interactions within the CB1 LBP, 
compound 67 shares many of the same interactions with HU-210; however, there is one 
key difference, which I believe helps compound 67 gain an edge. One of the key 
interactions within the CB1 LBP is the simultaneous interaction of the ligand with both 
F200(3.36) and W279(5.43). While HU-210 is obviously able to accomplish this by 
being an agonist at CB1, I believe that compound 67 is able to demonstrate a more 
favorable interaction with these residues via π-π stacking interactions rather than strictly 
hydrophobic interactions present in HU-210. 
3.5.1.4. (Optional) C-11 (“Northern”) hydroxyl.  With none of the compounds 
in the KM-series having this moiety present in the parent drug, I have not included it as 
part of this current study; however, it is included as part of this discussion, due to the fact 
that the primary metabolite of the KM series is a C-11 hydroxyl.259 S383(7.35) shows 
itself to be equally important in binding of molecules along with stabilizing the LBP. 
S383(7.35) can hydrogen bond with the C-11 (“Northern”) hydroxyl251 (if present) or the 
benzochromene oxygen249,254, but more importantly it helps to stabilize the LBP by 
maintaining the shape of the Trans-Membrane Helix 1-2-7 binding pocket.251 The 
“Northern” hydroxyl group may, theoretically, H-bond with K192(3.28). 
3.5.2. Interactions with the CB2 LBP 
As previously discussed (Section 1.2.3), CB2 receptors are also seven 
trans-membrane GPCRs; however, CB2 only shares 48% homology with CB1 – a trait 
unique to the CB1 and CB2 receptors among GPCRs, which generally share a much 
higher level of homology among receptors of the same family.14 The SAR of the CB2 
LBP has yet to be fully developed, especially in terms of a reliable homology model or 
much less as a crystal structure. In the absence of a refined homology model, it is not 
possible to predict specific ligand amino acid interactions.  However, very basic 
interpretations of the results are possible by comparing and contrasting to current 
literature standards. Specifically, the KM series possess high receptor affinity, and no 
functional activity, indicative of a neutral antagonist. Based on this, a plausible 
comparison between S-(-)-WIN-55,212-3 (a neutral antagonist) and R-(+)-WIN-55,212-2 
(a weak agonist) and the activity of the KM series at CB2 may be presented. 
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B 
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D 
Figure 3.21. CB1 LBP π-π stacking interactions and key residue interactions 
Notes: Panel A (top view) and Panel B (side view) depict the interactions of HU-210 within the CB1 LBP. Panel C (top view) 
and Panel D (side view) depicts the proposed interactions of 67 in the CB1 LBP. Demonstrating the proximity of key receptor 
activators F200 and W279 as well as the π-π stacking residue F189. Homology supplied by Dr. Chang.249 
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 Attention now turns to the trans-B/C ring-junction. With data relatively limited 
for CB2’s LBP, especially in the arena of classical core compounds, one must make some 
inferences based on available aminoalkylindole derivative homology model data. One 
such extrapolation lies in WIN-55,212-2’s biologically assumed conformation to be 
s-trans-conformer.260 With the s-cis-conformer, there are suggested steric interactions 
with V113(3.32) (Figure 3.22).261 By extension, WIN-55,212-3, the S-(-) isomer of 
WIN-55,212-2 and antagonist, may also orient the morpholino side chain such to prevent 
critical amino acids interactions in the CB2 LBP as discussed below. 
Taking WIN-55,212-2 and ascribing its moieties to those of the representative 
example of KM-233 (63) (Figure 3.23), one can see that there are many similarities. 
While the similarities are numerous, the differences are profound as well, because the 
steric interactions of WIN-55,212-2 with V113(3.32) are non-existent with the KM-
series. The steric issue comes in with what I hypothesize to be the “northern” aliphatic 
hydroxyl region, or C-11 substituted derivatives of Δ8-THC, thus the KM-series has little 
to contend with in this arena. It does raise an important question, though, for future 
design, synthesis and study of the classical core ligands – would incorporation of bulky 
C-11 substituents, especially conformationally (cis or trans) restricted derivatives, impact 
the CB2 selectivity and functional ability of compounds? 
3.6. Conclusions 
The KM Series of compounds represent a unique group of ligands for modulating 
the CB1 and CB2 receptor system. Increases in binding affinity come about from taking 
advantage of residues present in the binding pocket otherwise not adequately utilized, 
such as L359(6.51) and I354(6.46). Key interactions with the “toggle” switch at CB1 
(W356(6.48)) to hold it in the active state. Future study in this would test the hypothesis 
of the residue-ligand interactions via homology modeling studies. Additionally, testing 
the series as antagonists of CB2 against known agonists would functionally confirm this 
as a mechanism. 
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Figure 3.22. CB2 LBP steric hinderance of cis and trans isomers of WIN-55,212-2 
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Figure 3.23. Comparison of analogous functional groups of WIN-55,212-2, KM 
233 and WIN-55,212-3 
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CHAPTER 4. FUNCTIONAL EVALUATION OF A NOVEL CLASS OF 
HETEROCYCLIC CORE ANALOGUES OF HEXAHYDRO Δ8-THC 
4.1. Introduction 
As previously discussed (Section 1.1), classical cannabinoids are tricyclic 
compounds possessing a benzopyran core – these are of either natural origin or synthetic 
analogues thereof. The naturally occurring, prototypes for these compounds are Δ9-THC 
and Δ8-THC, which both bind to CB1 and CB2 receptors and exert a partial agonist 
activity.14 Within the classical compounds impacting the CB1 receptor novel means of 
dealing with anti-nociception, mitigation of chemotherapeutic-induced nausea and 
vomiting, decreasing intra-ocular pressure in glaucoma, increasing appetite in patients 
with wasting syndromes, reduction of muscle spasticity caused by diseases such as 
multiple sclerosis and treating diarrhea by slowing intestinal motility are present.14 It is 
well known in the literature that CB1 receptors are responsible for causing the untoward 
psychotropic effects of cannabinoid compounds. With CB2 receptors serving the body as 
modulators of cytokine release, agents targeting these compounds show great promise in 
inflammation, especially in instances of inflammation-induced organ damage.136,165 The 
drawback exists in separating CB1 and CB2 activity so as to retain or augment the desired 
therapeutic outcome while simultaneously mitigating the negative psychotropic effects of 
such compounds. This desire for such potentially impactful compounds for various 
disease states which have favorable therapeutic use profiles has led to a bevy of research 
into the classical cannabinoids with regard to their pharmacology and structural activity 
relationships/requirements (SAR). 
For the classical cannabinoids it is established that substitution of the A-ring, 
aside from positions 1 and 3, is generally detrimental to the Ki of compounds, and 
substitution of the 1 position with anything other than hydroxyl is equally detrimental, 
though it can afford some selectivity for CB2 (Section 4.2.1). Manipulation of the B-ring 
of the classical core improves the potency of compounds over the parent THC compound 
(Section 4.2.2). Finally, desaturating the C-ring (as in ca   nnabinol) serves to increase 
affinity and impart selectivity to compounds (Section 4.2.3). Considering these along 
with the previously mentioned C-3 modifications (Section 3.2), the classical core is rife 
with opportunities to exploit increases in affinity and specificity. 
The non-classical cannabinoids provide a further insight on cannabinoid action as 
well. From the aminoalkylindoles (AAIs) it becomes apparent that size is of concern 
when substituting at the N-1 position, but this can be optimized to afford highly potent 
compounds (Section 4.3.1.1). From the AAIs one may also gather that C-2 substitution 
does increase potency, but at the expense of CB2 specificity (Section 4.3.1.2). At C-3 one 
gathers that conformation and size play a crucial role in cannabinoid binding and activity 
(Section 4.3.1.3). Finally, the AAI compounds demonstrate how substitution of the 
indole ring system can result in highly potent and specific compounds (Section 4.3.1.4). 
The other non-classical cannabinoid class, which provides valuable information in 
the development of this novel series of cannabinoids, is the well-known diarylpyrazole 
class. Much like the AAIs, size and electron-withdrawing substituents at N-1 aid in 
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compound specificity (Section 4.3.2.1). C-3 derivatives of this class afford the 
knowledge that CB1 prefers a long and flexible moiety (Section 4.3.2.2). C-4 and C-5 
derivatives for this class are relatively few; however, derivatives thereof provide 
knowledge that electron-withdrawing groups are preferred (Section 4.3.2.3 and Section 
0). Summing all of this knowledge from classical (Figure 4.1) and non-classical 
cannabinoids gave rise to a true hybrid series of compounds, the pyridine- and 
pyrimidine-hexahydro-THC compounds (Figure 4.2). 
The aim of this study is to utilize the ACTOne Assay (Chapter 2) to explore the 
functional ramifications of a heterocyclic A-ring, inconjunction with a hexahydro C-ring 
and C-1′ substituents similar to the KM series (Chapter 3) (Section 4.4). Taking this 
functional data, I will then reconcile these outcomes against current literature standards’ 
binding and homology models to propose hypothetical interactions with CB1 and CB2 – 
in an attempt to further understanding of cannabinoid SAR and the unique MoA for these 
compounds. 
4.2. Classical Cannabinoids – Modifying the A/B/C Ring 
Three pharmacophoric elements exist for classical cannabinoids to exert 
cannabimimetic activity (Figure 4.1): 
1. C-1 phenolic hydroxyl group 
2. Trans ring junction at the B and C rings (6aR, 10aR - required)18 
3. Lipophilic C-3 alkyl side chain 
For the purposes of examining this novel series of compounds, we will leave C-1 
phenolic hydroxyl and the trans ring junction intact, and we will not bring into account 
the optional elements of the northern and southern hydroxyl groups. We will vary the 
A-ring with heterocyclic moieties and fully saturate the C-ring. Several sections of this 
chapter use a muricidal rat model as an in vivo characterization of cannabinoid activity. 
This model was utilized because several of the compounds were synthesized and tested 
prior to the isolation and characterization of the cannabinoid receptors, thus no Ki values 
are reported, but the relative biological activity is. While this method does not provide a 
perfect 1:1 comparison, it does give a distinct picture the rank order of the compounds 
4.2.1. Modifying the A-ring. 
Variations about the A-ring are one of the most widely studied modifications 
within the tricyclic core. Several groups have manipulated this ring in an attempt to 
augment LBP interactions. Substitutions within the A-ring, with exception of the C-1 
hydroxyl and C-3 aliphatic, greatly reduce affinity of the compounds for CB1 receptors 
(Figure 4.3). 262 C-4-bromo-Δ8-THC (79) (CB1 Ki = 5250 nM) and C-4-nitro-Δ8-THC 
(80) (CB1 Ki = 1630 nM) greatly reduce the affinity over Δ9-THC (1) (CB1 Ki = 44 
nM).262 A C-2-nitro-Δ8-THC (82), C-2,4-diiodo-Δ8-THC (83) or C-2,4-dinitro-Δ8-THC 
(84) substitution abolishes all affinity for the compounds at CB1 (CB1 Ki = >10,000 
nM).262 A C-2-Iodo-Δ8-THC (81) (CB1 Ki = 89 nM) substitution confers roughly a 
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Figure 4.1. Classical cannabinoid with pharmacophoric elements 
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Figure 4.2. Design progression for the hexahydro series of compounds 
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Figure 4.3. A-ring substituted compounds 
aJ.W. Huffman265 
bJ.W. Huffman242 
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CB1 Ki = 61 nM 
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2-fold decrease in binding affinity relative to Δ9-THC (1); however, a C-2-Iodo-Δ8-THC-
DMH (85) (CB1 Ki = 61 nM) gives almost an 80-fold decrease in binding affinity at CB1 
versus Δ8-THC-DMH (32) (CB1 Ki = 0.77 nM).262 These data point to a need for the A-
ring to have a stable π-electron system for optimal π-π stacking interactions in the LBP. 
The most extensive modification to the ABC core ring system of the classical 
series of compounds takes place at C-1 of the A-ring, which naturally exists as a hydroxyl 
group. Data suggest that in the Δ6a,10a derivatives, it may be replaced by an amine and 
retain equivalent biological activity. In the muricidal rat model, used as a means of 
testing compounds due to the lack of CB receptor characterization at that time, to 
Δ9-THC only if the C-3 substituent contains C-1′,2′-dimethylheptyl (86) (5 mg/kg) 
(Figure 4.4).263 Binding studies have confirmed in the Δ9-THC derivatives (Figure 4.4) 
that, while reduced in affinity relative to C-1-hydroxyl, there is a manner of CB2 
selectivity for C-1-amine (87) (CB1 Ki = 616 nM; CB2 Ki = 215 nM).
264 Larger C-1-
amine substituents further reduce the affinity for both CB1 and CB2, but there are some 
instances where this garners some CB2 selectivity – e.g. C-1-cyano (88) (CB1 Ki = 1720 
nM, CB2 Ki = 387 nM); methylcarbamate (89) (CB1 Ki = >3000 nM, CB2 Ki = 1400 nM); 
methylsulfite (90) (CB1 Ki = >3000 nM, CB2 Ki = 1720 nM); isonicotinamide (91) (CB1 
Ki = >3000 nM, CB2 Ki = 1770 nM);  methoxymethanamine (92) (CB1 Ki = >3000 nM, 
CB2 Ki = 1400 nM); methylurea (93) (CB1 Ki  = >3000 nM, CB2 Ki = 782 nM); and 
methylacetamide (94) (CB1 Ki = >3000 nM; CB2 Ki = 1500 nM) show this trend.
264 This 
effect was even more profound for these derivatives when C-3-1′,1′-dimethylheptyl was 
present in lieu of C-3-n-pentyl, especially in the case of C-3-CN, C-3-acetamide and C-3-
methylsulfite (Table 4.1).264 Acidic and amide derivations at C-1 (Figure 4.5) were less 
active, with N-methylformamide (95) (CB1 Ki = >3000 nM; CB2 Ki = 1260 nM) and 
N,N-dimethylformamide (96) (CB1 Ki = >3000 nM; CB2 Ki = 1210 nM) showing the 
most promise for CB2 selectivity and activity.
264 The C-1 substituent may not be a thiol 
group, this abolishes biological activity in the muricidal rat model, again this model is 
used due to the predating of CB receptor characterization,  with C-3-n-pentyl (97) or 
C-3-1′,2′-dimethylheptyl (98) (Figure 4.5).263 Interestingly, though, conversion of the C-
1 substituent to a methylthiol with C-3-n-pentyl (99) (Figure 4.5) yields a compound 
with lower binding affinity, but nearly a 2-fold selectivity for CB2 over CB1 (CB1 Ki = 
955 nM; CB2 Ki = 465 nM).
264 
Replacing C-1-hydroxyl with C-1-F causes a staunch drop in CB1 affinity and a 
moderate drop in CB2 affinity, which would allow for selective ligands at CB2 (Figure 
4.6). As an example, when 3-heptyl-Δ8-THC (100) (CB1 Ki = 22 nM) is compared to 
1-fluoro-1-deoxy-3-heptyl-Δ8-THC (101) (CB1 Ki = 1560 nM; CB2 Ki = 45 nM) one sees 
the precipitous drop in CB1 affinity and immense CB2 selectivity present therein.
266 It is 
noteworthy that there is no binding data available in current literature for 
3-heptyl-Δ8-THC (100), so a true comparison of any CB2 activity gained or lost is not 
possible. I noticed a similar trend when comparing C-1-hydroxy and C-1-methyoxy 
derivatives of compounds (Figure 4.6). Examining 3-(6′-azido-2′-hexynyl)-Δ8-THC 
(102) (CB1 Ki = 2.14 nM; CB2 Ki = 1.12 nM) to 1-methoxy-3-(6′-azido-2′-hexynyl)-
Δ8-THC (103) (CB1 Ki = 82.5 nM; CB2 Ki = 11.2 nM) one may note the nearly 40-fold 
increase in CB1 as compared to the 10-fold increase at CB2.
266 The preference of 
C-1-methoxy for CB2 receptors holds true when comparing C-3-(1′,1′-dimethylheptyl)- 
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Figure 4.4. Amino and aminomethyl derivatives 
Note: aJ.W. Huffman265 M.E.D. stands for Minimum Effective Dose 
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Table 4.1. CB1/CB2 Ki ratios for selected compounds 
 
R1 
CB1/CB2 Ratio 
R2 = n-pentyl 
CB1/CB2 Ratio 
R2 = 1′,1′-dimethylheptyl 
-CN 4 13 
-NH2 3 4 
-NHCOCH3 >2
c 6 
-NHCONHCH3 >1.5
c 1 
 
>2c >3c 
-NHSO2CH3 >2
c 7 
cValues cannot be calculated accurately due to a CB1 affinity in excess of 3µM. 
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Figure 4.5. Amide and thiol derivatives 
aJ.W. Huffman265 
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Figure 4.6. C-1 deoxy and methoxy derivatives 
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Δ8-THC (104) (CB1 Ki = 713 nM; CB2 Ki = 57 nM)267 to C-3-(1′,1′-dimethylheptyl)-Δ8-
THC (32) (CB1 Ki = 0.77 nM; CB2 Ki = 0.27 nM).
242 Complete absence of a C-1- 
hydroxyl allows for good selectivity of CB2 (Figure 4.6).
250,267-270 This deoxy preference 
is exemplified by 1-deoxy-3-(1′,1′-dimethylheptyl)-Δ8-THC (105) (CB1 Ki = 22.8 nM; 
CB2 Ki = 2.9 nM) – a trend augmented by addition of C-11-hydroxy, with 
1-deoxy-11-hydroxy-3-(1′,1′-dimethylheptyl)-Δ8-THC (106) (CB1 Ki = 1.2 nM; CB2 Ki = 
0.03 nM) showing the highest CB1/CB2 ratio.
250,267 The data show the CB2 LBP has an 
inclination for C-1-deoxy or C-1-methoxy when compared to the CB1 LBP 
2 – which may 
indicate that the hydrogen bond in the LBP may not be as necessary as it is in the CB1 
LBP. Further derivation of these compounds utilizing C-1-Br have been tested and 
showed a similar preference for CB2, again downplaying the need for LBP H-bonding 
(Figure 4.6). In this modification of the C-1 substituent, 3-(1′,1′-dimethylhexyl)-1-Br-Δ8-
THC (107) (CB1 Ki = 1444 nM; CB2 Ki = 28 nM) exhibited the best CB1/CB2 ratio.
270 
4.2.2. Modifying the B-ring 
In most synthetic and all naturally occurring cannabinoids, the B ring is a pyran; 
however, there are synthetic derivatives wherein this ring exists as a piperidine (108)  
(Figure 4.7) (CB1 Ki = 0.6 nM) without any loss of activity compared to the pyran parent 
compound.271,272  Further derivation of the B ring into Δ6a,10a derivatives or oxepane 
derivatives gives some insight into the binding of these compounds into the LBP. For 
example, Δ6a,10a-lactones (109) (Figure 4.7) show inactivity at testing doses in a 
muricidal rat model (>10 mg/kg)273; however, the Δ6a,10a-C-6-gem-dimethyl (110) 
(Figure 4.7) showed substantially better activity (0.62 mg/kg)273 over Δ9-THC (1) 
(Figure 4.7) (5.0 mg/kg)273 in the same model. This demonstrates that Δ6a,10a increases 
efficacy; however, there is a need for hydrophobic substituents at C-6 to maximize this 
benefit.  
Expansion of the B ring to the oxepane and substituting C-6 and C-7 with 
concomitant unsaturation (Δ7a,11a) shows the limitations of the binding pocket about the 
tricyclic core. In the case of Δ7a,11a compounds where both C-6 and C-7 are unsubstituted 
(111) (Figure 4.7) (1.25 mg/kg)273, there is a gain relative to Δ9-THC (5.0 mg/kg) (1), but 
a loss compared to the Δ6a,10a-C-6-gem-dimethyl pyran derivative (0.62 mg/kg) (110) in 
the muricidal rat model. Further exploration of the oxepan derivatives shows that C-6-
gem-dimethyl (112) (Figure 4.7) (2.5 mg/kg)273 is better than a C-6-lactone (113) 
(Figure 4.7) (5 mg/kg),273 which further shows the need for hydrophobic substitution at 
this position. Interestingly, a C-7-gem-dimethyl substitution, with (114) (Figure 4.7) or 
without (115) (Figure 4.7) C-6-ketone, results in completely inactive compounds at 
tested doses (>10 mg/kg)273 – showing C-7 substitution may be detrimental. 
4.2.3. Modifying the C-ring 
 As is the case for the two novel classes examined in this chapter, unsaturation of 
the C-ring resulting in either Δ8 or Δ9 compounds is not necessary for activity.274-276 For  
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Figure 4.7. B-ring modifications 
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both  the hot plate and anti-writhing test models, conversion of Δ9-THC (1) (Figure 4.8) 
(>100 mg/kg and 43 mg/kg, respectively) to a Δ6a,10a derivative (116) (Figure 4.8) (9.3 
mg/kg and 3.0 mg/kg, respectively) showed a dramatic decrease in EC50.
276 
Completeunsaturation resulting in a benzene ring, in conjunction with a C-6 ketone 
moiety (117, 119, 121) (Figure 4.8), yields compounds near or better at CB2 receptors 
than those containing C-6-gem-dimethyl (118, 120, 122) (Figure 4.8) – it is noteworthy, 
that the C-6 ketone compounds did bear a great deal more selectivity for CB2 over 
CB1.
277 Along with this, conversion of the C-ring to a heterocyclic ring does not impede 
or improves activity.274-276 In fact, converting the C-ring to pyridine (123, 124) (Figure 
4.9) increased the efficacy of compounds over THC (1) (Figure 4.9) in both the rat tail 
flick and acetic acid writhing tests.274 Conversion of these pyridine C-ring derivatives to 
pyridine oxide rings (125, 126) (Figure 4.9) causes a substantial drop in efficacy,274 
suggesting that destabilization of the pi-ring system and/or size constraints about the C-
ring cause an issue. In cases where the C-ring was a Δ6a,10a-tetrahydropyridine (127, 128) 
(Figure 4.9), compounds exhibited an activity equivalent to or worse than Δ9-THC (1) 
(Figure 4.9) except in cases where the substituent on the tetrahydropyridine nitrogen was 
a small aliphatic group.275 There are references278,279 and compounds synthesized that 
attempt to modify C-11 into esters and ethers as an attempt to garner a prodrug and/or 
peripherally restricted compound. I discounted these modifications in this analysis 
because they are inactive until converted, at which time the active drug’s properties 
predominate. 
4.3. Non-Classical Cannabinoids – Heterocyclic Ring-Containing Compounds 
4.3.1. Aminoalkylindoles (AAIs) 
The aminoalkylindole (AAI) compounds, originally developed in the early to 
mid-1990s as non-steroidal anti-inflammatory drugs (NSAIDs), sought to inhibit the pain 
and inflammation pathways while diverting from the ulcerogenic properties common 
among non-COX-2 specific NSAIDs.280 These compounds have found favor and infamy 
in the synthetic cannabis designer drug realm. Some of the compounds herein are found 
in trace amounts in over-the-counter “herbal incense.” Recreational use of these herbal 
incense products has led to serious injury and death because of the cannabinoids 
hallucinogenic properties. Due to these serious issues, addictive potential and non-
regulated production and use, the DEA has classified many of these compounds as 
Schedule I controlled substances, despite their therapeutic potential. Structurally, they 
have no resemblance to classical cannabinoids; however, the eventual assignment of anti-
nociception via cannabinoid receptors281,282 has cemented these compounds as part of the 
cannabinoid family. By far the most widely studied of these compounds is WIN-55,212-2 
(Figure 4.10). WIN-55,212-2 is thus know to be a potent agonist at both CB1 and CB2. 
The close examination of this molecule has allowed the study of cannabinoids to draw 
some potential conclusions with regard to requirements and/or potential switches for 
functional activity.  
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Figure 4.8. C-ring unsaturation 
aJ.W. Huffman265 
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Figure 4.9. Heterocyclic derivatives of the C-ring 
Notes: aNumbers in parentheses are oral doses in mg/kg, percentages are percent 
reduction vs. control (THC). bN/A: Not Active 
  
  
 
Δ9-THC (1) 
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Anti-writhing: (43)
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Rat Tail Flick: (3.07)
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Anti-writhing: (3.3)
a
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Rat Tail Flick: (5.7)
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Anti-writhing: (7.1)
a
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Rat Tail Flick: (>27)
a
 
Anti-writhing: (>43)
a
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Rat Tail Flick: (>27)
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Anti-writhing: (>43)
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Rat Tail Flick: 132% (40)
a 
Anti-writhing: 82% (40)
a 
 
128 
Rat Tail Flick: N/A
b
 
Anti-writhing: N/A
b
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Figure 4.10. Derivations of N-1 of aminoalkylindoles 
Notes: aReference 225.272 bConcentration of compound required to inhibit 50% of 0.5 nM 
[3H]WIN-55,212-2 binding in rate cerebellum membranes as described in reference XX. 
Values are the IC50 or percent inhibition at the highest tested dose (nM). Negative values 
indicate stimulation rather than inhibition. cReference 247.282 dReference 248.283 
eReference 249.284 fReference 250.285 
Within the aminoalkylindoles, four pharmacophoric elements exist: 
 
  
 
WIN-55,212-2 
CB1 Ki = 1.9 nM 
CB2 Ki = 0.3 nM 
AM-630 
CB1 Ki = >5000 nM 
CB2 Ki = 31.2 nM 
Pravadoline (129) 
CB1 Ki = 2510 nM
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CB2 Ki = 320 nM
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b
 = 3155 nM
c 
   
130 
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 = 34% @ 3000 nM
c 
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IC50
b
 = 1.22 nM
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CB2 Ki = 3.4 nM
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CB2 Ki = 6.1 nM
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Study of WIN-55,212-2 led to a more refined understanding of the CB1 and CB2 LBP. 
1. N-1 substituents 
2. C-2 substituents 
3. C-3 substituents 
4. Indole ring substituents and derivatives 
4.3.1.1. N-1 substitutions of aminoalkylindoles. Other groups have synthesized 
and tested a number of indole analogs bearing different aminoalkyl substituents at N-1.282 
One such study found the aminoethyl substitution as an optimal requirement with  
morpholino (129), thiomorpholino (130) and piperidino (131) analogs – aminopropyl 
morpholino (132) demonstrated an induced rather than inhibitory binding for 
[3H]-WIN-55,212-2 (Figure 4.10). The respective acyclic amine, deemed to be possible 
metabolites, and piperazine analogs demonstrated activity similar to that of 132.282  
The Sterling Winthrop and Makriyannis laboratories further explored structural 
requirements at the N-1 position by synthesizing novel analogs in which the aminoalkyl 
chain of the indole ring is attached to a heterocyclic amine through a C–C bond. These 
analogs are generally more potent compared to the C–N analogs and exhibit more 
favorable physicochemical properties. Potency was optimum for 
N-methylpiperidinyl-2-methyl substitution at the N-1 position (133, Figure 4.10), with 
activity residing predominately in the R-enantiomer.283 
Mackriyannis, et al. developed AM-1241 (134, Figure 4.10), a highly 
CB2-selective and potent agonist.
284,286 Design of this molecule incorporated the 
N-methylpiperidinyl-2-methyl substituent at the N-1 position and a novel 
2-iodo-5-nitrobenzoyl group at C-3. AM-1241 exhibits remarkably high peripheral 
analgesia in vivo and does not produce catalepsy, hypothermia, inhibition of spontaneous 
locomotor activity or impairment of performance on the rotarod apparatus. This agent 
could thus see higher use in experimental neuropathic pain model experiments.287,288 
Replacement of the aminoalkyl substituent by an alkyl chain results in N-alkyl 
indoles (non-aminoalkylindoles) (e.g., 135, Figure 4.10). The SAR of cannabimimetic 2-
methylindoles indicates that compounds with N-alkyl substituents from n-propyl to n-
hexyl have good affinities for both CB1 and CB2 receptors and a preference for CB2. 
Previous reports of the in vivo potencies for these compounds are consistent with their 
receptor affinities.285,289,290 
4.3.1.2. C-2 substituents of aminoalkylindoles. Analysis of the effect of C-2 
substitution on cannabinoid receptor affinity in aminoalkylindoles reveals a strong 
preference for a small substituent at C-2. Thus, hydrogen or methyl groups are well 
tolerated with the C-2 H analogs (e.g., 136, Figure 4.11) (CB1 Ki = 245 nM; CB2 Ki = 11 
nM) exhibiting slightly higher affinities for the CB2 than C-2 methyl analogs (137, 
Figure 4.11) (CB1 Ki = 8 nM; CB2 Ki = 29 nM).
282,291,292 Recently, researchers at Bristol- 
Myers-Squibb reported their discovery of indazole carboxamides (e.g., 138, Figure 4.11), 
replacing the C-2 carbon of 3-amido aminoalkylindoles (136) with nitrogen. The indazole 
analog 138 exhibits high affinity for the CB2 receptor (Ki = 2.0 nM) compared to the 
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Figure 4.11. Modifications to C-2 of aminoalkylindoles 
  
  
136 
CB1 Ki = 245 nM 
CB2 Ki = 11 nM 
137 
CB1 Ki = 8 nM 
CB2 Ki = 29 nM 
  
  
138 
CB2 Ki = 2 nM 
139 
CB2 Ki = 1 nM 
 
 106 
corresponding AAI analogs.292 Indolopyridones (e.g., 139, Figure 4.11), which 
areconformationally restricted C-3 amido aminoalkylindoles, exhibit increased affinities 
for the CB2 receptor (Ki = 1.0 nM) and possess anti-inflammatory properties when 
administered orally in an in vivo murine inflammation model.292 
4.3.1.3. C-3 substituents of aminoalkylindoles. Pravadoline (129, Figure 4.10), 
was originally developed as an NSAID to circumvent the gastric issues of currently 
available NSAIDs; however, it was found to be anti-nociceptive via CB2, and it serves as 
the prototype for elucidating C-3 substituent variations.280,282 Additionally, this 
compound preceded and led to the discovery of WIN-55,212-2.281,293 The p-methoxy of 
129 gives good activity; however, ortho-substitution of the benzene ring with other 
groups such as CH3, OH, Cl, CN, or F (e.g. 140, Figure 4.12) diminishes activity. The 
presence of an ethyl group at the para position (141, Figure 4.12) improves potency, but 
further increase in chain length results in diminished potency. The 1-naphthoyl (142, 
Figure 4.12) (IC50 = 19 nM) substitution at C-3 is more potent than the 2-napthoyl (143, 
Figure 4.12) (IC50 = 128 nM) analog. Replacement of the naphthyl ring with an alkyl 
(e.g., CH3) or alkenyl [(CH3)2C=CH] groups results in complete loss of CB1 receptor 
affinity (Ki >10,000 nM).
289 
NMR and X-ray crystallography studies of 129 and its C-2 H analog have 
revealed that aminoalkylindoles can exist in two distinct conformations based on the 
orientation of the C-3 aryl system.260,280 In the s-trans (Figure 4.13A) conformation, 
which predominates when the C-2 substitution is hydrogen, the aryl group is nearest C-2, 
while the carbonyl oxygen locates near C-4. In the s-cis (Figure 4.13B) conformation, 
which predominates when the C-2 substituent is a methyl group, the conformational 
preference shows the aryl ring to be located near C-4, and the carbonyl oxygen near C-2.  
Naphthylidene-substituted alkylindenes (e.g., 144, Figure 4.12) were originally 
designed to circumvent the CNS side effects of 129.294 These analogs were tested as a 
mixture of E- and Z-isomers and exhibited higher CB1 affinity compared to 129. Later, it 
was shown that the CB1 and CB2 affinities and pharmacological potencies were higher 
for the E-isomer (144) compared to the Z-isomer.260 By removing the carbonyl oxygen of 
the C-3 aryl group in AAIs, having an unsubstituted C-2, one gets a moderate reduction 
in affinity for CB1 relative to their carbonyl precursors.
295 This loss of affinity is larger in 
the 2-methyl substituted analogs (145, Figure 4.12). Both observations support the 
hypothesis that the s-trans conformation of AAIs, such as WIN-55,212-2, is the preferred 
conformation for interaction at both CB1 and CB2 receptors, and that aromatic stacking of 
the ligands with aromatic residues in helices 3, 4, and 5 of both receptors may be an 
important interaction for AAIs at these receptors.260,295,296 
 The spatial and electronic requirements of the C-3 substituent were further 
explored by Bristol-Myers-Squibb, introducing a C-3 amide group. The AAI C-3 amide 
ligand 146 (Figure 4.12) with a methoxy group at C-7, exhibited high CB2 affinity (Ki = 
8 nM) and selectivity (CB1/CB2 = 500).
291 Replacement of the amino acid moiety in 146 
with the S-fenchylamine component resulted in slightly reduced affinity for the CB2 
receptor (Ki = 30 nM); however, when hydrogen replaced the 2-methyl group in indole, 
the resulting ligand (147, Figure 4.12) showed improved CB2 affinity (Ki = 11 nM).
291 
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Figure 4.12. Modifications to C-3 of aminoalkylindoles 
aConcentration of compound required to inhibit 50% of 0.5 nM [3H]WIN-55,212-2 
binding in rate cerebellum membranes as described in reference 238. Values are the IC50 
or percent inhibition at the highest tested dose (nM). Negative values (140) indicate 
stimulation rather than inhibition.   
   
  
 
140 
IC50
a
 = –2% @ 1000 nM 
141 
IC50
a
 = 306 nM 
142 
IC50
a
 = 19 nM 
   
   
143 
IC50
a
 = 128 nM 
144 
IC50
a
 = 1 nM 
145 
A R = H; CB1 Ki = 113 nM 
B R = CH3; CB1 Ki = 41 nM 
C R = OMe; CB1 Ki = 20 nM 
   
   
146 
CB1 Ki = 4000 nM 
CB2 Ki = 8 nM 
147 
CB1 Ki = 245 nM 
CB2 Ki = 11 nM 
148 
CB1 Ki = 221 nM 
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Figure 4.13. Confirmations of Pravadoline (129) 
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Derivation of the 4-alkyloxy indole analogs (e.g., 148, Figure 4.12) resulted from 
the translocation of the C-3 substituent of AAIs to C-4 via an ether linkage. Some of 
these exhibited in vivo cannabimimetic activity, but most of them lacked cannabinoid 
receptor affinity.297 
4.3.1.4. Indole Ring Substituents and Modifications. Introduction of a methyl 
group at C-4 or various substituents such as CH3, OCH3, F, Br or OH at C-5 of 129 
diminishes affinity. Conversely, C-6 substitution with CH3, OCH3 or Br groups improves 
receptor affinity, but the ligands exhibit diminished agonist properties.282 Incorporation of 
an iodo group at C-6 led to AM-630 (Figure 4.10), a ligand that exhibits improved 
affinity as well as selectivity for CB2.
298,299 This compound is selective inverse agonist 
for CB2,
300 and I have since confirmed confirmed through use of the ACTOne assay. 
 Substitution at C-7 (Figure 4.11; Figure 4.12) gives modest improvement in 
binding affinity. Potent analogs came to be by conformationally restricting the N-1 side 
chain through the formation of a six membered ring between the N-1 and C-7 substituents 
(not shown).281 For N-alkyl indoles, replacement of the indole phenyl ring with a 
cyclohexyl ring led to an analog with reduced affinities for both CB1 and CB2.
301 
Removal of the phenyl ring in AAIs or non-AAIs led to a pyrrole class.290,301 Most of the 
pyrrole-derived analogs are less potent than the corresponding indole derivatives; 
however, the 4-bromopyrrole analog shows high affinity for CB1 and CB2 (EC50 = 13.3 
nM for rCB1 and 6.8 nM for hCB2), comparable to WIN-55,212-2.
301 
4.3.2. Diarylpyrazoles 
The most widely studied compound of the diarylpyrazole class is SR-141716A 
(Rimonabant) (Figure 4.14) developed by Rinaldi-Carmona and co-workers at Sanofi.302 
Originally touted as a “wonder drug” for use in anti-obesity treatment, it was approved 
for use in Europe in 2006; however, it was withdrawn from the market in 2009 for the 
same reason approval was never granted in the United States of America – psychiatric 
side effects, some quite serious.211 This highly potent and selective CB1 receptor ligand 
has served as a unique pharmacological and biochemical tool for further characterization 
of the CB1 cannabinoid receptor
303,304 – serving as the prototype CB1 inverse agonist for 
evaluation of the compounds presented herein (Chapter 2). In vitro, SR-141716A 
antagonizes the inhibitory effects of cannabinoid agonists on both mouse vas deferens 
contractions305 and adenylyl cyclase activity.306 SR-141716A also antagonizes the 
pharmacological and behavioral effects produced by CB1 agonists after intraperitoneal 
(IP) or oral (PO) administration.302 
Other diarylpyrazole ligands that have contributed to our understanding of CB1 
pharmacology are AM-251 and AM-281, both of which are specialized CB1 antagonists 
known as inverse agonists (Figure 4.14), and capable of displacing [3H]SR-141716A and 
[3H]CP-55,940 in CB1 receptor membrane preparations.303 Both AM-251 and AM-281 
share the ability of SR-141716A to attenuate the responses to established cannabinoid 
receptor agonists like WIN-55,212-2 or CP-55,940; however, data show that AM-251 
may have a more “CB1-selective” role than SR-141716A.307 In addition to AM-630 (93), 
the most notable CB2 receptor inverse agonist is SR-144528 (Figure 4.14), a 
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Figure 4.14. Known standards of diarylpyrazole class of cannabinoid ligands  
  
 
 
SR-141716A (Rimonabant) 
CB1 Ki = 11.5 nM 
CB2 Ki = 1640 nM 
SR-144528 
CB1 Ki = 437 nM 
CB2 Ki = 0.6 nM 
  
  
AM-281 
CB1 Ki = 12 nM 
CB2 Ki = 4200 nM 
AM-251 
CB1 Ki = 7.5 nM 
CB2 Ki = 2290 nM 
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diarylpyrazole developed by Sanofi, exhibiting 700-fold selectivity for the CB2 receptor 
over CB1.
308Structural requirements for SR-141716A-like compounds are similar to those 
found in the aminoalkylindoles: 
1. N-1 substituents 
2. C-3 substituents 
3. C-4 substituents 
4. C-5 substituents 
4.3.2.1. N-1 substituents of diarylpyrazoles. 2,4-Dichlorophenyl (SR-141716A) 
is the optimal substituent for both high CB1 affinity and subtype selectivity.
303,309 Its 
replacement with (5-isothiocyanate)-pentyl (149, Figure 4.15) group decreased CB1 
affinity by a factor of four.310 The inclusion of strictly a phenyl (150, Figure 4.15), 
4-butylphenyl (151, Figure 4.15) or a 4-pentylphenyl (152, Figure 4.15) group at N-1 
significantly reduces affinity311,312 while n-pentyl (153, Figure 4.15), n-hexyl (154, 
Figure 4.15), n-heptyl (155, Figure 4.15) substitution retains good affinity, relative to 
SR-141716A.311 A 4-methylbenzyl group as represented in SR-144528 contributes 
optimal selectivity for CB2.308  
In the 2,4-dichlorophenyl moiety of SR141716A, elimination of p-chloro (156, 
Figure 4.16) substitution of o-chloro with o-fluoro (157, Figure 4.16) or o-methoxy 
(158, Figure 4.16) groups led to low-affinity analogs.313 Replacement of the 2,4-
dichlorophenyl moiety of SR141716A with cycloalkyl (159, Figure 4.16) groups 
decreased both CB1 and CB2 affinities, while the 3-methyl and 4-methylcyclohexyl 
analogs exhibited moderate improvement in CB2 affinity without any enhancement in 
selectivity compared to SR-141716A.314 
4.3.2.2. C-3 substituents of diarylpyrazoles. Alkylation of the amide group  
(e.g. 160) as well as replacement of the amide group by a ketone, alcohol or ether (e.g. 
161) greatly decreases CB1 affinity (Figure 4.17).
312,315 Replacement of the piperidinyl 
group with the respective five- or seven-membered heterocyclic rings or by a cyclohexyl 
group (e.g. 162, Figure 4.17) does not alter CB1 binding affinity. While replacement of 
the piperidinyl group with a morpholine group (163, Figure 4.17) leads to reduction in 
CB1 affinity. However, this seems to be true only in cases where the C-5-p-phenyl 
substituent is not iodine, as AM-281 retains good activity and excellent specificity.303 To 
probe the structural and steric requirements of this pharmacophore, alkyl hydrazines, 
amines and hydroxyalkylamines replace the aminopiperidinyl moiety.316 For alkylamides, 
hydroxyalkyl amides and alkyl hydrazides, affinity for CB1 increased directly with 
increasing chain length (across this group of compounds) from ethyl to butyl up to and 
including pentyl. Increasing the carbon chain length beyond pentyl reduces affinity for 
both receptors. Alkylamide analogs (e.g. 164, Figure 4.17) exhibited enhanced CB1 
selectivity when compared to SR-141716A, conversely hydroxyalkyl amide and 
alkylhydrazide analogs (e.g. 165, Figure 4.17) had both decreased affinities and 
equivalent to slightly worse selectivity for CB1 or CB2.
316 
4.3.2.3. C-4 substituents of diarylpyrazoles. Compounds with methyl, ethyl, 
bromo, or iodo substituents in the 4-position of the pyrazole ring are approximately  
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Figure 4.15. Alkyl N-1 modifications of diarylpyrazoles 
   
   
149 
CB1 Ki = 46 nM 
150 
CB1 Ki = 150 
151 
CB1 Ki = 226 nM 
   
   
152 
CB1 Ki = 433 nM 
153 
CB1 Ki = 23 nM 
154 
CB1 Ki = 21 nM 
   
 
155 
CB1 Ki = 47 nM 
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Figure 4.16. Aromatic and cycloalkyl modifications to N-1 of diarylpyrazoles 
  
  
  
156 
CB1 Ki = 8 nM 
157 
CB1 Ki = 37.8 nM 
  
  
158 
CB1 Ki = 440 nM 
159 
A R = cyclohexyl CB1 Ki = 351 nM 
CB2 Ki = 3210 nM 
B R = 3-methylcyclohexyl CB1 Ki = 494 nM 
CB2 Ki = 281 nM 
C R = 4-methylcyclohexyl CB1 Ki = 264 nM 
CB2 Ki = 479 nM 
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Figure 4.17. Modifications of C-3 of diarylpyrazoles 
 
  
 
 
160 
CB1 Ki = 100 nM 
161 
CB1 Ki = 221 nM 
  
  
162 
CB1 Ki = 11.7 nM 
CB2 Ki = 1010 nM 
163 
CB1 Ki = 125 nM 
CB2 Ki = 4580 nM 
  
  
164 
CB1 Ki = 18.1 nM 
CB2 Ki = 6870 nM 
165 
CB1 Ki = 50.9 nM 
CB2 Ki = 2850 nM 
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equipotent, whereas replacement of methyl with hydrogen results in a 12-fold decrease in 
CB1 affinity.
312 
4.3.2.4. C-5 substituents of diarylpyrazoles. The 4-chloro group of the phenyl 
ring can be replaced by bromo (e.g. 162) or alkyl groups (e.g. 156) but not by nitro or 
amino groups.222,303,312 Replacement of 4-chloro with a 4-iodo substituent (e.g. AM-251) 
leads to significant CB1 affinity and selectivity. Conversely, replacement of the aromatic 
ring with alkyl groups abolishes CB1 affinity.
303  
Solvay first reported some rigid SR-141716A, tricyclic CB1-selective ligands in 
which the 4- and 5-substituents are conformationally restricted through the formation of a 
relatively rigid tricyclic system.272,317 In these compounds the 4-methyl group is 
connected with the ortho position of the aromatic 5-aryl substituent to form 
benzocycloheptapyrazole analogs, i.e. 166 (Figure 4.18) that exhibited higher CB1 
affinity than the parent, SR-141716A.272,317 Later Pinna and co-workers reported similar 
tricyclic pyrazole analogs in which the additional 7-membered ring of 166 was replaced 
by a five-membered ring (e.g. 167, Figure 4.18).318 Of note, most ligands in this class 
had high affinity and selectivity for CB2 compared to 166 and SR-141716A. 
Solvay also reported a novel class of 3,4-disubstituted pyrazoline analogs 
exhibiting high CB1 selectivity (e.g., 168, Figure 4.18).
319 Another novel class of CB1 
antagonists that has received only limited attention includes the 3-alkyl-5-arylhydantoins 
(e.g. 169, Figure 4.18).320 
4.4. Novel Series of C-1′-Dimethyl-Hexahydro-Pyridine/Pyrimidine-THC Analogs 
(Hexahydro Series) 
4.4.1. Rationale of design 
Previous work from our group saw the synthesis of cycloalkyl234 and aromatic235 
substituents introduced at C-1′. Both groups of compounds saw marked improvement in 
affinity for CB1 and CB2 receptors (Chapter 3). To further expand upon this discovery, 
the novel pyridine and pyrimidine hexahydro compounds (Table 4.2) attempt to 
incorporate the advantages of the hexahydro compound’s increased potency271,272,276 as 
well as the increase in selectivity for CB2 added by addition of nitrogen into the ABC 
ring system.264,271,272 The binding data (Table 4.3) do show that the addition of the 
nitrogen(s) to the A-ring does not negatively impact the binding affinity relative to the 
carbocyclic hexahydros. In fact, this small change lends some increase and a measure of 
selectivity toward CB2. With an increase in binding affinity, coupled with the presence of 
favorable potential H-bonding interactions within the LBP of both CB1 and CB2 and the 
potential for a more therapeutically favorable preference of CB2 over CB1, a need existed 
to establish a functional mechanism for these compounds. 
Analysis of compound 172 via 1H-15N HSQC, 1H-13C HSQC and 1H-1H NOSY 
shows that the compound exists as the acetamide form (Figure 4.19). A diagnostic amide 
peak in the IR sepctra (1640 – 1690) was used to confirm that amide structure of the 
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Figure 4.18. Conformationally constrained and non-traditional diarylpyrazoles 
  
  
  
166 
CB1 Ki = 6.9 nM 
167 
CB1 Ki = 8.25 nM 
CB2 Ki = 0.23 nM 
  
  
168 
CB1 Ki = 16.6 nM 
CB2 Ki = >1000 nM 
169 
CB1 Ki = 70.3 nM 
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Table 4.2. Hexahydro-THC derivatives 
 
Pyridine Hexahydro-THC Pyrimidine Hexahydro-THC 
Compound Y R  Compound Y R 
170 CH 
 
 174 N 
 
171 CH 
 
 175 N 
 
172 CH 
 
 176 N 
 
173 CH 
 
 177 N 
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Table 4.3. Binding affinities for hexahydro series 
Compound CB1 Ki (nM) CB2 Ki (nM) 
170 1481 (N=1) 678 (±347.1) 
171 - - 
172 - 83 (±42.51) 
173 - - 
174 55 (N=1) 8.33 (±1.53) 
175 18.5 (±16.26) 1.67 (±1.15) 
176 >10,000 137 (±13.23) 
177 - 52.33 (±28.18) 
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Figure 4.19. NMR structure confirmation of the pyridine hexahydro compounds 
Notes: Panel A shows the actual structure of compound 172  in solution, and a possible 
way (in an aqueous environment) it would exist when interacting with the LBP. Panel B 
shows the existence of the N-H and thus amide composition of the A-ring. Panel C shows 
that position 4 is C, and thus the N-H must be at position 2 of the A-ring. Panel D shows 
the NOE correlation between the C-4 hydrogen and the C-6 methyl groups (weak) and C-
1′ methyl groups (strong). 
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remaining pyridine-related structures. Initial findings via the 1H-15N HSQC show that the 
nitrogen of the pyridine ring exists, at least in solvent, with a hydrogen atom attached to 
it; however, the question was if it remained at the 2 or 4 position of the A-ring. 1H-13C 
HSQC demonstrated that the 4 position was, indeed, a carbon with a hydrogen attached - 
1H-1H NOSY confirmed this finding by demonstrating weak coupling into both C-6 
methyl moieties and very strongly into both C-1′ methyl moieties. 
4.4.2. Objectives of the current study 
Utilizing this novel series of compounds, I explored the functional pharmacology 
of each in relation to CB1, CB2 and the parental HEK-293-CNG cell lines (covered in 
greater detail in Chapter 2) to better understand the mechanism of action (MoA) in a 
cell-based functional assay. Furthermore, to aid in explanation of the observed functional 
data, I will reconcile known literature with regard to binding and homology models. 
4.5. Functional Pharmacology 
4.5.1. ACTOne assay 
Assay development and conductance, discussed in detail in Chapter 2. Briefly, 
stably transfected HEK-293 cells co-expressed with modified CNG channels along with 
CB1 or CB2 or their parental cells (without CB1 or CB2; HEK-CNG) were plated at an 
appropriate density in a clear, 96-well, Poly-D-Lysine plate and allowed to incubate at 
37°C and 5% overnight. After the overnight incubation period, I added 100 μL of 
ACTOne membrane potential dye to each well of the culture plate and allowed to sit in a 
dark area at room temperature for 60 additional minutes. After the 60 minute incubation 
period a baseline read in a BioTek Synergy 2 plate reader with an excitation of 540/25 
nm and an emission of 590/20 nm. Following the baseline read, 50 μL of drug stock 
solution containing (Figure 4.20): appropriate concentrations of drug, Forskolin and Ro 
20-1724 in DPBS with 2.5% DMSO was added to the cell culture plate. The plate was 
then placed on the plate reader with 1 read per well per minute with an excitation of 
540/25 nm and an emission of 590/20 nm for 60 minutes. 
Screening of compounds against CB1 and CB2 were completed as technical 
replicates of n = 6 each. Screenings against HEK-CNG Parental and CB1/CB2 PTx-
sensitive Gi/o-inactivation were completed as technical replicates of n = 3 each. Utilizing 
the lower number of replicates for HEK-CNG Parental and CB1/CB2 PTx-sensitive 
Gi/o-inactivation was employed due to the expected lack of response from these 
compounds to those three (3) groups of assays, in an effort to maximize time and 
resource management without compromising data integrity or statistical significance. 
Primary data were analyzed with customized VBA macros (Chapter 2), 
developed internally, within Microsoft Excel (Redmond, WA). The experimental 
maximum response (100 % activity) was determined by Column 11 (lowest [drug]) at 
each individual time point, and the experimental basal response was determined by the  
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Figure 4.20. Drug plate layout and concentrations 
Notes: Columns 1 through 11 contain test compound, and Column 12 contains control 
wells. All listed concentrations are the final concentrations once added to the testing 
plate, so in the drug plate all compounds are at 5x of the listed concentrations in Columns 
1 through 11. Control wells (Column 12) are: “Blank” (cells, media and dye), “Ro” 
(“Blank” + 125 μM Ro 20-1724 [25 μM, Final]), “Ro/For” (“Ro” + 4 μM Forskolin [800 
nM, Final]) and "CP CTRL” (“Ro/For” + 25 μM CP-55,940 [5 μM, Final]). 
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average response given by the 2 “Ro” control wells. All data were normalized with these 
minimum and maximum values via Equation 2.1. The EC50 values were calculated from 
concentration-response curves by non-linear regression and automatic outlier elimination 
analysis utilizing GraphPad Prism Software (San Diego, CA). 
4.5.2. CB1 functional activity for the Hexahydro series 
Plates were run as previously described (Section 4.5.1) in six (6) replicates with  
CP-55,940 as the internal control for all six (6) replicates (Figure 4.21; Table 4.4). All 
compounds, with the exception of compound 176, bind with good affinity to the CB1 
receptor.259 Compounds 170, 171, 174 and 175 (Figure 4.22) demonstrated good agonist 
activity at CB1 with an EC50 of 78.9 nM, 209 nM, 276 nM and 56.3 nM, respectively, 
with percent cAMP inhibition ranging from 72 to 77%, 50 minutes after compound 
addition into the assay plate. These three (3) compounds exhibit a decrease in cAMP 
production equivalent to our standard of CP-55,940, albeit at a higher EC50 than for CP-
55,940. Special notation should be given to compound 173, because it shows itself to be a 
special type of antagonist, known as an inverse agonist – with an EC50 of 48.9 nM. 
4.5.3. CB2 functional activity for the Hexahydro series 
Plates were run as previously described (Section 4.5.1) in six (6) replicates with  
CP-55,940 as the internal control for all six (6) replicates (Figure 4.23; Table 4.4). All 
compounds in the series bind with good affinity to the CB2 receptor.
259 As was the case 
with the CB1 functional activity assays, compounds 170, 171, 174 and 175 (Figure 4.24) 
demonstrated agonist activity; however, they were not equipotent in terms of EC50 or 
percent cAMP inhibited at CB2 compared to CB1. EC50 for compounds 170, 171, 174 and 
175 were 333 nM, 835 nM, 682.1 nM and 66.8 nM, respectively, with percent cAMP 
inhibition ranging from 27 to 51%. Interestingly, compound 173 did not exhibit its 
inverse agonist activity against CB2, as it had for CB1. 
4.5.4. CNG parental functional activity for the Hexahydro series 
Plates were run as previously described (Section 4.5.1) in three (3) replicates with  
CP-55,940 as the internal control for all three (3) replicates (Figure 4.25; Table 4.4). As 
was expected, all compounds in the series failed to elucidate any change in the cAMP 
production of the cells, including the reference standard of CP-55,940. 
4.5.5. CB1 PTx-sensitive Gi/o-inactivation for the Hexahydro series 
Plates were run as previously described (Section 4.5.1) in three (3) replicates 
with CP-55,940 as the internal control for all three (3) replicates (Figure 4.26; Table 
4.4). All compounds failed to alter cAMP production, including the reference 
standard of CP-55,940. Only compounds 170, 171, 174 and 175 were screened in the 
PTx-sensitive Gi/o-inactivation assays due to their ability to elucidate a response in the 
standard CB1 assay. 
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Figure 4.21. CB1 functional activity of hexahydro series compounds, 50 minutes after compound addition. 
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Table 4.4. EC50 values for hexahydro series functional assays 
Compound 
CB1  
EC50 
or 
Concentration 
(% baseline) 
CB2  
EC50 
or 
Concentration 
(% baseline) 
CNG  
EC50 (nM) 
CB1 PTx  
EC50 (nM) 
CB2 PTx  
EC50 (nM) 
170 78.9a 333a n/a n/a n/a 
171 209a 835a n/a n/a n/a 
172 25 (40%)b n/a n/a - - 
173 250 (25%)b n/a n/a - - 
174 276a 682.1a n/a - n/a 
175 56.3a 66.8a n/a n/a n/a 
176 100 (12%)b 500 (36%)b n/a - - 
177 n/a n/a n/a - 
- 
 
Note: All concentrations are listed as nM, percentages indicate the change from baseline. n/a: Not active, based on no 
statistically significant change in cAMP from baseline. “-“ Indicates test not performed. a Indicates a decrease in cAMP as 
compared to baseline. b Indicates an increase in cAMP as compared to baseline. 
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Figure 4.22. CB1 functional activity for select hexahydro series compounds, 50 minutes after compound addition 
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Figure 4.23. CB2 functional activity for hexahydro series, 50 minutes after compound addition 
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Figure 4.24. CB2 functional activity for select hexahydro series compounds, 50 minutes after compound addition 
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Figure 4.25. HEK-CNG parental cell functional activity for hexahydro series, 50 minutes after compound addition 
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Figure 4.26. CB1 PTx-sensitive Gi/o-inactivation of functional activity for hexahydro series, 50 minutes after 
compound addition 
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4.5.6. CB2 PTx-sensitive Gi/o-inactivation for the Hexahydro series 
Plates were run as previously described (Section 4.5.1) in three (3) replicates with 
CP-55,940 as the internal control for all three (3) replicates of compounds 170, 171, 174 
and 175 As was expected, all compounds failed to alter cAMP production, including the 
reference standard of CP-55,940 (Figure 4.27).  
 
4.6. Discussion 
4.6.1. Interactions with the CB1 LBP 
As previously discussed (Section 1.2.2), CB1 receptors are 7 trans-membrane 
G-protein coupled receptors (GPCRs).14 Interaction of classical cannabinoids within 
the LBP of CB1 occurs primarily in domains 3, 6 and 7. Several homology models 
help to elucidate the residues important for binding and functional activity. 
To generate hypotheses, gain some insight into the possible explanations and 
interplay between ligand and receptor, I performed docking of the compound. Dr. 
Chang of The University of California, Riverdale, kindly supplied the models for the 
CB1 receptor. Dr. Chang provided 4 models: “ACEA” – to mimic the 
endocannabinoid binding, “HU-210” – to mimic the classical core binding, 
“SR-141716A” – to mimic the inverse agonist binding and “WIN-55,212-2” – to 
mimic the non-classical agonist binding.249 The hexahydro series of compounds, 
being similar in form to that of HU-210, I believe adopt a similar binding mode 
within the LBP, thus this was the model used for docking studies. 
4.6.1.1. C-1 hydroxyl. K192(3.28) plays a very important role in both receptor 
binding and function. Since it is a very flexible residue in the LBP, it may hydrogen 
bond with the C-1 hydroxyl, C-11 (“Northern”) hydryoxyl, C-6 (“Southern”) 
hydroxyl or even the benzochromene oxygen.250 However, newer data suggest that 
K192(3.28) plays a primary role as H-bond acceptor of the C-1 hydroxyl,251 
presumably this occurs after being activated by donating a H-bond to F189(3.25) 
(Figure 4.28).249 S383(7.35) interacts by donating a H-bond to either the 
benzchromene oxygen or the C-6 hydroxyl, if present (Figure 4.28).251 Additionally, 
data suggest that the resting state of the CB1 receptor exists when the salt bridge 
between K192(3.28) and D366(6.58) is intact.252 
The hexahydro series of compounds sought to further the functional activity and 
binding affinity of the KM Series (Chapter 3), and therein brought about novel activity. 
Within this series, aromatic substitutions yielded inverse agonists at CB1 and neutral 
antagoinsts CB2, while aliphatic substitutions at C-1′ yielded agonists at both CB1 and 
CB2. This is unique when considering the change between KM-233 (63), compounds 172 
and 176 are the inclusion of a pyridine and pyrimidine A-ring, respectively. NMR data 
shows the hexahydro compounds exist in solution as an amide at the A-ring, which may 
contribute to the binding modes in the LBP and change in activity compared to the KM 
series. 
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Figure 4.27. CB2 PTx-sensitive Gi/o-inactivation of functional activity for hexahydro series, 50 minutes after 
compound  
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Figure 4.28. CB1 LBP – amide and benzchromene oxygen interactions of 170, as compared to HU-210 
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Looking at compounds 170, 171, 174 and 175 and considering their agonist 
activity, two literature-reported interactions should be present for agonist activity:  
1. The K192(3.38) and D366(6.58) salt bridge must be severed.252  
2. Each of these ligands has to interact with both residues F200(3.36) and 
W279(5.43) to exert agonist effect.257 
The first is the severance of the salt bridge by interacting with K192(3.38). I hypothesize 
that this novel series of compounds binds similarly to classical cannabinoids; however, 
the key difference lies in the presence of the amide moiety in the A-ring. This moiety 
may cause the ABC ring to bind more deeply into the tricyclic (ABC ring) pocket to 
facilitate H-bonding between the amide N-H and K192(3.28) (Figure 4.28B). 
4.6.1.2. C-3 lipophilic side chain. A predominantly lipophilic pocket exists, 
seemingly as two lobes – as evidenced in the fact that 3-(1′,1′-dimethylheptyl)-Δ8-THC 
binds with higher affinity than does 3-heptyl-Δ8-THC along with 3D-QSAR models 
which demonstrate this trait.253 In one homology model, residues V196(3.32), 
T197(3.33), F200(3.36), Y275(5.39), W279(5.43), L359(6.51) and M363(6.55) form a 
hydrophobic pocket which encompasses the A-ring and C-3 side chain of HU-210.254 
More recent homology models form this pocket from I354(6.46), C355(6.47), 
W356(6.48), L359(6.51), L360(3.52) and M363(6.55) (Figure 4.29A).249Interestingly, 
mutations studies conducted on this hydrophobic pocket show that M363A(6.55) 
mutation greatly impacts binding affinity for HU-210 but has virtually no impact on THC 
which would suggest that this is an important residue for C-1′ substituted derivatives.255 
The hexahydro series, given that it shares a C-1′-gem-dimethyl substituent, likely share a 
similar interaction with M363(6.55) (Figure 4.29B). 
The second element suggested for an agonist is the simultaneous interaction with 
residues F200(3.36) and W279(5.43). Compounds 170, 171, 174 and 175, with their long, 
flexible, aliphatic C-3 substituents may still provide necessary interactions with both 
F200(3.36) and W279(5.43). The more compact and rigid aromatic substituents of 
compounds 176 and 177 may not provide these interactions as a result of the deeper 
binding into the tricyclic (ABC ring) pocket or stronger intra-molecular π-π interactions 
(Figure 4.30) and lack of activity. 
Looking at the special case of compounds 172, 173, 176 and 177 within the CB1 LBP, 
there is a unique situation. Given the current functional data generated from my assay 
conductance suggests that these compounds are members of a special class of 
antagonists, known as inverse agonists. Two key interactions are reported in literature to 
help stabilize the CB1 receptor in its inactive state: 
1. A salt bridge between residues K192(3.28) and D366(6.58).252 
2. A π-π stacking, rotameric “toggle” switch between residues F200(3.36) and 
W356(6.48).256,321,322 
I hypothesize that in order for compounds to bind into the LBP, they must break the salt 
bridge between K192(3.28) and D366(6.58). Thus, the salt bridge represents an inactive 
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A B 
Figure 4.29. CB1 hydrophobic C-3 substituent binding pocket 
Note: Panel A depicts HU-210 in the CB1 LBP, with focus given to the hydrophobic pocket. Panel B depicts Compound 170 in 
the CB1 LBP, with focus given to the hydrophobic pocket. 
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A B 
Figure 4.30. CB1 LBP – comparison of the aliphatic and aromatic hexahydro interactions 
Note: Panel A depicts Compound 170 interacting with W279(5.43). Panel B depicts Compound 176 with a lack of interaction. 
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state for the CB1 receptor; however, it does not represent a ligand-bound state of the 
receptor, because the act of binding ligand to receptor results in a severance of this 
salt bridge. The aromatic C-3 substituent of 172, 173, 176 and 177 would then 
potentially stabilize the “toggle” switch of F200(3.36) and W356(6.48) (Figure 4.31). 
The F200(3.36)/W356(6.48) stabilization is reported for inverse agonists. Given that 
the compounds in this series bind, but the aliphatic-substituted compounds lack of 
ability to stabilize the “toggle” switch points to a unique mechanism of aromatic 
substituents in CB1 LBP interactions. This hypothesis would be more consistent with 
the work of homology modeling of SR141716A322 and of McAllister, et al.256 – the 
group who thus behave as an inverse agonist. Dashed green lines indicate π-π 
interactions. Helix 3 shown in yellow, helix 6 shown in blue. originally proposed the 
salt bridge252 concept. In addition, it is important to note, that in the KM series there 
exists a thiophene derivative 78, which was an agonist at CB1. Thus, stabilization of 
the “toggle” switch in conjunction with a lack of interaction with both F200(3.36) and 
W279(5.43) – which is suggested to arise from the inclusion of a heteroatom-
containing A-ring, though the exact root cause is currently unknown – give the unique 
CB1 mechanism. 
4.6.1.3. ABC ring system. Residues F174(2.61) and F177(2.64) are not suggested 
to be involved in binding to HU-210, but rather they help stabilize the tricyclic (ABC 
ring) pocket where the ABC benzochromene ring binds the LBP.255 Residues 
F200(3.36) and W279(5.43) appear to play an  important a role in both in terms of 
binding (in the case of AEA and CP-55,940) and  receptor activation (Figure 
4.30).257That is to say, a ligand’s hydrophobic substituents at the C3 position may 
bind well without interacting with these two residues, but agonists MUST have 
interaction with these residues to exert their effect.254 F189(3.25) is key at providing a 
π-π stacking interaction with HU-210  (Figure 4.32A), and is instrumental in binding 
of AEA to the pocket as its mutation to alanine causes a 7-fold drop in affinity for the 
receptor.258 F189(3.25) also seems to form the “ceiling of the anandamide binding 
pocket in CB1.”257 From a π-π stacking standpoint, the hexahydro series shares these 
interactions (Figure 4.32B) – though not depicted on the 2D output. However, the 
major difference lies in the compounds’ ability to interact with the key residues, 
which were addressed previously. 
4.6.1.4. (Optional) C-11 (“Northern”) hydroxyl. While there is not data 
currently to confirm, logical extension of the known fact that C-11 hydroxylation is the 
primary metabolite of the KM series would suggest that this would be a. metabolite of the 
hexahydro series. As a result of this metabolite potentially contributing to the overall 
activity of the compound in vivo, this potential interaction is discussed and explored. 
S383(7.35) shows itself to be equally important in binding of molecules along with 
stabilizing the LBP. S383(7.35) can hydrogen bond with the C-11 hydroxyl251 (if present) 
or the benzochromene oxygen249,254, but more importantly it helps to stabilize the LBP by 
maintaining the shape of the trans-membrane helix 1-2-7 binding pocket.251 The 
“Northern” hydroxyl group may also H-bond with K192(3.28); however, this is not a 
preferred interaction in several recent homology models. 
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Figure 4.31. Stabilization of the CB1 LBP in the inactive state 
Note: Panel A depicts the two (2) key residues involved in stabilizing the inactive state of 
CB1. Panel B depicts these two (2) residues in the active state of the receptor. Panel C is 
the hypothesized interaction of 173 to stabilize the CB1 receptor in the inactive state. 
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Figure 4.32. CB1 LBP proposed π-π stacking and key residue interactions 
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4.6.2. Interactions with the CB2 LBP 
As previously discussed (Section 1.2.3), CB2 receptors are also 7 trans-membrane 
GPCRs; however, CB2 only shares 48% homology with CB1 – a trait unique to the CB1 
and CB2 receptors among GPCRs, which generally share a much higher level of 
homology among receptors of the same family.14 The SAR of the CB2 LBP has yet to be 
fully developed – even less so with the classical cores. B/C ring trans junction. With data 
relatively limited for CB2’s LBP, especially in the arena of classical core compounds, one 
must make some inferences based on available aminoalkylindole derivative homology 
model data. One such extrapolation lies in WIN-55,212-2’s biologically assumed 
conformation to be s-trans-conformer.260 Docking the s-cis-conformer, there are steric 
interactions with V113(3.32) (Figure 4.33).261 Existence of this clash may suggest a trans 
junction of the B/C ring allows for proper orientation in the LBP to circumvent this steric 
interaction with V113(3.32) within the classical core molecules. By extension, WIN-
55,212-3, the S-(-) isomer of WIN-55,212-3, may also orient the morpholino side chain 
such to prevent critical amino acids interactions in the CB2 LBP as discussed 
below.Taking WIN-55,212-2 and ascribing its moieties to those of the representative 
example of 172 (Figure 4.34), one can see that there are many similarities. While the 
similarities are numerous, the differences are profound as well, because the steric 
interactions of WIN-55,212-2 with V113(3.32) are apparently non-existent with the 
hexahydro series. The steric issue comes in with what I hypothesize to be the “northern” 
aliphatic hydroxyl region, or C-11 substituted derivatives of Δ8-THC, thus the hexahydro 
series has little to contend with in this arena. 
4.6.2.1. C-1 Hydroxyl, benzchromene oxygen and (optional) C-6 hydroxyl. 
Mutation studies with HU-210, CP-55,940 and WIN-55,212-2 have shown that binding 
of both HU-210 and CP-55,940 experience negative consequence with a S292A 
mutation. This mutation-induced change of binding strongly suggests S292(7.46) is 
involved in H-bonding with the benzchromene oxygen – assuming a similar LBP 
arrangements relative to the CB1 LBP.
323 Though WIN 55-212-2’s ketone is in suggest to 
be in proximity to residue S193(5.42) it does not appear to hydrogen bond.261 In the case 
where amide linkages exist between the aryl groups, it is suggested that S193(5.42) does 
act as a H-bond donor.324,325 
4.6.2.2. Hydrophobic and π-π stacking. As has been the case previously, it 
remains so that many of the interactions derive from the aminoalkylindole derivative 
WIN-55,212-2. Beginning with the indole ring of WIN-55,212-2, there are reported π-π 
stacking interactions between it and residues F197(5.46), W258(6.48) and F117(3.36).261 
There also exists a shared π-π stacking between the indole ring and napthyl ring with 
residue W194(5.43).261 The napthyl ring has an added π-π stack with residue 
F106(3.25).261 More recent 2-pyridone derivatives add additional residues to the binding 
pocket for π-π stacking, namely Y190(5.39) and F281(7.35) along with a C288(7.42) 
residue.324,325 For the 2-pyridone analog containing N-butyl, there involves a hydrophobic 
interaction with I198(5.47).325 
4.6.2.3. Proposed interactions of the hexahydro series with the CB2 LBP. Due 
to their similarities, compounds 170, 171, 174 and 175 are the aliphatic constellation and  
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Figure 4.33. CB2 LBP steric hinderance of cis and trans isomers of WIN-55,212-2 
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Figure 4.34. Comparison of analogous functional groups of WIN-55,212-2, 172 and 
WIN-55,212-3 
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compounds 172, 173, 176 and 177 are the aromatic constellation. Similar to the KM 
Series, I hypothesize that the binding mode for the hexahydro series is more similar to 
THC, in that the ABC ring occupies the tricyclic (ABC ring) pocket of the LBP and the 
C-3 substituents project into the major pocket. Therein the major pocket lies the key 
residue of W258(6.48), the rotameric “toggle” switch for CB2 – proposed to H-bond with 
L255(6.45) to open place C2.57(6.47) in optimal range for agonist interaction.326  As was 
the case in CB1, compounds 170, 171, 174 and 175, with their long, flexible, aliphatic C-
3 substituents can then still provide necessary interactions with W258(6.48) while still 
allowing the rotameric change from gauche+ to trans of the residue (Figure 4.35). 
4.7. Conclusions 
The pyridine and pyrimidine hexahydro series of compounds represent a novel 
series of compounds, which may also give insight into the binding mode and residue 
interactions of these compounds in the CB1 LBP. The presence of the amide moiety in the 
A-ring causes these series of compounds to bind further into the tricyclic (ABC ring) 
pocket of the CB1 LBP making interaction with the two (2) key residues, F200(3.36) and 
W279(5.43), possible only with a long, flexible C-3 substituent – such as that found on 
170, 171, 174 and 175. Unique mechanisms with regard to heterocyclic stabilization of 
the CB1 receptor’s inactive state by aiding in the π-π stacking of residues F200(3.36) and 
W356(6.48) to yield an inverse agonist. Interactions within the CB2 LBP can only be 
postulated in the absence of a refined model. Hoewever, aromatic C-3 substituents seem 
to stabilize the gauche+ rotamer of W258(6.48) in order to yield an antagonist at CB2 – 
aliphatic substituents allow for rotation of W258(6.48) and thus receptor activation. 
Future studies to test these hypotheses would be to conduct homology model 
studies with these compounds – more specifically to reconcile the divergence of binding 
mode for these compounds and further solidify key residues. Additionally, synthesis of 
other derivatives would help to determine a more exact functional pharmacophore. 
Lastly, testing of the antagonist compounds against known CB1 and CB2 agonists will 
confirm this mechanism and establish EC50 doses for these compounds. 
 143 
 
Figure 4.35. Proposed CB2 LBP residues for compound 170 
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CHAPTER 5. FUNCTIONAL EVALUATION OF A NOVEL CLASS OF 
TRIARYL CANNABINERGIC LIGANDS 
5.1. Introduction 
As previously discussed (Section 1.1), classical cannabinoids are tricyclic 
compounds possessing a benzopyran core – these are of either natural origin or synthetic 
analogues thereof. The naturally occurring, prototypes for these compounds are Δ9-THC 
and Δ8-THC, which both bind to CB1 and CB2 receptors and exert a partial agonist 
activity.14 Chapter 3 and Chapter 4 have been examples of the extensive study and 
mining of these classical core compounds for functional pharmacophoric elements. To 
further the field and probe CB1 and CB2 further, new chemical scaffolds are essential. To 
move away from the classical core and parse out even more functional pharmacophoric 
elements, the non-classical cannabinoids came into their own right. These non-classical 
cannabinoids sought to simplify the overall structure of cannabinoid ligands and to 
augment the understanding of CB1 and CB2 ligand requirements. 
It has been established through study of these non-classical cannabinoids that 
simplifying the overall structure to that of an AC-bicyclic increases the affinity for both 
CB1 and CB2; however, transition from AC-bicyclic to ACD-tricyclic allows for 
selectivity between CB1 and CB2 (Section 5.2.1). Merging traits of the classical with 
these AC-bicyclic and ACD-tricyclic compounds gave rise to a hybrid crossover series, 
with increased affinity for both without any appreciable selectivity (Section 5.2). The 
biaryl class of cannabinoid compounds sought to take the best of the classical C-3 
substituent and merge it with the bicyclic structure of the AC-bicyclic compounds, 
resulting in a series with very good affinity and specificity towards CB2 (Section 5.2.3). 
A final derivative in the non-classical cannabinoid derivatives was that of the triaryl 
bis-sulfones, which were the result of the diarylpyrazole derivatives and resulted in 
extremely potent and selective compounds at CB2 (Section 5.2.4). 
Taking this non-classical knowledge and amalgamating it with the previous 
classical, KM series and hexahydro-heteroaromatic compounds, gave rise to 4 distinct 
classes of triaryl cannabinoid ligands: HB series, SMM series, pyridine triaryl series and 
pyrimidine triaryl series (Figure 5.1; Section 5.3). The aim of this study is to utilize the 
ACTOne Assay (Chapter 2) to explore the functional effects of the HB series (Section 
5.4.2), SMM series (Section 0), pyridine triaryl series (Section 5.4.4) and pyrimidine 
triaryl series (Section 5.4.5). Following this, I will reconcile these data against current 
literature standards’ binding and homology models to propose hypothetical interactions 
within the CB1 and CB2 LBP to further develop the SAR, functional pharmacophore and 
unique MoA of these compounds. 
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Figure 5.1. Triaryl series design flow 
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5.2. Non-Classical Cannabinoids 
5.2.1. AC-bicyclic and ACD-tricyclic compounds 
These series of compounds were developed by Pfizer and omit the B-ring of the 
classical cannabinoid compounds, which is generally a pyran ring. The best known of 
these series is CP-55,940 (Figure 5.2), which works to incorporate many of the 
previously mentioned elements of the classical cannabinoids without, itself, being a 
classical cannabinoid. This AC-bicyclic structure has very good affinity and no 
specificity for CB1 and CB2 (CB1 Ki = 0.6 nM; CB2 Ki = 0.7 nM). Closely related to 
CP-55,940 is CP-47,497 (Figure 5.2) which incorporates all of the same elements with 
the notable exception of a southern aliphatic hydroxyl (SAH). Lack of the SAH in 
CP-47,497 causes almost a 4-fold increase in affinity for the CB1 receptor (CB1 Ki = 2.1 
nM). While this is in no way a poor compound, it does show the added benefit of the 
SAH moiety in these compounds. Knowing that the SAH is a useful component of the 
cannabinoid compounds, a more conformationally restricted ACD-tricyclic derivative 
was synthesized with CP-55,244 (Figure 5.2) (CB1 Ki = 0.21 nM). Restricting the SAH 
to project into the tricyclic (ABC ring) pocket allows for a compound that is more potent 
than the prototype CP-55,940. Still missing was the lack of specificity for targeting CB2 
over CB1; however, the advent of the AC"D"-tricyclic ligand of HU-308 (Figure 5.2) 
(CB1 Ki = >10,000 nM; CB2 Ki = 22.7 nM) helped to change that. 
5.2.2. Hybrid cross-over compounds 
After the advent of the non-classical cannabinoid compounds, and with good 
understanding of classical cannabinoids, compounds were synthesized to take advantage 
of useful aspects of both – more namely the C3-1′,1′-dimethylheptyl of the classical and 
the SAH of the non-classical compounds. These compounds served a unique purpose in 
the understanding of cannabinoids by providing three-dimensional probes for the CB1 
and CB2 LBP. Data from studies conducted in the Makriyannis lab group demonstrated 
that C-6 β-hydroxypropyl (178a, Figure 5.3) (CB1 Ki = 70.5 nM) had a higher affinity 
for CB1 than did its α-hydroxypropyl (178b, Figure 5.3) (CB1 Ki = 1353 nM) epimer.327-
329 Further derivation of these hybrid compounds led to unsaturation at the 1′ position of 
the C-6 SAH substituent. The alkyne (179, Figure 5.3) demonstrates great affinity for 
both CB1 (Ki = 1.2 nM) and CB2 (Ki = 0.3 nM), with a slight affinity for CB2. The alkene 
(180, Figure 5.3) demonstrates good affinity for both CB1 (Ki = 0.7 nM) and CB2 (Ki = 
8.6 nM), with a >10-fold affinity for CB1 – the C1′′ cis isomer (not pictured) of 180 
demonstrated a difference in activity (CB1 Ki = 2.24 nM; CB2 Ki = 0.33 nM).
330 It is 
noteworthy, that the values listed for compounds 179 and 180 are for the racemic 
mixture, and that work by Thakur and co-workers demonstrated that the active isomer of 
180 is, as drawn, the 6S, 6aR, 9R, 10aR configuration.331 
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Figure 5.2. Non-classical cannabinoids 
  
  
CP-55,940 
CB1 Ki = 0.6 nM 
CB2 Ki = 0.7 nM 
CP-47,497 
CB1 Ki = 2.1 nM 
  
  
CP-55,244 
CB1 Ki = 0.1 nM 
HU-308 
CB1 Ki = >10,000 nM 
CB2 Ki = 22.7 nM 
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Figure 5.3. Hybrid cannabinoid ligands  
  
 
 
178a 
CB1 Ki = 70.5 nM 
178b 
CB1 Ki = 1353 nM 
  
  
179 
CB1 Ki = 1.2 nM 
CB2 Ki = 0.3nM 
180 
CB1 Ki = 0.7 nM 
CB2 Ki = 8.6 nM 
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5.2.3. Biaryl cannabinoids 
As an added attempt to bridge the gap among the non-classical cannabinoids and 
further hone in upon a CB2-selective compound, the biphenyl compounds were developed 
by Makriyannis’ group. These compounds sought to build upon the work at Pfizer with 
the “CP” compounds, and add the selectivity of HU-308. The group, overall, has good 
affinity, with the prototype compound (181, Figure 5.4) having good affinity for both 
receptors, with a CB1 Ki = 2.6 nM and a CB2 Ki = 0.6 nM. Addition of more substituents 
to the “C”-ring (e.g. 182 and 183, Figure 5.4) led to a nearly 100-fold and 300-fold 
preference for CB2 over CB1, respectively. Incorporation of a heteroaromatic (furan) ring 
as the “C”-ring (184, Figure 5.4) confers a great deal of CB2 selectivity (CB1/CB2 ratio = 
90).332 This class of compounds has been disclosed in patent literature; however, little 
outside thereof has come to be known about these compounds. 
5.2.4. Triaryl bis-sulfones 
Initial discovery of these compounds was a direct result of work in the discovery 
and development of the diarylpyrazoles, such as SR-141716A. These were originally 
conceived as biaryl sulfone compounds (e.g. 185, Figure 5.5); however, analogs of this 
compound and an ultra-pure sample of this compound showed poor activity. Analysis of 
185 via LCMS demonstrated a tainted sample – which in light of the pure sample’s 
failure to elucidate effect, were likely contributing to the activity in vitro. Of these 
impurities, compound 186 (Figure 5.5) became the new lead molecule for 
development.333 Derivation of this lead compound centered initially on the substituents 
attached to the B- and C-ring, where investigation demonstrated a penchant for 
substitution at the 2 position of the C-ring and small alkyl/halogen substitution at the 4 
position of the B-ring.334 Also examined were the linkages between A- and B-rings and 
B- and C-rings, with sulfone being the only link tolerated between B- and C-rings and 
ultimately the best choice for both junctions.334 Next in the elucidation and optimization 
for these compounds was the amide moiety, attached to the A-ring. Modifications about 
this position seemed to favor small substituents, with a preference for electron 
withdrawing groups. The primary example being the trifluoromethyl derivative (186) 
(CB1 Ki = 235 nM; CB2 Ki = 0.3 nM). This trait was further exemplified by the 
methylsulfonamide derivative (187, Figure 5.5) (CB1 Ki = 905 nM; CB2 Ki = 0.4 nM) – 
showing inverse agonist activity in the [35S]GTPγS assay, with an EC50 of 0.6 nM.333  
Further development of 187 saw modifications to the C-ring, where o-F-phenyl 
(188, Figure 5.5) (CB2 Ki = 1.3 nM; CB1 Ki/CB2 Ki = 4387) and 2-pyridine (189, Figure 
5.5) (CB2 Ki = 2.9 nM; CB1 Ki/CB2 Ki = 4403) exhibited similar selectivity ratios, but 
o-F-phenyl demonstrated a superior CB2 Ki.
335 With a newly optimized C-ring, the amide 
moiety of the A-ring was re-examined, and data demonstrated that a 
trifluromethylsulfonamide (190, Figure 5.5) (CB2 Ki = 2 nM) held top honors.
335 The 
next step in optimization of the compound was to examine the halogen substitution on the 
B-ring; however, Cl held its place atop the possible moieties examined.335 To complete 
the cycle, the C-ring was examined with the newly optimized trifluoromethylsulfonamide 
present on the A-ring, and as with the Cl, o-F-phenyl retained its spot.335 
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Figure 5.4. Biaryl cannabinoid ligands 
  
  
  
181 
CB1 Ki = 2.6 nM 
CB2 Ki = 0.6 nM 
182 
CB1 Ki = 1365 nM 
CB2 Ki = 15.3 nM 
  
  
183 
CB1 Ki = 241 nM 
CB2 Ki = 0.8 nM 
184 
CB1 Ki = 3223 nM 
CB2 Ki = 35.4 nM 
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Figure 5.5. Triaryl bis-sulfone derivatives 
  
  
  
185 
Impure CB2 Ki = 31 nM 
Pure CB2 Ki = >1000 nM 
186 
CB1 Ki = 235 nM 
CB2 Ki = 0.3 nM 
  
  
187 
CB1 Ki = 905 nM 
CB2 Ki = 0.4 nM 
188 
CB2 Ki = 1.3 nM 
CB1 Ki/CB2 Ki = 4387 
  
  
189 
CB2 Ki = 2.9 nM 
CB1 Ki/CB2 Ki = 4403 
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CB2 Ki = 2 nM 
CB1 Ki/CB2 Ki = 3393 
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5.3. Novel Series of Triaryl Cannabaergic Ligands 
5.3.1. Rationale of design 
As previously examined in Chapter 3, the C-1′-dimethyl-aryl-Δ8-THC analogs 
demonstrated a unique mechanism in that they were agonists at CB1 and antagonists at 
CB2. Additionally, considering the increase in binding affinity gained with this novel 
series, they are good agents in their own right; however, as scientists are in the pursuit of 
as near perfection as one may attain, “good” is not good enough. Recall, too, the increase 
in binding affinity gained from the biaryl cannabinoids (Section 5.2.3) – though these 
particular cannabinoids did not lend themselves to specificity. With the combination of 
these two series, a third novel series was born – the HB series (Table 5.1). 
Success of the HB series compounds in testing led one-step further in 
development – combine the qualities and attributes of the HB series with those of the 
triaryl bis-sulfones (Section 5.2.4). The hypothesis is that one may retain the well-
established attributes of a C-1′ derivative while maximizing the hydrophilic interactions 
within the LBP – thus the SMM series (Table 5.2) came to be. To further hone activity, 
consideration was given to the classes of the aminoalkylindoles (Section 4.3.1) and 
diarylpyrazoles (Section 4.3.2), which have proven repeatedly that they are a potent 
classes of compounds. Additionally, the successes of the hexahydro heterocyclic 
derivatives discussed in Chapter 4 add another layer of consideration to the developing 
cannabinoid pharmacophore. Coupling all of these components with the SMM and HB 
series spawned two unique series to mimic the heterocyclic central core of the 
diarylpyrazoles and aminoalkylindoles. A heterocyclic A-ring afforded the pyridine 
(Table 5.3) and pyrimidine (Table 5.4) triaryl series of compounds. All were synthesized 
to separate affinity and/or activity to yield therapeutically viable compounds. 
5.3.2. Objectives of the study 
Utilizing these 4 novel series (Figure 5.6), I explored the functional 
pharmacology of each in relation to CB1, CB2 and the parental HEK-293-CNG cell lines 
(greater detail in Chapter 2) to better understand the functional activity. Further, 
reconciliation of known literature of binding and homology models helps to explain 
observed data and interaction of the ligands with the LBP of CB1 and/or CB2 receptors. 
 
Figure 5.6. Generic triaryl structure nomenclature 
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Table 5.1. HB triaryl series analogues 
 
ID R1 (C-ring) R2 (D-ring) R3 
191 
 
 
H 
192 
 
 
OH 
193 
 
 
OH 
194 
 
 
OMe 
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Table 5.2. SMM triaryl series analogues 
 
ID R1 (C-ring) R2 (D-ring) R3 R4 R5 
195 
 
 
OH OH 
 
196 
 
 
OMe OMe 
 
197 
 
 
OMe OMe 
 
198 
 
 
OMe OMe 
 
199 
 
 
OMe OMe 
 
200 
 
 
OMe OMe 
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Table 5.2. (Continued) 
 
 
ID R1 (C-ring) R2 (D-ring) R3 R4 R5 
201 
 
 
OMe OMe 
 
202 
 
 
OMe OMe 
 
203 
 
 
OMe OMe 
 
204 
 
 
OMe OMe 
 
205 
 
 
OMe OMe 
 
206 
 
 
OH OMe 
 
 
 156 
Table 5.2. (Continued) 
 
 
ID R1 (C-ring) R2 (D-ring) R3 R4 R5 
207 
 
 
OH OH 
 
208 
 
 
OH OMe 
 
209 
 
 
OH OH 
 
210 
 
 
OH OMe 
 
211 
 
 
OH OH 
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Table 5.2. (Continued) 
 
 
ID R1 (C-ring) R2 (D-ring) R3 R4 R5 
212 
 
 
OMe OMe 
 
213 
 
 
OMe OMe 
 
214 
 
 
OH OH 
 
215 
 
 
OH OH 
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Table 5.3. Pyridine triaryl series compounds 
 
ID R1 R2 
216 
  
217 
 
 
218 
 
 
219 
 
 
220 
 
 
221 
 
 
 
 
 159 
Table 5.3. (Continued) 
 
 
ID R1 R2 
222 
 
 
223 
 
 
224 
 
 
225 
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Table 5.3. (Continued) 
 
 
ID R1 R2 
226 
 
 
227 
 
 
228 
 
 
229 
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Table 5.4. Pyrimidine triaryl series compounds 
 
ID R1 R2 
230 
 
 
231 
 
 
232 
 
 
233 
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Table 5.4. (Continued) 
 
 
ID R1 R2 
234 
 
 
235 
 
 
236 
  
237 
 
 
238 
  
239 
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5.4. Functional Pharmacology 
5.4.1. ACTOne Assay 
 Assay development and conductance was discussed in detail in Chapter 2. 
Briefly, stably transfected HEK-293 cells co-expressed with modified CNG channels 
along with CB1 or CB2 or their parental cells (without CB1 or CB2; HEK-CNG) were 
plated at an appropriate density in a clear, 96-well, Poly-D-Lysine plate and allowed to 
incubate at 37°C and 5% overnight. After the overnight incubation period, 100 μL of 
ACTOne membrane potential dye was added to each well of the culture plate and allowed 
to sit in a dark area at room temperature for 60 additional minutes. After the 60 minute 
incubation period a baseline read in a BioTek Synergy 2 plate reader with an excitation of 
540/25 nm and an emission of 590/20 nm. Following the baseline read, 50 μL of drug 
stock solution containing appropriate concentrations of drug (Figure 5.7), Forskolin and 
Ro 20-2304 in DPBS with 2.5% DMSO was added to the cell culture plate. The plate was 
then placed on the plate reader with 1 read per well per minute with an excitation of 
540/25 nm and an emission of 590/20 nm for 60 minutes. 
Screening of compounds against CB1 and CB2 were completed as technical 
replicates of n = 6 each. A decrease in the number of replicates (n = 3) for HEK-CNG 
Parental and CB1/CB2 PTx-sensitive Gi/o-inactivation was employed due to the expected 
lack of response from these compounds to those three (3) groups of assays, thus 
maximizing resource allocation and ensuring accurate data evaluation. 
Primary data were analyzed with customized VBA macros (Chapter 2), 
developed internally, within Microsoft Excel (Redmond, WA). Column 11 (lowest 
[drug]) determined the experimental maximum response (100 % activity) at each 
individual time point, and the experimental basal response was determined by the average 
response given by the 2 blank control wells. All data were normalized with these 
minimum and maximum values via Equation 2.1. The EC50 values were calculated from 
concentration-response curves by non-linear regression and automatic outlier elimination 
analysis utilizing GraphPad Prism Software (San Diego, CA). 
5.4.2. Functional activity for HB triaryl series 
5.4.2.1. CB1 functional activity for the HB series. Plates were run as previously 
described (Section 4.5.1) in six (6) replicates with CP-55,940 as the internal control for 
all six (6) replicates (Figure 5.8). Compounds 192 and 193 demonstrated agonist activity 
at CB1 with an EC50 of 993 nM, 1429 nM, respectively, with percent cAMP inhibition 
ranging from 46% to 57%, 50 minutes after compound addition into the assay plate 
(Table 5.8). These two (2) compounds exhibit a decrease in cAMP production equivalent 
to our standard of CP-55,940, albeit at a higher EC50. Compound 191 was tested at a 
lower concentration gradient than the other three (3) compounds to examine the effects of 
its mono-hydroxy A-ring more directly with compound 195. However, data do suggest 
that shifting the concentrations to the higher range may result in curves more similar to 
192 and 193, with a 10% decrease in cAMP at 1 μM drug concentration.  
 164 
 
Figure 5.7. Drug plate layout and concentrations 
Notes: Columns 1 through 11 contain test compound, and Column 12 contains control 
wells. All listed concentrations are the final concentrations once added to the testing 
plate, so in the drug plate all compounds are at 5x of the listed concentrations in Columns 
1 through 11. Control wells (Column 12) are: “Blank” (cells, media and dye), “Ro” 
(“Blank” + 125 μM Ro 20-2304 [25 μM, Final]), “Ro/For” (“Ro” + 4 μM Forskolin [800 
nM, Final]) and "CP CTRL” (“Ro/For” + 25 μM CP 55,940 [5 μM, Final]). 
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Figure 5.8. CB1 functional activity of HB triaryl series, 50 minutes after compound addition 
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Table 5.5. EC50 values for HB triaryl series 
Compound 
CB1   
EC50 
or 
Concentration 
(% baseline) 
CB2  
EC50 
or 
Concentration 
(% baseline) 
HEK-CNG  
EC50 (nM) 
CB1 PTx 
 EC50 (nM) 
CB2 PTx 
 EC50 (nM) 
191 n/a 25 (10%)b n/a - - 
192 993a 10.3a n/a n/a n/a 
193 1429a 7.4a n/a n/a n/a 
194 1000 (10%)a 1000 (10%)a n/a - n/a 
Notes: All concentrations are listed as nM, percentages indicate the change from baseline. n/a: Not active, based on no 
statistically significant change in cAMP from baseline. “-“ Indicates test not performed. a Indicates a decrease in cAMP as 
compared to baseline. b Indicates an increase in cAMP as compared to baseline 
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5.4.2.2. CB2 functional activity for the HB Series. Plates were run as previously 
described (Section 5.4.1) in six (6) replicates with CP-55,940 as the internal control 
(Figure 5.9). All compounds in the series bind with good affinity to the CB2 receptor.
259 
Similar to CB1 functional activity assays 192 and 193 (Figure 5.9) demonstrated agonist 
activity; however, it was not as effective in terms the percent cAMP inhibited at CB2. 
Compounds 192 and 193 did demonstrate an EC50 that was significantly better than it had 
fared at CB1. EC50 for 192 and 193 was 10.3 nM and 7.4 nM, with percent cAMP 
inhibition of approximately 17% and 14%, respectively. Additionally, 191 and 194 
showed a 10% change in cAMP in an inverse agonist and agonist fashion, respectively. 
5.4.2.3. CNG parental functional activity for the HB series. Plates were run as 
previously described (Section 5.4.1) in three (3) replicates with CP-55,940 as the internal 
control for all three (3) replicates (Figure 5.10). As was expected, all compounds in the 
series failed to elucidate any statistically significant change in the cAMP production of 
the cells, including the reference standard of CP-55,940.  
5.4.2.4. CB1 PTx-sensitive Gi/o-inactivation for the HB series. Plates were run 
as previously described (Section 5.4.1) in three (3) replicates with CP-55,940 as the 
internal control for all three (3) replicates (Figure 5.11). As was expected, all compounds 
failed to alter cAMP production, including the reference standard of CP-55,940. Only 
compounds 192 and 193 were screened in the PTx-sensitive Gi/o-inactivation assays due 
to their ability to elucidate a response in the standard CB1 functional assay. 
5.4.2.5. CB2 PTx-sensitive Gi/o-inactivation for the HB series. Plates were run 
as previously described (Section 5.4.1) in three (3) replicates with CP-55,940 as the 
internal control for all three (3) replicates (Figure 5.12). As was expected, the tested 
compound failed to alter cAMP production, including the reference standard of 
CP-55,940. Only compound 192 was screened in the PTx-sensitive Gi/o-inactivation 
assays due to its ability to elucidate a response in the standard CB2 functional assay.  
5.4.3. Functional activity for SMM Triaryl series 
5.4.3.1. CB1 functional activity for the SMM series. Plates were run as 
previously described (Section 5.4.1) in six (6) replicates – unless the compound was 
known to not bind, in which case it was run in three (3) replicates – with CP-55,940 as 
the internal control for all replicates (Figure 5.13). As evidenced in Figure 5.13, nearly 
half of the compounds had no appreciable effect on the cAMP levels. Of those with some 
alteration of cAMP activity, all demonstrated an increase; however, most did not result in 
curves with a good fit upon data analysis. Compounds 200, 206 and 210 showed a 
maximum effect at 5 μM with an increase in cAMP of 48%, 32% and 24%, respectively. 
Compounds 202 and 203 showed a maximum effect at 50 nM, with an increase in cAMP 
of 85% and 75%, respectively. Three compounds 204, 211 and 213 (Figure 5.14), 
demonstrate inverse agonist activity at CB1, with an EC50 of 469 nM, 1497 nM and 153 
nM, respectively (Table 5.6), with percent cAMP induction ranging from 37% to 68% 
over basal. These compounds failed to attain the level of cAMP induction relative to our 
standard inverse agonist of SR-41716A (80% increase); however, they are worth noting. 
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Figure 5.9. CB2 functional activity of HB triaryl series, 50 minutes after compound addition 
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Figure 5.10. CNG functional activity of HB triaryl series, 50 minutes after compound addition 
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Figure 5.11. CB1 PTx-sensitive Gi/o-inactivation of HB triaryl series, 50 minutes after compound addition 
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Figure 5.12. CB2 PTx-sensitive Gi/o-inactivation of HB triaryl series, 50 minutes after compound addition 
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Figure 5.13. CB1 functional activity of SMM triaryl series, 50 minutes after compound addition 
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Figure 5.14. CB1 functional activity of select SMM triaryl series compounds, 50 minutes after compound addition 
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Table 5.6. EC50 values for SMM triaryl series 
Compound 
CB1 
EC50 
or 
Concentration 
(% baseline) 
CB2   
EC50 
or 
Concentration 
(% baseline) 
HEK-CNG  
EC50 (nM) 
CB1 PTx 
EC50 (nM) 
CB2 PTx 
EC50 (nM) 
195 n/a 744 n/a - n/a 
196 n/a - n/a - - 
197 n/a - n/a - - 
198 n/a - n/a - - 
199 n/a 5000 (81%)b n/a - - 
200 5000 (48%)b 5000 (20%)b n/a - - 
201 n/a - n/a - - 
202 50 (85%)b - n/a - - 
203 50 (75%)b 5000 (50%)b n/a - - 
204 469b 5000 (43%)b n/a n/a - 
205 n/a - n/a - - 
206 5000 (32%)b 5000 (97%)b n/a - n/a 
207 n/a 97.6b n/a - n/a 
208 n/a 5000 (73%)b n/a - - 
209 n/a 5000 (110%)b n/a - - 
210 5000 (24%)b 5000 (85%)b n/a - - 
211 1497b 702b n/a n/a n/a 
212 n/a - n/a - - 
213 153b 5000 (125%)b n/a n/a - 
214 n/a 5000 (200%)b n/a - n/a 
215 n/a 5000 (110%)b n/a - n/a 
Notes: All concentrations are listed as nM, percentages indicate the change from baseline. 
n/a: Not active, based on no statistically significant change in cAMP from baseline. “-“ 
Indicates test not performed. a Indicates a decrease in cAMP as compared to baseline. b 
Indicates an increase in cAMP as compared to baseline. 
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5.4.3.2. CB2 functional activity for the SMM series. Plates were run as 
previously described (Section 5.4.1) in six (6) replicates – unless the compound was 
known to not bind, in which case it was run in three (3) replicates – with CP-55,940 as 
the internal control for all replicates (Figure 5.15). All compounds in the series bind with 
good affinity to the CB2 receptor, except 200, 201, 202, 205 and 212.
259 Unlike the CB1 
functional assays, none of the compounds in demonstrated agonist activity at CB2. 
Compounds 195 (744 nM), 206 (>5000 nM), 207 (>5000 nM), 211 (702 nM), 214 
(>5000 nM) and 215 (>5000 nM) (Figure 5.16) all demonstrated induction of cAMP in 
excess of our standard(s) SR-144528 (and AM-630 (Table 5.5), with a percent cAMP 
induction ranging from 148% to 266% over baseline. It is important to note that the EC50 
values for these compounds are not possible to calculate due to lack of a saturation 
response with all of the compounds except 195 and 211. 
5.4.3.3. CNG parental functional activity for the SMM series. Plates were run 
as previously described (Section 5.4.1) in three (3) replicates with CP-55,940 as the 
internal control for all three (3) replicates (Figure 5.17). As was expected, all compounds 
in the series failed to elucidate any statistically significant change in the cAMP 
production of the cells, including the reference standard of CP-55,940.  
5.4.3.4. CB1 PTx-sensitive Gi/o-inactivation for the SMM series. Plates were 
run as previously described (Section 5.4.1) in three (3) replicates with CP-55,940 as the 
internal control for all replicates (Figure 5.18). As was expected, all compounds failed to 
alter cAMP production, including the reference standard of CP-55,940. Only compounds 
204, 211 and 213 were screened in the PTx-sensitive Gi/o-inactivation assays due to their 
ability to elucidate a response in the CB1 functional assay. 
5.4.3.5. CB2 PTx-sensitive Gi/o-inactivation for the SMM series. Plates were 
run as previously described (Section 5.4.1) in three (3) replicates with CP-55,940 as the 
internal control for all replicates (Figure 5.19). As was expected, the tested compound 
failed to alter cAMP production, including the reference standard of CP-55,940. Only 
compounds compounds 195, 206, 207, 211, 214 and 215 were screened in the PTx-
sensitive Gi/o-inactivation assays due to their ability to elucidate a response in the CB2 
functional assay. 
5.4.4. Functional activity for pyridine triaryl series 
5.4.4.1. CB1 functional activity for the Pyridine Triaryl series. Plates were run 
as previously described (Section 5.4.1) in six (6) replicates – unless the compound was 
known to not bind, in which case it was run in two (2) replicates – with CP-55,940 as the 
internal control for all replicates (Figure 5.20). Only compounds 217, 218, 219 and 222 
were known to bind with any appreciable affinity to CB1, and compound 223 has no 
binding data available, so it was treated as a known binder.259 EC50 values for these 
compounds ranged from 76.1 nM to 3238 nM, with a percent decrease in cAMP ranging 
from 27% to 65% (Table 5.7). Despite binding to CB1, compounds 219 and 222 did not 
have any impact on cAMP and showed themselves to be antagonists, the steady rise of 
222 in Figure 5.21 is attributable to the drift that is occasionally noticed within the assay, 
as discussed in Chapter 2. 
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Figure 5.15. CB2 functional activity of SMM triaryl series 
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Figure 5.16. CB2 functional activity of select SMM triaryl series compounds 
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Table 5.7. EC50 values for pyridine triaryl series 
Compound 
CB1  
EC50 
or 
Concentration 
(% baseline) 
CB2   
EC50 
or 
Concentration 
(% baseline) 
HEK-
CNG  
EC50 
(nM) 
CB1 PTx 
EC50 
(nM) 
CB2 PTx 
EC50 
(nM) 
216 n/a n/a n/a - n/a 
217 5000 (38%)a n/a n/a n/a n/a 
218 5000 (63%)a 470.1a n/a n/a n/a 
219 n/a 108.6a n/a n/a n/a 
220 n/a - - - - 
221 5000 (40%)*a 389.4a n/a - n/a 
222 n/a n/a n/a n/a n/a 
223 5000 (34%)a 294.8a n/a n/a n/a 
224 123.54*b - n/a - - 
225 131.25*b - n/a - - 
226 364.7*b 5000 (43%)b n/a - n/a 
227 5000 (16%)*b 5000 (39%)b n/a - n/a 
228 5000 (21%)b 5000 (30%)b n/a - n/a 
229 5000 (21%)b 5000 (30%)b n/a - n/a 
Notes: All concentrations are listed as nM, percentages indicate the change from baseline. 
n/a: Not active, based on no statistically significant change in cAMP from baseline. “-“ 
Indicates test not performed. a Indicates a decrease in cAMP as compared to baseline. b 
Indicates an increase in cAMP as compared to baseline. “*” = N=3. 
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Figure 5.17. CNG functional activity for SMM triaryl series 
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Figure 5.18. CB1 PTx-sensitive Gi/o-inactivation for selected SMM triaryl series compounds 
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Figure 5.19. CB2 PTx-sensitive Gi/o-inactivation for select SMM triaryl series compounds 
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Figure 5.20. CB1 functional data for pyridine triaryl compounds 
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Figure 5.21. CB1 functional activity of known binders within pyridine triaryl series 
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As evidenced in Figure 5.22, some of the compounds (224, 225, 226 and 227) 
demonstrated a functional effect without having any known binding affinity for the CB1 
LBP. Of great intrigue is the fact that the compounds containing either a C-1′ cyclohexyl 
or phenyl demonstrated an inverse agonist activity at CB1. Compound 227 and 221 did 
not elucidate a discernable curve upon analysis, and this could be because these 
non-binding compounds were not run in a large enough sample size to obtain a viable 
curve. These data taken in the context of the whole warrants further investigation of this 
compound. 
5.4.4.2. CB2 functional activity for the pyridine triaryl series. Plates were run 
as previously described (Section 5.4.1) in six (6) replicates – unless the compound was 
known to not bind, in which case it was run in three (3) replicates – with CP-55,940 as 
the internal control for all replicates (Figure 5.23). All compounds in the series bind with 
good affinity to the CB2 receptor, except 224, 225 and 220.
259 As with the CB1 assay, 
there is mixed activity within this class of compounds. Compounds 218, 219, 221 and 
223 (Table 5.3) all demonstrated inhibition of cAMP production, with and EC50 of 470.1 
nM, 108.6 nM, 389.4 nM and 294.8 nM, respectively (Figure 5.24; Table 5.7), with a 
percent cAMP reduction ranging from 11.5% to 45%.  
Additional compounds in this series known to bind are 216, 217, 222, 226, 227, 
228 and 229 (Table 5.3). Within these compounds, neither 216, 217 nor 222 (all with 
linear aliphatic C-3 substituents) showed any change in cAMP production – in fact, 216 
and 217 were virtually identical in their lack of activity; however, 226, 227, 228 and 229 
all demonstrated a very weak inverse agonist activity (Figure 5.25). The EC50 for these 
compounds was not determined, as they are all in excess of my limit of 5 µM; however 
there was an approximately 40% increase in cAMP for these compounds at 5 µM.  
5.4.4.3. CNG parental functional activity for the pyridine triaryl series. Plates 
were run as previously described (Section 5.4.1) in three (3) replicates with CP-55,940 as 
the internal control for all three (3) replicates (Figure 5.26). As was expected, all 
compounds in the series failed to elucidate any statistically significant change in the 
cAMP production of the cells, including the reference standard of CP-55,940.  
5.4.4.4. CB1 PTx-sensitive Gi/o-inactivation for the pyridine triaryl series. 
Plates were run as previously described (Section 5.4.1) in three (3) replicates with 
CP-55,940 as the internal control for all replicates (Figure 5.27). As was expected, all 
compounds failed to alter cAMP production, including the reference standard of 
CP-55,940. Only compounds 217, 218, and 223 were screened in the PTx-sensitive Gi/o-
inactivation assays due to their ability to elucidate a response in the CB1 functional assay. 
5.4.4.5. CB2 PTx-sensitive Gi/o-inactivation for the pyridine triaryl series. 
Plates were run as previously described (Section 5.4.1) in three (3) replicates with 
CP-55,940 as the internal control for all replicates (Figure 5.28). As was expected, all 
compounds failed to alter cAMP production, including the reference standard of 
CP-55,940. Only compounds 217, 218, 219, 222 and 223 were screened in the PTx-
sensitive Gi/o-inactivation assays due to their ability to elucidate a response in the CB1 
functional assay. 
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Figure 5.22. CB1 active compounds with unknown Ki values.  
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Figure 5.23. CB2 functinal data for pyridine triaryls  
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Figure 5.24. CB2 functional agonists of the pyridine triaryl series 
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Figure 5.25. CB2 functional activity of non-agonists with known binding within the pyridine triaryl series 
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Figure 5.26. HEK-CNG functional assay with pyridine triaryl series 
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Figure 5.27. CB1 PTx-sensitive Gi/o-inactivation with pyridine triaryl series 
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Figure 5.28. CB2 PTx-sensitive Gi/o-inactivation with pyridine triaryl series 
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5.4.5. Functional activity for pyrimidine triaryl series 
5.4.5.1. CB1 functional activity in the pyrimidine triaryl series. Plates were 
run as previously described (Section 5.4.1) in six (6) replicates – except the known non-
binding 231, which was run in two (2) replicates – with CP-55,940 as the internal control 
for all replicates (Figure 5.29). EC50 values for these compounds were inconclusive due 
to a lack of saturation response; however, the percent increase ranged from 8% to 27%. 
This increase is over the non-specific increase noted in the HEK-CNG cells but the 
significance remains to be determined and was not treated as significant. 
5.4.5.2. CB2 functional activity in the pyrimidine triaryl series. Plates were run 
as previously described (Section 5.4.1) in six (6) replicates – with CP-55,940 as the 
internal control (Figure 5.30). Only compounds 231 and 233 are known to bind with 
good affinity to CB2, all others are unknown and treated as if they bind CB2.
259 Contrary 
to the CB1 assay, 3 compounds set themselves apart  and demonstrated agonist activity. 
Compounds 231, 236, 238 and 239 showed signs of partial agonist activity with EC50 
values of 475.4 nM, 167.9 nM, 5 μM (21%) and 5 μM (29%), respectively, with a percent 
inhibition of cAMP for all compounds of approximately 30% (Figure 5.31; Table 5.8).. 
5.4.5.3. CNG parental functional activity in the pyrimidine triaryl series. 
Plates were run as previously described (Section 5.4.1) in three (3) replicates with 
CP-55,940 as the internal control for all three (3) replicates (Figure 5.32). As was 
expected, all compounds in the series failed to elucidate any change in the cAMP 
production of the cells, including the reference standard of CP-55,940.  
5.4.5.4. CB1 PTx-sensitive Gi/o-inactivation in the pyrimidine triaryl series. 
Plates were run as previously described (Section 5.4.1) in three (3) replicates with 
CP-55,940 as the internal control for all replicates (Figure 5.33). As was expected, all 
compounds failed to alter cAMP production, including the reference standard of 
CP-55,940. All compounds were tested except 231, due to its known lack of binding 
affinity and all other compounds appearing to be inverse agonists. 
5.4.5.5. CB2 PTx-sensitive Gi/o-inactivation in the pyrimidine triaryl series. 
Plates were run as previously described (Section 5.4.1) in three (3) replicates with 
CP-55,940 as the internal control for all replicates (Figure 5.34). As was expected, all 
compounds failed to alter cAMP production, including the reference standard of 
CP-55,940. Only compounds 231, 236 and 239 were screened in the PTx-sensitive Gi/o-
inactivation assays due to their ability to elucidate a response in the CB1 functional assay. 
5.5. Discussion 
5.5.1. Interactions with the CB1 LBP 
5.5.1.1. CB1 LBP interactions with non-classical ketone moiety. Interactions 
within the CB1 LBP for the non-classical cannabinoids differs among the main branches. 
Most differences center around the presence or absence of interactions with K192(3.28). 
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Figure 5.29. CB1 functional activity for pyrimidine triaryl series 
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Figure 5.30. CB2 functional activity of pyrimidine triaryl series 
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Figure 5.31. CB2 functional activity for select agonists in pyrimidine triaryl series 
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Table 5.8. EC50 values for pyrimidine triaryl series 
Compound 
CB1  
EC50 
or 
Concentration 
(% baseline) 
CB2   
EC50 
or 
Concentration 
(% baseline) 
HEK-
CNG  
EC50 
(nM) 
CB1 PTx 
EC50 
(nM) 
CB2 PTx 
EC50 
(nM) 
230 n/a n/a n/a n/a - 
231 - 475.4a n/a - n/a 
232 n/a 5000 (14%)b n/a n/a - 
233 n/a n/a n/a n/a - 
234 n/a 5000 (23%)b n/a n/a - 
235 n/a n/a n/a n/a - 
236 n/a 167.9a n/a n/a - 
237 n/a 5000 (14%)b n/a n/a n/a 
238 n/a 5000 (21%)a n/a n/a - 
239 n/a 5000 (29%)a n/a n/a n/a 
Notes: All concentrations are listed as nM, percentages indicate the change from baseline. 
n/a: Not active, based on no statistically significant change in cAMP from baseline. “-“ 
Indicates test not performed. a Indicates a decrease in cAMP as compared to baseline. b 
Indicates an increase in cAMP as compared to baseline. 
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Figure 5.32. HEK-CNG functional activity of the pyrimidine triaryl series 
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Figure 5.33. CB1 PTx-sensitive Gi/o-inactivation for select pyrimidine triaryl compounds 
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Figure 5.34. CB2 PTx-sensitive Gi/o-inactivation for select pyrimidine triaryl compounds 
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 For the diarylpyrazoles (prototype, SR-141716A), K192(3.28) plays an important 
role in H-bonding with the carbamide oxygen (Figure 5.35A).249,252,257,336 In the case of 
WIN-55,212-2 there are conflicting data regarding K192(3.28) – it is held that the 
interaction between K192(3.28) and F189(3.25) help to hold each other in proper 
orientation to facilitate one, the other or both interacting with the ligand.249,254 Mutation 
of K192A(3.28) will negatively impact the binding of SR-141716A and the classical or 
endogenous ligands, but has a negligible effect on WIN-55,212-2337 – further cause to 
keep this interaction in perspective and consider it only in certain instances with the non-
classical agents. Overall, this is not as integral an interaction with the non-classical agents 
as it was with the classical ligands. Additionally, SR-141716A literature shows 
interactions with N187(3.23) and S173(2.60) as H-bond interactions on the ketone.249 
Mutagenesis S173A(2.60) has little effect on CP-55,940 binding, and thus is 
hypothesized to have little effect on SR-141716A,251 though it has not been tested to date. 
Within the HB triaryl series of compounds, functional data show compounds 192 
and 193 exert agonist activity at CB1, with EC50 values of 993.4 nM and 2008 nM, 
respectively and total percent inhibition of cAMP production at around 50%. While these 
are not as potent as our reference compound, CP-55,940, they do achieve a similar level 
of efficacy and are qualified as a full agonist. Also worth noting is the fact that a methoxy 
group (194) or a mono hydroxyl substitution (191) present on the A ring results in a 
compound that has antagonist activity at CB1. Thus, our first requirement would be for 
1,5-dihydroxy on the A-ring of our triaryl series of compounds. The need for this 
1,5-dihydroxy A-ring points strongly to the importance of K192(3.28) in H-bonding with 
these molecules (Figure 5.35B). The current homology model249 used for these cursory 
data show a possible involvement of S383(7.37) (Figure 5.35B). A similar trend shows 
within the SMM series, although these do not have the same impact. 
The SMM triaryl series, gives us another valuable insight into the SAR of the 
triaryl compounds, as well as building upon previous data within the HB triaryl series. 
The first confirmation of SAR findings within this series is the utility of a 3,5-dihydroxy 
A-ring, as compounds 196, 197, 198, 199, 200, 201, 202, 203, 205, 206, 208, 210 and 
212 all contain either a 1,5-dimethoxy or a mono-hydroxy A-ring and lack any effect at 
CB1. However, within this series, we see certain situations where a 1,5-dimethoxy is of 
benefit. One such case is the presence of a 3,5-dichloro C-ring with a heteroaromatic 
“D”-ring (205), as compared to a m-toluyl C-ring with a heteroaromatic “D”-ring (213). 
205 does not elucidate any response of cAMP production at CB1, whereas 213 
demonstrates a weak inverse agonist activity. Di-deprotection of 205 results in 211, 
showing activity similar to 213 – the mono-deprotected product, 210, shows antagonist 
activity at CB1. Conversely, di-deprotection of 213 to yield 214 results in no impact of 
cAMP production at CB1. From this, I hypothesize that heteroaromatic “D”-rings coupled 
to electronegative C-rings require deprotection for activity at CB1, whereas these same 
“D”-rings coupled to non-electronegative C-rings require di-protected A-ring hydroxyls 
(Figure 5.35D) to alter cAMP production.  
5.5.1.2. CB1 LBP π-π stacking interactions. Far and away, the π-π stacking 
interactions within the LBP are the most important to consider for the non-classical 
agents. Considering WIN-55,212-2 and SR-141716A, there exists a great deal of  
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A B 
  
C D 
Figure 5.35. CB1 LBP hydrophilic interactions 
Note: Panel A depicts SR-141716A and the proposed LBP residue interactions. Panel B 
depicts 193 and the proposed LBP residue interactions. Panel C depicts 194 and the 
proposed LBP residue interactions – loss of one of the hydroxyl groups results in an 
antagonist. Panel D depicts 213 and the proposed LBP interactions. Green lines indicate 
π-π interactions. Dashed pink arrows indicate H-bond interactions. 
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common amino acids within the LBP of CB1. Commonalities are: F174(2.61), 
F189(3.25), F200(3.36), Y275(5.39), W279(5.43), W356(6.48), F379(7.35) and 
F381(7.35). Of these shared residues, F200(3.36) and W279(5.43) show themselves to be 
crucial in binding, as the mutation F200A(3.36) causes a precipitous drop in binding 
affinity for both WIN-55,212-2 and SR-141716A, and W356(6.48) adds itself as an 
additional imperative interaction for SR-141716A.249,252,257 One additional residue, 
F177(2.64),  shows itself as important for binding of WIN-55,212-2 but not SR-141716A. 
F174(2.61) and F177(2.64) have been demonstrated in classical cannabinoid SAR to be 
important in maintaining patency of the minor groove of the LBP; however, they have 
not shown themselves to be involved in the binding of those ligands.255 In the case of 
WIN-55,212-2, they coordinate with the naphthyl moiety of the molecule as a π-π 
stack.249 SR-141716A shows no additional unique π-π interactions relative to WIN-
55,212-2. 
5.5.1.3. CB1 LBP additional known interactions of non-classical agents. 
Remaining interactions for our prototype non-classical agents are only for SR-141716A. 
Remaining interactions are hydrophilic interactions with S383(7.39) and M384(7.40). 
These residues are suggested to stabilize the pyrazole ring of SR-141716A within the 
LBP, and may play an important role in augmenting the binding potential of ligands built 
off its scaffold.249 Mutagenesis S383A(7.39) has a profound effect on binding of 
CP-55,940 to CB1, and so it is hypothesized that this may play a more critical role in 
binding of SR-141716A but not WIN-55,212-2.251 
5.5.1.4. CB1 LBP interactions of the hydrophobic pocket. As a result of the 
physical nature of the non-classical agents is a more compact, aromatic nature, 
interactions within the hydrophobic pocket of the LBP are not discussed per se; however, 
some of the key interactions from the π-π stacking and receptor activation/stabilization 
are located in this region. For purposes of discussion, I will consider the classical agent of 
HU-210 and its interaction within the LBP. A predominantly lipophilic pocket exists, 
seemingly as two lobes – as evidenced in the fact that 3-(1′,1′-dimethylheptyl)-Δ8-THC 
binds with higher affinity than does 3-heptyl-Δ8-THC along with 3D-QSAR models 
which demonstrate this trait.253 In one homology model, residues V196(3.32), 
T197(3.33), F200(3.36), Y275(5.39), W279(5.43), L359(6.51) and M363(6.55) form a 
hydrophobic pocket which encompasses the A-ring and C-3 side chain of HU-210.254 
More recent homology models form this pocket from I354(6.46), C355(6.47), 
W356(6.48), L359(6.51), L360(3.52) and M363(6.55) (Figure 5.36).249 Interestingly, 
mutations studies conducted on this hydrophobic pocket show that M363A(6.55) 
mutation greatly impacts binding affinity for HU-210 but has virtually no impact on THC 
which would suggest that this is an important residue for C-1′ substituted derivatives.255 
The novel SMM triaryl series offers insight within the C-3 binding domain. One 
such element found within the SMM triaryl series is the function of a ketone at C-1′. 
Recalling that 192 and 193 are both 1′,1′-gem-dimethyl derivatives and that they exert 
full agonist activity, we compare them to 214 and 211, respectively. By exchanging the 
C-1′ substituent, we either flip or erase the agonist activity. In the case of 192/214 we 
move from a full agonist (192) to an antagonist (214) at CB1 and with 193/211 the 
functional activity transitions from a full agonist (193) to an inverse agonist (211).  
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A B 
Figure 5.36. CB1 hydrophobic C-3 substituent binding pocket 
Note: Panel A depicts HU-210 in the CB1 LBP, with focus given to the hydrophobic pocket. Panel B depicts Compound 170 in 
the CB1 LBP, with focus given to the hydrophobic pocket. 
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Bearing in mind that agonists at CB1 cause the negative psychotropic effects of 
cannabinoids, this simple change – since 214 and 211 are the precursors to 192 and 193, 
respectively – results in a very desirable therapeutic implication, as the psychotropic 
effects of these cannab inoid derivatives could prove to be rendered null in whole-animal 
studies. However, this is not the only gem gathered from the SMM series data in 
functional assay. 
Related to the presence or absence of an electro-negative C-ring is the fact that a 
C-3 heptyl substituent with C-1′ ketone (204) demonstrates inverse agonist activity, while 
a C-3 cyclohexyl with C-1′ ketone (203) shows antagonist activity. The implications here 
are that the linear chain fares better with di-protected hydroxyls, while the cycloalkyl has 
no cAMP impact regardless of its state of A-ring deprotection (di-protected (203), mono-
deprotected (208) or di-deprotected (209)). It is also of note that the C-3 heptyl (204) 
derivative  is an inverse agonist only at CB1. These trends take a slight detour with the 
heterocyclic derivatives. 
The pyridine and pyrimidine triaryl series are a constellation due to their 
similarities. Looking at the C-3 aliphatic chains, we see that compounds 217, 218, 219, 
221 and 223 have agonist activity at CB1. Comparatively, 222, 224, 225, 226 and 227 
have either an aromatic or cyclohexyl C-3 substituent and exhibit an inverse agonist 
activity. Though the current lack of further study and/or more robust modelling 
capabilities do not allow for a more precise diagnosis of mechanism, it is noteworthy and 
warrants further study. Inclusion of a heteroaromatic C-3 substituent seems to yield a 
non-binding compound with an obvious null effect on cAMP production. None of the 
pyrimidine compounds exerted any effect on CB1; however, to call them antagonist 
would not be prudent, as we do not currently have binding data on these compounds. 
5.5.2. Interactions with the CB2 LBP 
Given the varied functional activity of the triaryl compounds at CB1, and the fact 
that CB2 only shares a 48% homology with CB1, the potential for more targeted 
exploitation of this receptor exists. Though the SAR of the CB2 LBP is not as well-
characterized as CB1, there are still data which help to highlight some of the important 
residues and interactions within the LBP. Unfortunately, without a validated CB2 model, 
insights into the triaryl series are not feasible.  
5.5.2.1. C-1 Hydroxyl, Benzchromene Oxygen and (optional) C-6 Hydroxyl. 
Mutation studies with HU-210, CP-55,940 and WIN-55,212-2 have shown that binding 
of both HU-210 and CP-55,940 experience negative consequence with a S292A 
mutation. This mutation-induced change of binding strongly suggests S292(7.46) is 
involved in H-bonding with the benzchromene oxygen – assuming a similar LBP 
arrangements relative to the CB1 LBP.
323 Though WIN 55-212-2’s ketone is in proximity 
to residue S193(5.42) some data suggest it does not hydrogen bond.261 In the case where 
amide linkages exist between the aryl groups, S193(5.42) does act as a H-bond 
donor.324,325 These interactions may help to provide nsight into why di-protected triaryls 
do not behave as their di-deprotected counterparts. 
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As was the case in CB1, so it remains in CB2, the requirement for 1,5-dihydroxy 
A-ring, as 191 and 194 failed to cause a change in the cAMP production. Next, it is 
evident that an m-toluyl C-ring (192) shows agonist activity at both CB1 and CB2, and has 
an increased potency at CB2, with an EC50 of 18.7 nM and a 35% reduction in cAMP 
production. While 192 is only a partial agonist of CB2 (not as efficacious as CP-55,940), 
it is in line with CP-55,940’s potency. 
Considering now the SMM series, again the SAR requirements for CB1 begin to 
reemerge as similarly pertinent in CB2. First, comparing 193 to 211, we see how a C-1′ 
ketone again allows a change to an inverse agonist from a neutral antagonist. It becomes 
evident within the SMM triaryl series at CB2 that the C-1′ substituent must be a ketone 
for this inverse agonist, as 195 is a very effective CB2 inverse agonist, but when C-1′ is a 
hydroxyl (the direct precursor of 195), all activity is lost. 
5.5.2.2. Hydrophobic and π-π stacking. As has been the case previously, it 
remains so that many of the interactions derive from the aminoalkylindole, WIN-55,212-
2, and play a central role in non-classical binding. Beginning with the indole ring of WIN 
55,212-2, there are π-π stacking interactions between it and residues F197(5.46), 
W258(6.48) and F117(3.36).261 There also exists a shared π-π stacking between the 
indole ring and napthyl ring with residue W194(5.43).261 The napthyl ring has a proposed 
added π-π stack with residue F106(3.25).261 More recent 2-pyridone derivatives add 
additional residues to the binding pocket for π-π stacking, namely Y190(5.39) and 
F281(7.35) along with C288(7.42).324,325 For the 2-pyridone analog containing N-butyl, 
there is a proposed hydrophobic interaction with I198(5.47).325 Though little data exists, 
it is suggested that SR-144528 (a CB2-selective inverse agonist) has interaction with 
W194(5.43) and F197(5.46),338 which may play a role in stabilizing the inactive state and 
impart inverse agonist activity. However, the 2-pyridone shows agonist activity and 
interaction with W194(5.43) and F197(5.46), so interaction with these residues does not 
impart inverse agonist activity. Considering the triaryl composition of this series of 
cannabinergic agents, it is logical to hypothesize that the π-π interactions are important to 
receptor recognition and function. Future modelling is necessary and will be used to 
identify potential interactions within the CB2 LBP for further ligand refinement. 
From the SMM series, one may speculate about another CB2 SAR – the need for 
an aromatic D-ring to obtain inverse agonist activity (Figure 5.37). Compounds 195, 206, 
207, 211, 213 and 215 all contain aromatic D-rings, and when compared to 204 with its 
linear aliphatic and 203, 208 and 209 with their cycloalkyl, we see that non-aromatic 
compounds take on a neutral antagonist role. Interestingly, the effect of deprotection is 
not as staunch in the CB2 receptor studies; however, there is a requirement for at least a 
mono-deprotected A-ring, as evidenced in 202 (di-methoxy), 206 (mono-methoxy) and 
207 (di-hydroxy). Compound 206, a mono-deprotected A-ring, and its successor 207, a 
di-hydroxy A-ring, demonstrate the same trend, with the efficacy being similar at high 
concentrations, but the potency of 207 (EC50 89.7 nM) greatly exceeds that of 206 (EC50 
>5000 nM) (Figure 5.37). These data suggest the CB2 pocket has a varied hydrophilic 
requirement of the CB1 pocket and could allow for more selective targeting of 
compounds. However, the heteroaromatic compound data do not show the same 
bifurcation of CB1 and CB2, at least with the pyridine derivatives. 
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Figure 5.37. CB2 required D-ring and A-ring elements for compound 195 
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At CB2, the pyridine trend holds, with compounds 217, 218, 219, 221 and 223 
having agonist activity, and 222, 224, 225, 226 and 227 having inverse agonist activity 
(Figure 5.38). It is at CB2 where we begin to see the utility of the pyrimidine series, with 
231, 236 and 239, all with aliphatic C-3 substituents demonstrating agonist activity. With 
the exception of 231, these compounds have saturated aliphatic substituents at both C-3 
and C-6 of the A-ring. Comparing 236 to 237 we see the effect of an aromatic 
substitution at C-6, with a loss of agonist activity. Looking at 231 and 235, we see a loss 
of activity. This holds when comparing 236 to 238 where one sees the incorporation of a 
heteroaromatic ring at C-1′ results in a non-active compound (Figure 5.39). 
5.6. Conclusions 
In this chapter, I have demonstrated by utilization of a functional assay how small 
synthetic changes help to yield more selective or opposing actions on CB1 and CB2. The 
first of which is the ability to convert from an agonist to an inverse agonist by the 
exchange of theC-1′-gem-dimethyl substituent for C-1′ ketone – a trend that holds true in 
both CB1 and CB2.  
Additionally, I demonstrated how to target CB2 more effectively by mono-
deprotection of the 3 and 5 position of the A-ring, as this is permissible in CB2 assays but 
not in CB1. Lastly, I provided evidence of functional interchange within a given series – 
incorporation of a heterocyclic A-ring allows for linear aliphatic C-3 substituents to exert 
agonist activity and cycloalkyl/aromatic substituents to provide an inverse agonist effect. 
In addition, this heterocyclic A-ring with cycloalkyl/aromatic C-3 substituent provides 
evidence of a non-competitive inverse agonist. 
Future directions for this project are to synthesized matched derivatives within 
each of the four (4) triaryl series to ensure that we have a more accurate comparison of 
these SAR findings via functional assay validation. Additionally, further derivation of 
heterocyclic D-ring and C-ring, along with cycloalkyl C-ring derivatives – matched 
across the 4 series – will help to solidify this trait. Unsaturation along the C-3 heptyl 
chain, coupled with chain extension and redaction, would help to probe the depth and 
orientation of the pocket to optimize their activity. Finally, as we saw in the HB and 
SMM triaryl series, changing the pyridine and pyrimidine to C-1′ ketone could further 
solidify this as a key interchange for activity in the CB1 and CB2 receptor. 
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Figure 5.38. CB2 required C-1′ elements for pyridine triaryls 
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Figure 5.39. CB2 required C-6 and C-1′ elements for pyrimidine triaryls 
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CHAPTER 6. FUNCTIONAL PHARMACOPHORE 
As has been demonstrated, minor changes in a compound’s structure – be it a 
bioisosteric replacement, heteroatom substitution or a change in the oxidation state of one 
atom – have generated functionally distinct and potentially therapeutically significant 
molecules. One of the first examples presented was the interaction of the KM series 
(Figure 6.1) with the CB1 and CB2 receptors, wherein it was shown that these 
compounds are CB1 agonists and CB2 antagonists – a trait not displayed in other 
compounds with a classical core scaffold. Next, compounds built directly from this series 
sought to incorporate one (pyridine) or two (pyrimidine) nitrogen atoms in the A-ring of 
the classical benzchromene core (Figure 6.1). From the hexahydro series it was shown 
that aliphatic C-1′ substituents were able to retain the traditional agonist properties of 
classical core compounds; however, pyridine A-ring with C-1′-phenyl demonstrate CB1 
inverse agonist activity and pyrimidine A-ring with C-1′-phenyl CB2 inverse agonists. 
Finally, the triaryl series (Figure 6.1) demonstrated another unique and potentially 
therapeutically useful switch. Within this series, a small change at the C-1′, going from a 
C-1′-gem-dimethyl to a C-1′ ketone, results in a switch from a full agonist to an inverse 
agonist. All of these minor chemical changes result in such staunch, sometimes opposing 
and potentially therapeutically exploitable switches and options. This leads to the 
question: What is happening within the respective receptors, and what residues may be 
involved that could be even further exploited for new therapeutic agents?  Herein, I will 
summarize and highlight interactions, which may help to direct and drive future 
development. Further, with a validated CB1 homolgy model, I will propose LBP residues 
and interactions, which may further highlight the potentially therapeutically exploitable 
facets of the CB1 receptor. Unfortunately, I lack access to a validated CB2 homology 
model, and thus the same propositions are not possible. 
To generate hypotheses and to gain some insight into the possible explanations 
and interplay between ligand and receptor, docking of the compounds was performed. Dr. 
Chang of The University of California, Riverdale, kindly supplied the models for the 
CB1 receptor.249 Compounds in the KM series and the hexahydro (pyridine and 
pyrimidine) series were docked and compared in the “HU-210” model. Classical and 
non-classical inverse agonists were docked and compared in the “SR-141716A” model. 
Finally, non-classical agonists were docked and compared in the “WIN-55,212-2” model. 
All tested/docked compounds were minimized and prepped with LigPrep, receptor grid 
generation and docking was completed utilizing these prepared ligands in GLIDE. 
6.1. CB1-Specific Proposed Functional Switches 
Within the CB1 “HU-210” model, one can see that HU-210 and Δ9-THC occupy 
nearly the same space (Figure 6.2). As previously mentioned (Section 3.5.1), the KM 
series may exhibit a binding mode in the CB1 pocket that very closely mimics that of Δ9-
THC (Figure 6.3). One notable exception is that the pentyl side chain of Δ9-THC projects 
into the hydrophobic pocket more than the aromatic xylyl of 67. The aromatic xylyl, in 
this preliminary model, shows a preferential interaction with residue W356(6.48). The  
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Figure 6.1. Representative examples from each of the novel cannabinergic agents 
  
 212 
  
A B 
Figure 6.2. CB1 spatial relationship between HU-210 and Δ9-THC 
Note: Panel A shows the front view. Panel B shows the side view. For ease of visualization with the stacked molecules, HU-
210 is colored red and Δ9-THC is colored blue. 
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A B 
Figure 6.3. CB1 spatial relationship between Compound 67 and Δ9-THC 
Note: Panel A shows the front view. Panel B shows the side view. For ease of visualization with the stacked molecules, 67 is 
colored red and Δ9-THC is colored blue. 
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correlation of Δ9-THC to both HU-210 (the basis for this particular model) and 67 allow 
for my hypothesis about requirements and exploitations of the CB1 LBP. 
6.1.1. Common residue interactions 
Literature demonstrates time and again that F189(3.25) is important, if not crucial 
for binding of the endocannabinoids, such as AEA. In fact, the F189A CB1 mutant shows 
a 7-fold drop in affinity for AEA compared to w.t. The current model used for this 
examination, while rudimentary at best, does show the importance of an aromatic A-ring 
for interaction with this residue in the LBP (Figure 6.4). This interaction, I believe, is 
what secures and properly orients the molecule in the LBP. 
For most compounds, the classical core KM series and hexahydro series included, 
K192(3.28) plays an integral role in binding with the C1 hydroxy or amide oxygen 
(Figure 6.4). This holds true for most of the triaryl series, as well; however, other factors 
begin to outweigh the need for K192(3.28) in binding and exerting a functional effect. 
That said, having a moiety at C1 or an analogous position is one of the first and strongest 
considerations to be made in the design of targeted molecules. 
As previously mentioned (Section 3.5.1.2), M363(6.55) has an extremely 
profound effect on the binding affinity of HU-210 when methionine is exchanged for 
alanine in the M363A mutant receptor. This precipitous drop in affinity does not hold 
true for Δ8-THC, so it is a logical conclusion that the C1′-gem-dimethyl group interacts 
with this residue. This bears itself out in the non-molecular-dynamic-docking into the 
“HU-210” homology model, as well, with M363(6.55) showing good contact with the 
C1′-gem-dimethyl of 67, but not so with Δ9-THC (Figure 6.5). This residue does seem to 
provides a viable target to impart increased CB1 affinity, but is not necessary for function. 
For receptor activation to occur, interaction with W279(5.43) is essential, 
according to literature. The interactions, according to the current model, coupled with the 
functional data suggest that the interaction may be via π-π stacking or aliphatic 
interactions. The constant is that a functionally active compound models with some sort 
of interaction with this residue (Figure 6.4). 
6.1.2. The W356(6.48) “toggle” switch 
As previously discussed (Section 3.4.2), the KM series of compounds has an 
aromatic C-1′ substituent, and are agonists at CB1. Based on the current “HU-210” 
homology model, the aromatic substituent interact simultaneously with W279(5.43) and 
W356(6.48). Spatially, W356(6.48) is flanked by W279(5.43) and F200(3.36), and it is 
its interaction with one or the other which seemingly determines receptor activation 
(W279(5.43)) or stasis (F200(3.36)). Looking at the interaction of 67, an established CB1 
agonist, the model suggests a π-π stack which links W279(5.43) to W356(6.48) (Figure 
6.6) – presumably leading to receptor activation. To the converse of this point, 172 is 
similar to 67 except for the fact that the A-ring contains a nitrogen at position 2 and the 
C-1 hydroxyl is now an amide oxygen. This is a relatively small change to the molecule,  
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A B 
Figure 6.4. CB1 LBP common residues for classical core compound 67 
Note: Depicts the common residues found in classical core interactions. Panel A is side view with F189(3.35) removed. Panel 
B is the top view with K192(3.28) removed. Dashed green lines indicate π-π interactions, dashed yellow lines indicate H-bond. 
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A B 
Figure 6.5. CB1 M363(6.55) contact with compound 67 and Δ9-THC 
Note: Dashed green lines indicate “good” contact between receptor and ligand. 
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Figure 6.6. CB1 LBP W356(6.48) "toggle" switch presumed to be activated by compound 67 
Note: Dashed green lines indicate π-π stacking interactions. 
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but it has a large impact on its function. Based on the model, this small change in the 
A-ring alters the binding and preference of the aromatic C-1′ substituent to now co-
localize and π-π stack with W356(6.48) and F200(3.36) (Figure 6.7)– resulting in an 
inverse agonist. I hypothesize that this shift is due to the amide in the A-ring altering how 
the hydrophilic interactions take place and the overall conformation in the LBP.  
6.1.3. The lack of hydrophilic interaction within the LBP 
When examining the triaryl series of compounds, another unique trait began to 
emerge, which was quite contrary to previously held belief about the rigors and 
requirement for binding. As previously mentioned, K192(3.28) and S173(2.60) play a 
key role in H-bond formation with the ligand and subsequent stabilization in the LBP 
and/or a conformational change induction. That said, the requirement for hydrogen bond 
donor groups on the A-ring is negated when C-1′ is a heteroaromatic group, as in the case 
of 214. Too, stabilization of the W356(6.48) “toggle” switch in the inactive state is 
required for inverse agonist activity. The “HU-210” model does suggest a stabilization of 
the “toggle” switch, it is conceivable that the interaction could be occurring with  the 
aromatic thiol of 214 is near enough to have potential to interact in a dynamic system 
(Figure 6.8). To fully test this from a functional standpoint, one would need to synthesize 
a derivative with 1,5-dimethoxy and various C-1′ heteroaromatic groups and potentially 
anoxic A-ring derivatives. Synthesis of these additional derivatives coupled with more 
robust modelling and molecular dynamics runs would help to further elucidate the root 
cause of this interesting functional switch. 
6.1.4. C-1′ importance beyond binding affinity 
Previously, it was brought to light that M363(6.55) played a key role in increasing 
the binding affinity of classical core compounds, substituted with C-1′-gem-dimethyls. In 
the case of the triaryl compounds wherein the C-1′ substituent is a ketone, the compound 
turns from a full agonist to an inverse agonist and in many cases an extremely potent one, 
at that. Looking at the model, it is evident that there exists a small pocket in the LBP in 
the vicinity of C-1′ which contains a good number of cysteine residues – namely 
C355(5.47), C382(7.38) and C386(7.42). Further, looking at superimposed, docked 
ligands 192 and 214 (Figure 6.9), which are identical except for their C-1′ substituent 
and functional activity, one may see that the thiophene ring of 192 projects into this 
pocket while the C-1′ ketone of 214 occupies this space. It is my hypothesis that the 
ketone’s interaction with this cysteine pocket contributes to the inverse agonist activity of 
the compound through induction of a conformational change of the receptor. However, to 
fully validate, confirm and test this, more detailed binding studies, in conjunction with 
mutation and/or more detailed modelling and dynamic simulations would be necessary 
and may represent a potential direction to expand upon this current project. 
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Figure 6.7. CB1 LBP W356(6.48) “toggle” switch presumed to be deactivated by compound 172 
Note: Dashed green lines indicate π-π stacking interactions. 
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Figure 6.8. CB1 interaction of 214 and 192 with the W356 "toggle" switch 
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Figure 6.9. CB1 LBP cysteine pocket 
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6.2. CB2-Specific Proposed Functional Switches 
6.2.1. Common residue interactions  
Most of the common interactions currently well documented in CB2 modelling 
literature and precedent center around WIN-55,212-2. Residues F117(3.36), W194(5.43), 
F197(5.46) and W258(6.48) make up the bulk of the common aromatic interactions. 
Additionally, as was the case with CB1, a hydrophilic residue – usually S193(5.42), 
S292(7.46) or T114(3.33) – resides in the LBP and interacts with the ligand, if applicable. 
Currently, I am unable to utilize a validated homology model for CB2, unlike CB1. As a 
result, the key residues and/or binding sites – be they orthosteric or allosteric – cannot be 
given with sufficient certainty. However, there are certain moieties which seem to impart 
specific activity. 
6.2.2. The Di-hydroxy A-ring 
The first evidence of this requirement comes in the HB triaryl series. Compound 
191, a mono-hydroxy A-ring, showed a very modest 10% increase in cAMP production 
relative to baseline. Compound 194, a mono-deprotected A-ring, showed an agonist 
activity, with an approximately 15% decrease in cAMP, but only at the upper end of the 
tested concentrations. Compound 193, the di-deprotected A-ring, analog of 194 
demonstrated the same 15% decrease efficacy as 193; however, the potency of 194 (EC50 
7.4 nM) greatly exceeded that of 194 (EC50 494 nM) (Figure 6.10). Additionally, 
compound 192, another di-hydroxy A-ring analog, demonstrated an efficacy and potency 
nearly directly parallel to 194. Further foray into the necessity of this moiety being 
present appears in the SMM series. Compound 206, a mono-deprotected A-ring, and its 
successor 207, a di-hydroxy A-ring, demonstrate the same trend, with the efficacy being 
similar at high concentrations, but the potency of 207 (EC50 89.7 nM) greatly exceeds 
that of 206 (EC50 >5000 nM). Lastly, the majority of the di-protected SMM triaryl series 
failed to elucidate any change in cAMP production in the CB2 assay – except for 199 and 
213 at 5000 nM. Taken as a whole, the first requirement for optimal activity is the 
presence of a 1,3-dihydroxy A-ring. 
Further, as alluded to during the introduction, one can see that making a modification to 
the A-ring composition has a relatively profound effect upon the functional activity of the 
compound. Take for example, 195, 227 and 233 with a carbocyclic, pyridine and 
pyrimidine A-ring, respectively – all have a 3,5-dichloro C-ring and a phenyl D-ring; 
however, 227 and 233 have a C-1′-gem-dimethyl and 195 has a C-1′-ketone (Figure 
6.11). The difference in these compounds is quite profound, with 195 showing great CB2 
inverse agonist activity, 227 showing appreciable activity at the highest tested 
concentration (5000 nM) and 233 showing virtually no activity. This raises an interesting 
question: is this change in functional activity due to the heteroaromatic A-ring or the 
C-1′-gem-dimethyls? Further synthesis and expansion of this series is warranted to help 
gain some more definitive insight into the impact of a heteroaromatic A-ring and its help 
or hindrance of targeting agents within the cannabinoid system. 
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Figure 6.10. CB2 compounds demonstrating the requirement for di-hydroxy A-ring 
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Figure 6.11. CB2 C-1′ substituents and functional changes 
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6.2.3. The C-1′ substituent effect 
As was the case with CB1, C-1′ becomes extremely important when dealing with the 
functional switches and changes at CB2. Comparing 192 to 214, one can see that the only 
difference betwixt the two is a ketone vs. C-1′-gem-dimethyl substitution (Figure 6.12). 
The functional data shows that a change from C-1′-gem-dimethyl to ketone results in a 
compound switching from an agonist to a profoundly effective inverse agonist, 
respectively. Further, a ketone seems to be necessary, as a C-1′-hydroxy results in no 
effect when all else is equal and compared to a C-1′-ketone. Though it is not clear if this 
effect is due to the aforementioned di-protected A-ring or the hydroxyl itself – as the 
current library of compounds only has concomitant expression of the C-1′-hydroxyl and 
di-protected A-ring. One question that does arise from this study and data is whether 
testing of the C-1′-ketone moiety in the known CB2-binding KM series compounds would 
result in a similar or more potent/effective inverse agonist compound at CB2. 
6.2.4. The D-ring substituent effect 
The last component of the functional SAR garnered from this study is the D-ring 
effect. From this study, it is evident that incorporation of the previous two elements – 1,5-
dihydroxy A-ring and C-1′-ketone – requires, too, the presence of an aromatic D-ring for 
maximum potency and efficacy. Example of this comes in the form of the cycloalkyl 
derivative of 209 as compared to its aromatic counterpart of 195 (Figure 6.13). 
Compound 209 exerts an inverse agonist effect (111% increase over baseline) at the 
maximum concentration tested (5000 nM), as compared to the increase in both potency 
(744 nM) and efficacy (215% increase over baseline) for compound 195. 
6.3. Summary 
Overall, as this data shows that very small changes in the structure of a compound 
can have significant impact upon its activity or affinity for CB1 and/or CB2. To 
understand this causal relationship with more certainty, a few key advances need to 
occur: 
 A reliably predictable model (or crystal structure) for both the CB1 and CB2 
receptor needs to be created and validated against a bevy of current literature 
standard cannabinoid compounds. 
 For the compounds presented as products of this lab, matched sets, incorporating 
as similar as possible D-rings, C-1′ substituents, C-rings and A-ring oxidation, 
across all the series need to be synthesized and tested – in doing so, it will allow 
more definite trends to emerge. 
 A refinement of the functional assay to test for and qualify antagonists – not only 
from a potency standpoint, but also from a binding site standpoint, as some of 
these switches may be due to an all-together unique binding site. 
 A validation and assimilation of the data generated from this assay to an in vivo 
model of specific desease states. 
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Figure 6.12. CB2 C-1′ substituent effects - switch from agonist to inverse agonist 
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Figure 6.13. CB2 aromatic D-ring requirement 
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In summation, the field and this project has come leaps and bounds from where it 
originated not too long ago. It is an exciting time in the field of cannabinoid research, and 
emergence of better homology or crystal structure models coupled with expansion and 
refinement of this data will help to carry the field further. Combination of these 
approaches will help to ensure that cannabinoid research becomes more viable and 
targeted to usher it into its rightful place in therapy and treatment of various disease 
states. 
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